"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A2,WO 2006/020681 A2,029-467-802-388-468,2006-02-23,2006,US 2005/0028358 W,2005-08-10,US 91484804 A,2004-08-10,COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS,"The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.",HYGEIA BIOLOG SYSTEMS;;BANERJEE AMIT,BANERJEE AMIT,,https://lens.org/029-467-802-388-468,Patent Application,yes,0,8,6,6,0,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,A61K31/5383;;A61K31/506;;A61K31/53,,0,0,,,,PENDING
2,WO,A3,WO 2006/020681 A3,089-574-399-706-461,2006-12-21,2006,US 2005/0028358 W,2005-08-10,US 91484804 A,2004-08-10,COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS,"The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.",HYGEIA BIOLOG SYSTEMS;;BANERJEE AMIT,BANERJEE AMIT,,https://lens.org/089-574-399-706-461,Search Report,yes,1,0,6,6,0,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,A01N37/18,,1,1,014-444-342-839-013,10.1248/bpb.18.355;;7742812,"SHIRAHATA A. ET AL.: ""Enzymatic aminopropylation of certain secondary amines"", BIOL. PHARM. BULL., vol. 18, no. 2, February 1995 (1995-02-01), pages 355 - 359, XP008073879",PENDING
3,US,A1,US 2007/0191488 A1,036-568-418-860-349,2007-08-16,2007,US 64778806 A,2006-12-28,US 64778806 A;;US 91484804 A,2004-08-10,Method for the treatment of a ubiquitin conjugating disorder,"The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.",BANERJEE AMIT,BANERJEE AMIT,,https://lens.org/036-568-418-860-349,Patent Application,yes,4,0,6,6,3,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,A61K31/135;;C07C211/43;;C07D211/56;;G01N33/573,514/646;;435/7.4;;546/244;;564/305,0,0,,,,INACTIVE
4,US,B2,US 8003572 B2,075-531-912-236-74X,2011-08-23,2011,US 64778806 A,2006-12-28,US 64778806 A;;US 91484804 A,2004-08-10,Method for the treatment of a ubiquitin conjugating disorder,"The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.",BANERJEE AMIT,BANERJEE AMIT,,https://lens.org/075-531-912-236-74X,Granted Patent,yes,4,0,6,6,3,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,C40B30/02;;C12N9/10,506/8;;435/193,12,9,033-712-510-126-15X;;016-680-799-559-959;;058-202-297-713-570;;002-911-505-637-235;;022-843-675-414-687;;002-016-242-973-892;;054-482-364-525-136;;066-576-312-059-770;;014-444-342-839-013,7724550;;pmc42146;;10.1073/pnas.92.8.3264;;10.1016/s0969-2126(01)00657-8;;11591345;;10.1016/s1359-6446(02)02483-2;;12546894;;8090726;;pmc44693;;10.1073/pnas.91.19.8797;;1323239;;10.1146/annurev.bi.61.070192.003553;;10.1146/annurev.biochem.61.1.761;;12133807;;10.2741/goet;;10.2741/a749;;15078982;;10.4161/cbt.3.4.733;;14726656;;12874022;;10.1248/bpb.18.355;;7742812,"Rolfe et al. (""Reconstitution of p53-ubiquitinylation reactions from purified components: The role of human ubiquitin-conjugating enzyme UBC4 and E6-associated protein (E6AP),"" Proc. Acad. Sci. USA, 1995, 92, 3264-8.;;Hamilton et al. (""Structure of a Conjugating Enzyme-Ubiquitin Thiolester Intermediate Reveals a Novel Role for the Ubiquitin Tail,"" Structure, 2001, 9, 897-904).;;Lyne (""Structure-Based Virtual Screening: An Overview,"" Drug Discovery Today, 2002, 7, 1047-1055).;;Scheffner et al. (""Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53,"" Proc. Natl. Acad. Sci., 1994, 91, 8797-8801).;;Sadowski (""Tautomer and protonation pre-processor virtual screening,"" Abstract of Papers, 224th ACS National Meeting, Boston, MA, Aug. 18-22, 2002).;;Pearlman et al. (""ProtoPlex: user-control over tautomeric and protonation state,"" Abstract of Papers, 224th ACS National Meeting, Boston, MA, Aug. 18-22, 2002).;;Hershko, A., and Ciechanover, A.(1992) Ann Rev Biochem 61: 761-807. The ubiquitin System for protein degradation.;;Goettsch, S. and Bayer, P.(2002) Frontiers in Bioscience, 7, a148-162. Structural attributes in the conjunction of Ubiquitin, RUB and SUMO to protein substrates. Hershko, et al. J. Biol. Chem., 269:4940-46.;;""Overexpression of E2F-1 in Lung and Liver Metastases of Human Colon Cancer is Associated with Gene Amplification"", Iwamoto, et al. Cancer Biol Ther. Apr. 2004; 3(4):395-399.;;""UbcH10 is the Cancer-related E2 Ubiquitin-conjugating Enzyme"" Okamoto, et al. Cancer Res. 2003 63(14): 4167-73.;;Shirahata A. et al, Enzymatic aminopropylation of certain secondary amines. Biol.Pharm.Bull. Feb. 1995; 18(2):355-9.;;International Search Report for PCT/US05/28358 dated Sep. 21, 2006.",INACTIVE
5,EP,A2,EP 1778011 A2,087-356-929-326-856,2007-05-02,2007,EP 05802674 A,2005-08-10,US 2005/0028358 W;;US 91484804 A,2004-08-10,COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS,,HYGEIA BIOLOG SYSTEMS,BANERJEE AMIT,,https://lens.org/087-356-929-326-856,Patent Application,yes,0,0,6,6,0,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,A01N37/18,,1,0,,,See references of WO 2006020681A3,DISCONTINUED
6,US,A1,US 2006/0035890 A1,085-416-141-370-586,2006-02-16,2006,US 91484804 A,2004-08-10,US 91484804 A,2004-08-10,Compounds and methods for the treatment of ubiquitin conjugating disorders,"The present invention provides methods for identifying compounds that selectively bind one or more active sites within an ubiquitin conjugating enzyme. The compounds identified by the methods are useful in the treatment of disorders attributed to dysregulated ubiquitin conjugating enzyme function, specifically in hyperproliferative disorders.",AMIT BANERJEE,BANERJEE AMIT,,https://lens.org/085-416-141-370-586,Patent Application,yes,3,1,6,6,3,A61K31/506;;A61K31/506;;A61K31/53;;A61K31/53;;A61K31/5383;;A61K31/5383,A61K31/5383;;A61K31/506;;A61K31/53,514/229.2;;514/241;;514/317;;514/256;;514/303;;514/567;;514/614;;514/400;;514/406;;514/355,0,0,,,,DISCONTINUED
7,US,A1,US 2013/0002231 A1,101-329-571-760-00X,2013-01-03,2013,US 201213540376 A,2012-07-02,US 201213540376 A;;US 201161503706 P,2011-07-01,ELECTROPHORETIC BREAKING RATE METER FOR ASPHALT EMULSIONS,Described herein is a device that can be used to measure the breaking rate and total breaking energy of an emulsion. Also described is a method of determining the breaking rate of an emulsion.,BHASIN AMIT;;BANERJEE AMBARISH,BHASIN AMIT;;BANERJEE AMBARISH,BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2012-08-15),https://lens.org/101-329-571-760-00X,Patent Application,yes,6,3,1,1,0,G01N33/42;;G01N33/42,G01N27/00,324/71.1,0,0,,,,DISCONTINUED
8,WO,A1,WO 2020/172073 A1,056-107-519-802-328,2020-08-27,2020,US 2020/0018390 W,2020-02-14,US 201962807079 P,2019-02-18,ANALYZING IMAGE DATA TO DETERMINE RECTAL SAMPLE INFORMATION,"An analyzing platform may obtain a first image of a liquid in a receptacle. The analyzing platform may analyze the first image to determine a first set of visual characteristics concerning the liquid. The analyzing platform may obtain a second image of a rectal sample in the liquid in the receptacle, wherein the rectal sample originated from a bowel of a subject. The analyzing platform may analyze the second image to determine a second set of visual characteristics concerning the rectal sample. The analyzing platform may determine, based on the first set of visual characteristics and the second set of visual characteristics, rectal sample information. The analyzing platform may cause one or more actions to be performed based on the rectal sample information.",UNIV JOHNS HOPKINS,MATHEWS SIMON C;;BANERJEE AMIT,,https://lens.org/056-107-519-802-328,Patent Application,yes,5,2,2,2,0,G16H30/40;;G16H50/20;;G16H20/40;;G16H50/30;;G16H20/10;;G16H50/30;;G16H50/20;;G06T7/0014;;G06T2207/30004,A61B1/31;;A61B1/00;;A61B10/00;;A61B10/04;;G16H20/10;;G16H30/40,,0,0,,,,PENDING
9,EP,A4,EP 2788869 A4,063-505-419-526-028,2015-07-08,2015,EP 12856032 A,2012-12-06,US 201161568860 P;;US 2012/0068154 W,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,,KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/063-505-419-526-028,Search Report,no,4,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F9/44;;G06F11/36,,0,0,,,,DISCONTINUED
10,CA,A1,CA 2894270 A1,050-335-342-536-509,2013-06-13,2013,CA 2894270 A,2012-12-06,US 201161568860 P;;US 2012/0068154 W,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,"A computer-implemented method involves two phases. In a first phase (e.g., during a development or testing phase) a secondary computing environment is formed with secondary instances of one or more servers of a primary environment. A communication module configured to establish communication between the secondary instances of the servers in the secondary computing environment and remote computing resources (e.g., ""cloud"" based servers) via the communication module. The secondary instances of the servers of the primary environment are then operated in conjunction with the remote computing resources. In a second phase (e.g., a production phase), the communication module is reconfigured to establish communication between the servers of the primary environment and the remote computing resources via the communication module. The servers of the primary environment are then operated in conjunction with the remote computing resources.",KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/050-335-342-536-509,Patent Application,no,0,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F9/44;;G06F11/36,,0,0,,,,DISCONTINUED
11,WO,A1,WO 2023/064053 A1,040-990-125-651-672,2023-04-20,2023,US 2022/0042692 W,2022-09-07,US 202163256203 P,2021-10-15,CAMERA-BASED HEMOGLOBIN DETECTION,"A method for detecting a molecule in a sample includes applying a first filter to an image at a first wavelength. The method also includes applying a second filter to the image at a second wavelength. The method also includes applying a third filter to the image at a third wavelength. The first, second, and third wavelengths are within a predetermined wavelength range, and wherein first, second, and third wavelengths are different from one another. The method also includes detecting a spectral signature for the molecule in the sample in the image after the first, second, and third filters are applied to the image. The method also includes determining whether the molecule is present in the sample based at least partially upon the detected spectral signature.",UNIV JOHNS HOPKINS,MATHEWS SIMON;;BANERJEE AMIT;;PASRICHA PANKAJ,,https://lens.org/040-990-125-651-672,Patent Application,yes,6,0,1,1,0,G01J3/28;;G01N33/721;;G01N2021/1765;;G01N21/31;;A61B5/0075;;G01J3/42;;G01J3/2803;;G01J2003/2806;;G01J3/32;;A61B5/14535,G01J3/28;;G01N33/483;;G01J3/30;;G01N33/50,,0,0,,,,PENDING
12,EP,B1,EP 3821927 B1,069-076-557-741-32X,2022-01-19,2022,EP 19209288 A,2019-11-14,EP 19209288 A,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,GSK CONSUMER HEALTHCARE SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,GSK CONSUMER HEALTHCARE SARL (2021-12-08),https://lens.org/069-076-557-741-32X,Granted Patent,yes,2,0,4,14,0,A61K9/0014;;A61K9/0043;;A61K9/08;;A61K9/06;;A61K47/44;;A61K31/4174;;A61K31/164;;A61K31/505;;A61K31/045;;A61K31/455;;A61M2210/04;;A61M15/08;;A61K36/886;;A61K36/28;;A61M35/003,A61K31/045;;A61K9/06;;A61K9/08;;A61K31/164;;A61K31/4174;;A61K31/455;;A61K31/505;;A61K36/28;;A61K36/886;;A61K47/44;;A61M11/00;;A61M15/00;;A61M15/08;;A61M35/00;;B05B11/00,,0,0,,,,ACTIVE
13,US,A1,US 2010/0278069 A1,161-047-125-488-166,2010-11-04,2010,US 26342908 A,2008-10-31,US 26342908 A;;US 5905908 P,2008-06-05,Flow Path Discovery In Network To Guarantee Multiple Metric QoS Constraints,"Route discovery for an end-to-end path in a network is performed for a flow. A path is attempted to be discovered that satisfies QoS constraints for multiple metrics for the flow. The route discovery includes determining whether a path request for a path satisfying the QoS constraints is feasible, infeasible or undecideable based on information in a local QoS table. If the path request is determined to be undecideable, route discovery is performed with neighbors.",SHARMA PUNEET;;MONDAL AMIT;;BANERJEE SUJATA,SHARMA PUNEET;;MONDAL AMIT;;BANERJEE SUJATA,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2008-06-05),https://lens.org/161-047-125-488-166,Patent Application,yes,23,46,2,2,0,H04L45/02;;H04L45/124;;H04L45/302;;H04L45/38;;H04L45/64;;H04L45/70;;H04L45/033;;H04L45/302;;H04L45/124;;H04L45/38;;H04L45/70;;H04L45/02;;H04L45/64,H04L12/28,370/254,2,2,175-096-003-704-771;;175-096-003-704-771,10.1109/iwqos.2009.5201401;;10.1109/iwqos.2009.5201401,Mondal et al. - Supporting Application Network FLows with Multiple QoS Constraints - 2009;;Mondal et al. - Supporting Application Network FLows with Multiple QoS Constraints (Slides) - Uploaded 2007,ACTIVE
14,WO,A1,WO 2013/086124 A1,049-046-725-493-554,2013-06-13,2013,US 2012/0068154 W,2012-12-06,US 201161568860 P,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,"A computer-implemented method involves two phases. In a first phase (e.g., during a development or testing phase) a secondary computing environment is formed with secondary instances of one or more servers of a primary environment. A communication module configured to establish communication between the secondary instances of the servers in the secondary computing environment and remote computing resources (e.g., ""cloud"" based servers) via the communication module. The secondary instances of the servers of the primary environment are then operated in conjunction with the remote computing resources. In a second phase (e.g., a production phase), the communication module is reconfigured to establish communication between the servers of the primary environment and the remote computing resources via the communication module. The servers of the primary environment are then operated in conjunction with the remote computing resources.",KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/049-046-725-493-554,Patent Application,yes,7,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F9/44,,0,0,,,,PENDING
15,EP,B8,EP 4058112 B8,024-120-445-631-911,2024-02-14,2024,EP 20803574 A,2020-11-12,EP 19209288 A;;US 202015930847 A;;EP 2020081908 W,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,HALEON CH SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,"HALEON CH SARL (2024-01-24);;HALEON CH SARL, CH (2024-01-10)",https://lens.org/024-120-445-631-911,Amended Patent,yes,2,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61M11/00;;A23L33/105;;A45D40/24;;A61K8/02;;A61K8/92;;A61K9/06;;A61K9/08;;A61K31/00;;A61K31/4174;;A61K31/56;;A61K36/758;;A61K47/44;;A61M15/00;;A61M15/08;;A61M35/00;;A61P11/02;;A61P11/06;;A61P17/02;;A61Q19/00;;B05B11/00,,0,0,,,,ACTIVE
16,US,B2,US 8565218 B2,191-012-192-209-866,2013-10-22,2013,US 26342908 A,2008-10-31,US 26342908 A;;US 5905908 P,2008-06-05,Flow path discovery in network to guarantee multiple metric QoS constraints,"Route discovery for an end-to-end path in a network is performed for a flow. A path is attempted to be discovered that satisfies QoS constraints for multiple metrics for the flow. The route discovery includes determining whether a path request for a path satisfying the QoS constraints is feasible, infeasible or undecideable based on information in a local QoS table. If the path request is determined to be undecideable, route discovery is performed with neighbors.",SHARMA PUNEET;;MONDAL AMIT;;BANERJEE SUJATA;;HEWLETT PACKARD DEVELOPMENT CO,SHARMA PUNEET;;MONDAL AMIT;;BANERJEE SUJATA,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2015-10-27);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2008-06-05),https://lens.org/191-012-192-209-866,Granted Patent,yes,24,2,2,2,0,H04L45/02;;H04L45/124;;H04L45/302;;H04L45/38;;H04L45/64;;H04L45/70;;H04L45/033;;H04L45/302;;H04L45/124;;H04L45/38;;H04L45/70;;H04L45/02;;H04L45/64,H04L12/28;;G06F15/173,370/351;;370/392;;709/238,20,10,175-096-003-704-771;;175-096-003-704-771;;175-096-003-704-771;;143-506-189-497-528;;014-191-077-832-837;;007-714-451-565-748;;113-742-796-930-959;;031-475-062-355-848;;033-097-071-430-413;;111-695-594-610-402,10.1109/iwqos.2009.5201401;;10.1109/iwqos.2009.5201401;;10.1109/iwqos.2009.5201401;;10.1145/505222.505224;;10.1145/1151659.1159938;;10.1109/jsac.2003.818782;;10.1145/502047.502048;;10.1145/1162638.1162650;;10.1145/319151.319166;;10.1145/776325.776327,"Mondal et al. Supporting Application Network Flows with Multiple QoS Constraints.;;Supporting Application Network Flows with Multiple QoS-Mondal et al.-2007.;;Mondal et al.-Supporting Application Network FLows with Multiple QoS Constraints-2009.;;Mondal et al.-Supporting Application Network FLows with Multiple QoS Constraints (Slides)-Uploaded 2007.;;Chu , Y. et al., ""A Case for End System Multicast"", downloaded Jun. 2, 2008.;;Krishnamurthy, B. et al., ""On the Use and Performance of Content Distribution Networks"", ACM SIGCOMM Internet Measurement Workshop 2001.;;Gummadi, K. et al., ""Improving the Reliability of Internet Paths with One-hop Source Routing"", downloaded Jun. 2, 2008.;;Cho, K. et al., ""The Impact and Implications of the Growth in Residential User-to-User Traffic"", ACM SIGCOMM, Sep. 2006.;;Li, Z. et al., ""QRON: QoS-Aware Routing in Overlay Networks"", Jun. 8, 2003.;;Lao, L. et al, ""Distributed QoS Routing for Backbone Overlay Networks"", downloaded Jun. 2, 2008.;;Andersen, D. et al., ""Resilient Overlay Networks"", ACM SOSP '01, Oct. 2001.;;Subramanian, L. et al., ""OverQos: An Overlay Based Architecture for Enhancing Internet QoS"", downloaded Jun. 2, 2008.;;Wang, Z. et al., ""Quality of Service Routing for Supporting Multimedia Applications"", downloaded Jun. 2, 2008.;;Perkins, C. et al., ""Ad-Hoc On-Demand Distance Vector Routing"", downloaded Jun. 2, 2008.;;""The Openbgpd Project"", http://www.openbgpd.org/, downloaded Jun. 2, 2008.;;Yalagandula, P. et al., ""S3: A Scalable Sensing Service for Monitoring Large Networked Systems"", ACM SIGCOMM'06, Sep. 2006.;;Kohler, E. et al., ""The Click Modular Router"", ACM, downloaded Jun. 2, 2008.;;Tang, W. et al., ""MediSyn: A Synthetic Streaming Media Service Workload Generator"", ACM NOSSDAV'03, Jun. 2003.;;Open Shortest Path First (OSPF), http://www.cisco.com/en/US/docs/Internetworking/technology/handbook/OSPF.html, downloaded Jun. 2, 2008.;;Duan, Z. et al., ""Service Overlay Networks: SLAs, Qos and Bandwidth Provisioning"", downloaded Jun. 5, 2008.",ACTIVE
17,EP,C0,EP 4058112 C0,012-595-471-589-837,2023-12-27,2023,EP 20803574 A,2020-11-12,EP 19209288 A;;US 202015930847 A;;EP 2020081908 W,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,HALEON CH SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,"HALEON CH SARL (2024-01-24);;HALEON CH SARL, CH (2024-01-10)",https://lens.org/012-595-471-589-837,Unknown,no,0,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61M11/00;;A23L33/105;;A45D40/24;;A61K8/02;;A61K8/92;;A61K9/06;;A61K9/08;;A61K31/00;;A61K31/4174;;A61K31/56;;A61K36/758;;A61K47/44;;A61M15/00;;A61M15/08;;A61M35/00;;A61P11/02;;A61P11/06;;A61P17/02;;A61Q19/00;;B05B11/00,,0,0,,,,ACTIVE
18,US,A1,US 2021/0137888 A1,028-486-356-237-80X,2021-05-13,2021,US 202015930847 A,2020-05-13,US 202015930847 A;;EP 19209288 A;;US 201929712813 F,2019-11-12,NOVEL COMBINATION PRODUCT,"A combination product comprising a nasal spray dispenser containing a formulation for nasal administration, and a balm holder element containing a skin-care balm, attached to a bottom of the nasal spray dispenser.",GSK CONSUMER HEALTHCARE SA,SABHERWAL AMIT;;ATHANASE THIERRY;;BANERJEE SRIMAN,GSK CONSUMER HEALTHCARE S.A (2020-12-15);;HALEON CH SARL (2021-02-19);;GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC (2020-12-10),https://lens.org/028-486-356-237-80X,Patent Application,yes,1,1,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61K31/4164;;A61K9/00;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899;;A61P11/02;;A61P17/16,,1,0,,,CN2227615 translated doc (Year: 1996),PENDING
19,TW,B,TW 419621 B,056-820-444-456-355,2001-01-21,2001,TW 88104625 A,1999-03-24,US 6973398 A,1998-04-30,Voltage regulator and method of voltage regulation,"The voltage regulator includes a regulator circuit, connected between a high potential and a low potential, regulating an output voltage based on an input voltage. The regulator circuit includes a changing circuit which changes at least one of a voltage range of the output voltage and a rate at which the output voltage changes with respect to changes in the input voltage. The changing circuit selectively increases a maximum value of the voltage range of the output voltage, and also selectively increases the rate at which the output voltage changes with respect to changes in the input voltage.",LUCENT TECHNOLOGIES INC,BANERJEE AMIT KUMAR;;MCPARTLAND RICHARD JOSEPH,,https://lens.org/056-820-444-456-355,Granted Patent,no,0,0,4,4,0,G05F3/24;;G05F1/10;;G05F3/24,G05F3/24,,0,0,,,,EXPIRED
20,US,A,US 6104176 A,151-385-251-903-841,2000-08-15,2000,US 6973398 A,1998-04-30,US 6973398 A,1998-04-30,Voltage regulator and method of voltage regulation,"The voltage regulator includes a regulator circuit, connected between a high potential and a low potential, regulating an output voltage based on an input voltage. The regulator circuit includes a changing circuit which changes at least one of a voltage range of the output voltage and a rate at which the output voltage changes with respect to changes in the input voltage. The changing circuit selectively increases a maximum value of the voltage range of the output voltage, and also selectively increases the rate at which the output voltage changes with respect to changes in the input voltage.",LUCENT TECHNOLOGIES INC,MCPARTLAND RICHARD JOSEPH;;BANERJEE AMIT KUMAR,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;LUCENT TECHNOLOGIES INC (1998-04-24),https://lens.org/151-385-251-903-841,Granted Patent,yes,2,3,4,4,0,G05F3/24;;G05F1/10;;G05F3/24,G05F3/24,323/269;;323/313,0,0,,,,EXPIRED
21,HK,A1,HK 1203235 A1,154-895-995-594-649,2015-10-23,2015,HK 15103659 A,2015-04-15,US 2012/0068154 W;;US 201161568860 P,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,,KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/154-895-995-594-649,Patent Application,no,0,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F/,,0,0,,,,PENDING
22,EP,A1,EP 4058112 A1,027-361-324-482-83X,2022-09-21,2022,EP 20803574 A,2020-11-12,EP 19209288 A;;US 202015930847 A;;EP 2020081908 W,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,GSK CONSUMER HEALTHCARE SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,"HALEON CH SARL (2024-01-24);;HALEON CH SARL, CH (2024-01-10)",https://lens.org/027-361-324-482-83X,Patent Application,yes,0,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61M11/00;;A23L33/105;;A61K8/92;;A61K9/00;;A61K9/06;;A61K9/08;;A61K31/00;;A61K31/4174;;A61K31/56;;A61K36/758;;A61K47/44;;A61M15/00;;A61M15/08;;A61P11/02;;A61P11/06;;A61P17/02;;A61Q19/00;;B05B11/00,,0,0,,,,ACTIVE
23,ES,T3,ES 2909188 T3,046-380-016-482-048,2022-05-05,2022,ES 19209288 T,2019-11-14,EP 19209288 A,2019-11-14,Dispositivo de aplicación nasal interna y externa,"Producto de combinación que comprende un cabezal dispensador (10, 10') montado en la parte superior de un recipiente (20, 20') que contiene una formulación líquida para administración nasal, y un bálsamo para el cuidado de la piel solidificado (50) para su aplicación alrededor de la nariz contenido en un elemento de soporte de bálsamo (30, 30"") unido a la parte inferior (24) del recipiente (20).",GSK CONSUMER HEALTHCARE SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,,https://lens.org/046-380-016-482-048,Granted Patent,no,0,0,4,14,0,A61K9/0014;;A61K9/0043;;A61K9/08;;A61K9/06;;A61K47/44;;A61K31/4174;;A61K31/164;;A61K31/505;;A61K31/045;;A61K31/455;;A61M2210/04;;A61M15/08;;A61K36/886;;A61K36/28;;A61M35/003,A61K9/06;;A61K31/045;;A61K9/08;;A61K31/164;;A61K31/4174;;A61K31/455;;A61K31/505;;A61K36/28;;A61K36/886;;A61K47/44;;A61M11/00;;A61M15/00;;A61M15/08;;A61M35/00;;B05B11/00,,0,0,,,,ACTIVE
24,IN,A,IN 5690DEN2014 A,168-440-347-018-448,2015-04-03,2015,IN 5690DEN2014 A,2014-07-09,US 201161568860 P;;US 2012/0068154 W,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,A computer implemented method involves two phases. In a first phase (e.g. during a development or testing phase) a secondary computing environment is formed with secondary instances of one or more servers of a primary environment. A communication module configured to establish communication between the secondary instances of the servers in the secondary computing environment and remote computing resources (e.g. 'cloud' based servers) via the communication module. The secondary instances of the servers of the primary environment are then operated in conjunction with the remote computing resources. In a second phase (e.g. a production phase) the communication module is reconfigured to establish communication between the servers of the primary environment and the remote computing resources via the communication module. The servers of the primary environment are then operated in conjunction with the remote computing resources.,KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/168-440-347-018-448,Patent Application,no,0,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F9/44,,0,0,,,,PENDING
25,WO,A1,WO 2021/094451 A1,080-180-497-412-572,2021-05-20,2021,EP 2020081908 W,2020-11-12,EP 19209288 A;;US 202015930847 A,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,"A combination product comprising a dispensing head (10, 10') mounted on a top of a container (20, 20') containing a formulation for nasal administration, and a solidified skin-care balm (50) for application around the nose contained in a balm holder element (30, 30'') located on a bottom (24) of the container (20).",GSK CONSUMER HEALTHCARE SA,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,,https://lens.org/080-180-497-412-572,Patent Application,yes,5,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61M11/00;;A23L33/105;;A61K8/92;;A61K9/00;;A61K9/06;;A61K9/08;;A61K31/00;;A61K31/4174;;A61K31/56;;A61K36/758;;A61K47/44;;A61M15/00;;A61M15/08;;A61P11/02;;A61P11/06;;A61P17/02;;A61Q19/00;;B05B11/00,,0,0,,,,PENDING
26,US,A1,US 2013/0151679 A1,085-018-461-831-026,2013-06-13,2013,US 201213706720 A,2012-12-06,US 201213706720 A;;US 201161568860 P,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,"A computer-implemented method involves two phases. In a first phase (e.g., during a development or testing phase) a secondary computing environment is formed with secondary instances of one or more servers of a primary environment. A communication module configured to establish communication between the secondary instances of the servers in the secondary computing environment and remote computing resources (e.g., “cloud” based servers) via the communication module. The secondary instances of the servers of the primary environment are then operated in conjunction with the remote computing resources. In a second phase (e.g., a production phase), the communication module is reconfigured to establish communication between the servers of the primary environment and the remote computing resources via the communication module. The servers of the primary environment are then operated in conjunction with the remote computing resources.",KUBISYS INC;;KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,KUBISYS INC (2013-01-25),https://lens.org/085-018-461-831-026,Patent Application,yes,7,3,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,H04L12/24,709/221;;709/220,1,0,,,"Jeremy Sugerman, VMware, ""virtualizing I/O Devices on VMware Workstation`s Hosted Virtual Machine Monitor"", 2001, page1-14",DISCONTINUED
27,US,A1,US 2022/0387389 A1,123-455-470-506-542,2022-12-08,2022,US 202017776048 A,2020-11-12,US 202017776048 A;;EP 19209288 A;;US 202015930847 A;;EP 2020081908 W,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,"A combination product comprising a dispensing head ( 10, 10 ′) mounted on a top of a container ( 20, 20 ′) containing a formulation for nasal administration, and a solidified skin-care balm ( 50 ) for application around the nose contained in a balm holder element ( 30, 30 ″) located on a bottom ( 24 ) of the container ( 20 ).",GSK CONSUMER HEALTHCARE SARL,SABHERWAL AMIT;;ATHANASE THIERRY;;BANERJEE SRIMAN,GSK CONSUMER HEALTHCARE S.A (2020-12-03);;HALEON CH SARL (2021-02-19),https://lens.org/123-455-470-506-542,Patent Application,yes,0,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61K31/4164;;A61K9/00;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899;;A61P11/02;;A61P17/16,,0,0,,,,PENDING
28,EP,A1,EP 2788869 A1,040-897-452-185-14X,2014-10-15,2014,EP 12856032 A,2012-12-06,US 201161568860 P;;US 2012/0068154 W,2011-12-09,HYBRID VIRTUAL COMPUTING ENVIRONMENTS,,KUBISYS INC,BANERJEE AMIT;;URANO SHINICHI;;ACHARYA SOUBIR,,https://lens.org/040-897-452-185-14X,Patent Application,yes,0,0,7,7,0,H04L67/1095;;H04L41/0813;;H04L41/084;;H04L41/0813;;H04L41/084;;H04L67/1095,G06F9/44;;G06F11/36,,0,0,,,,DISCONTINUED
29,EP,B1,EP 4058112 B1,168-922-945-443-059,2023-12-27,2023,EP 20803574 A,2020-11-12,EP 19209288 A;;US 202015930847 A;;EP 2020081908 W,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,GSK CONSUMER HEALTHCARE SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,"HALEON CH SARL (2024-01-24);;HALEON CH SARL, CH (2024-01-10)",https://lens.org/168-922-945-443-059,Granted Patent,yes,2,0,7,14,0,A61M15/08;;A61K9/06;;A61K9/0014;;A61K31/4174;;A61P11/02;;A61K9/0043;;A61P11/06;;A61Q19/00;;A61P17/02;;A61K47/44;;A61M11/00;;A61K36/22;;A61M2210/04;;A61M2210/0618;;A61M2205/3606;;A61M15/0025;;A61K8/0216;;A61K2800/884;;A61K2800/87;;A45D40/24;;A45D2200/05;;A61M35/003;;A61P17/16;;A61P11/02;;A61K9/0014;;A61K9/0043;;A61K31/045;;A61K31/23;;A61K31/35;;A61K31/4164;;A61K31/569;;A61K36/185;;A61K36/22;;A61K36/47;;A61K36/54;;A61K36/758;;A61K36/899,A61M11/00;;A23L33/105;;A45D40/24;;A61K8/02;;A61K8/92;;A61K9/06;;A61K9/08;;A61K31/00;;A61K31/4174;;A61K31/56;;A61K36/758;;A61K47/44;;A61M15/00;;A61M15/08;;A61M35/00;;A61P11/02;;A61P11/06;;A61P17/02;;A61Q19/00;;B05B11/00,,0,0,,,,ACTIVE
30,PL,T3,PL 3821927 T3,173-582-758-486-427,2022-05-16,2022,PL 19209288 T,2019-11-14,EP 19209288 A,2019-11-14,DEVICE FOR INTERNAL AND EXTERNAL NASAL APPLICATION,,GSK CONSUMER HEALTHCARE SARL,ATHANASE THIERRY;;BANERJEE SRIMAN;;SABHERWAL AMIT,,https://lens.org/173-582-758-486-427,Patent Application,no,0,0,4,14,0,A61K9/0014;;A61K9/0043;;A61K9/08;;A61K9/06;;A61K47/44;;A61K31/4174;;A61K31/164;;A61K31/505;;A61K31/045;;A61K31/455;;A61M2210/04;;A61M15/08;;A61K36/886;;A61K36/28;;A61M35/003,A61K31/045;;A61K9/06;;A61K9/08;;A61K31/164;;A61K31/4174;;A61K31/455;;A61K31/505;;A61K36/28;;A61K36/886;;A61K47/44;;A61M11/00;;A61M15/00;;A61M15/08;;A61M35/00;;B05B11/00,,0,0,,,,PENDING
31,US,A1,US 2022/0076418 A1,080-555-312-884-783,2022-03-10,2022,US 202017310686 A,2020-02-14,US 202017310686 A;;US 201962807079 P;;US 2020/0018390 W,2019-02-18,ANALYZING IMAGE DATA TO DETERMINE BOWEL PREPARATION QUALITY,"An analyzing platform may obtain a first image of a liquid in a receptacle. The analyzing platform may analyze the first image to determine a first set of visual characteristics concerning the liquid. The analyzing platform may obtain a second image of a rectal sample in the liquid in the receptacle, wherein the rectal sample originated from a bowel of a subject. The analyzing platform may analyze the second image to determine a second set of visual characteristics concerning the rectal sample. The analyzing platform may determine, based on the first set of visual characteristics and the second set of visual characteristics, rectal sample information. The analyzing platform may cause one or more actions to be performed based on the rectal sample information.",UNIV JOHNS HOPKINS,MATHEWS SIMON C;;BANERJEE AMIT;;PASRICHA JAY,,https://lens.org/080-555-312-884-783,Patent Application,yes,3,0,2,2,0,G16H30/40;;G16H50/20;;G16H20/40;;G16H50/30;;G16H20/10;;G16H50/30;;G16H50/20;;G06T7/0014;;G06T2207/30004,G16H50/20;;G06T7/00;;G16H50/30,,0,0,,,,PENDING
32,DE,B3,DE 102020117045 B3,159-914-669-743-322,2021-03-11,2021,DE 102020117045 A,2020-06-29,DE 102020117045 A,2020-06-29,VERFAHREN ZUR DEVULKANISATION VON SCHWEFELVERNETZTEN KAUTSCHUKEN,"Die Erfindung bezieht sich auf das Gebiet der Polymerchemie und betrifft ein Verfahren zur Devulkanisation von schwefelvernetzten Kautschuken, welches beispielsweise für die Devulkanisation von Altreifen eingesetzt werden kann.Aufgabe der vorliegenden Erfindung ist die Angabe eines Verfahrens zur Devulkanisation von schwefelvernetzten Kautschuken, mit dem die Struktur der Kautschuke auch während der Devulkanisation im Wesentlichen erhalten bleibt.Die Aufgabe wird gelöst durch ein Verfahren, bei dem schwefelvernetzte vulkanisierte Kautschuke mit ungesättigten Doppelbindungen in der Polymerhauptkette zerkleinert werden und nachfolgend bei Temperaturen zwischen 60 und 200 °C innerhalb von 2 bis 60 min mit 1 bis 25 Gew.-% eines Flüssigmetalls oder einer Flüssigmetallmischung oder einer Flüssigmetalllegierung mit jeweils überwiegend Gallium als Metall, in der Mischung und/oder in der Legierung, gemischt werden, und nachfolgend die Kautschukbestandteile vom Flüssigmetall oder von der Flüssigmetallmischung oder von der Flüssigmetalllegierung mit jeweils überwiegend Gallium abgetrennt werden.",LEIBNIZ INST POLYMERFORSCHUNG DRESDEN EV,BANERJEE SHIB SHANKAR;;DAS AMIT;;FERY ANDREAS,,https://lens.org/159-914-669-743-322,Granted Patent,no,1,0,1,1,0,C08J11/10;;C08C19/08;;C08J2321/00;;Y02W30/62,C08J11/10;;C08C19/08;;C08L21/00,,0,0,,,,ACTIVE
33,CN,A,CN 1091472 A,003-241-114-694-124,1994-08-31,1994,CN 93119819 A,1993-11-02,US 97228692 A,1992-11-05,Stereoselective reduction of ketones,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G,,https://lens.org/003-241-114-694-124,Patent Application,no,0,4,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;C07C311/21;;C12P13/02;;A61K31/18;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,DISCONTINUED
34,US,A1,US 2023/0383672 A1,183-956-892-774-549,2023-11-30,2023,US 202217877792 A,2022-07-29,IN 202211030308 A,2022-05-26,SYSTEM AND METHOD FOR HYDRAULICALLY ACTUATING MAIN AND BYPASS VALVES OF A STEAM TURBINE,"A system includes a hydraulic power unit having a tank, a pump assembly, an accumulator assembly, and a header. The tank is configured to store a common hydraulic fluid. The pump assembly is configured to pump the common hydraulic fluid from the tank to provide a pressurized hydraulic fluid. The accumulator assembly is configured to store the pressurized hydraulic fluid. The header is coupled to the pump assembly and the accumulator assembly, wherein the header is configured to supply the pressurized hydraulic fluid to one or more main valves and one or more bypass valves of a steam turbine system.",GEN ELECTRIC,KHAMKAR AMIT LAXMANRAO;;ANSARI ARSHAD AMIN;;BANERJEE SHAURABH,GE INFRASTRUCTURE TECHNOLOGY LLC (2023-11-10);;GENERAL ELECTRIC COMPANY (2022-06-25),https://lens.org/183-956-892-774-549,Patent Application,yes,0,0,5,5,0,F01K13/02;;F01K23/101;;F01K23/106;;F01D17/105;;F01D17/26;;F01D17/145;;F01D21/16;;C10M2223/04;;F01D17/105;;F05D2220/31;;F05D2260/606,F01D17/10,,0,0,,,,PENDING
35,KR,A,KR 20230165125 A,172-414-683-098-93X,2023-12-05,2023,KR 20230062211 A,2023-05-15,IN 202211030308 A,2022-05-26,SYSTEM AND METHOD FOR HYDRAULICALLY ACTUATING MAIN AND BYPASS VALVES OF A STEAM TURBINE,"시스템(10)은 탱크(222), 펌프 조립체(300), 축적기 조립체(306) 및 헤더(304)를 갖는 유압 동력 유닛(18)을 포함한다. 탱크(222)는 공통 유압 유체를 저장하도록 구성된다. 펌프 조립체(300)는 탱크(222)로부터 공통 유압 유체를 펌핑하여 가압된 유압 유체를 제공하도록 구성된다. 축적기 조립체(306)는 가압된 유압 유체를 저장하도록 구성된다. 헤더(304)는 펌프 조립체(300) 및 축적기 조립체(306)에 결합되고, 여기서 헤더(304)는 가압된 유압 유체를 증기 터빈 시스템(16)의 하나 이상의 주 밸브(142, 166, 196) 및 하나 이상의 바이패스 밸브(150, 174, 204)에 공급하도록 구성된다.",GEN ELECTRIC,KHAMKAR AMIT LAXMANRAO;;ANSARI ARSHAD AMIN;;BANERJEE SHAURABH,,https://lens.org/172-414-683-098-93X,Patent Application,no,0,0,5,5,0,F01K13/02;;F01K23/101;;F01K23/106;;F01D17/105;;F01D17/26;;F01D17/145;;F01D21/16;;C10M2223/04;;F01D17/105;;F05D2220/31;;F05D2260/606,F01D17/26;;F01D17/14;;F01D21/16,,0,0,,,,PENDING
36,US,B2,US 8295548 B2,196-659-516-824-988,2012-10-23,2012,US 81821510 A,2010-06-18,US 81821510 A;;US 26931709 P,2009-06-22,Systems and methods for remote tagging and tracking of objects using hyperspectral video sensors,Detection and tracking of an object by exploiting its unique reflectance signature. This is done by examining every image pixel and computing how closely that pixel's spectrum matches a known object spectral signature. The measured radiance spectra of the object can be used to estimate its intrinsic reflectance properties that are invariant to a wide range of illumination effects. This is achieved by incorporating radiative transfer theory to compute the mapping between the observed radiance spectra to the object's reflectance spectra. The consistency of the reflectance spectra allows for object tracking through spatial and temporal gaps in coverage. Tracking an object then uses a prediction process followed by a correction process.,BANERJEE AMIT;;BURLINA PHILLIPPE M;;BROADWATER JOSHUA B;;UNIV JOHNS HOPKINS,BANERJEE AMIT;;BURLINA PHILLIPPE M;;BROADWATER JOSHUA B,JOHNS HOPKINS UNIVERSITY (2010-06-23),https://lens.org/196-659-516-824-988,Granted Patent,yes,23,6,2,2,0,G06T2207/10036;;G06T2207/20081;;G06T7/246;;G06T7/277;;G06V10/143;;G06V10/60;;G06T2207/10036;;G06T2207/20081;;G06T7/246;;G06T7/277;;G06V10/143;;G06V10/60,G01C3/08;;G06V10/143;;G06V10/60,382/103;;382/291;;356/3.12,0,0,,,,ACTIVE
37,US,B1,US 8868839 B1,112-137-934-022-413,2014-10-21,2014,US 201113081706 A,2011-04-07,US 201113081706 A,2011-04-07,Systems and methods for caching data blocks associated with frequently accessed files,"A computer-implemented method may include identifying a file that includes one or more data blocks stored within a storage device. The computer-implemented method may also include determining that the file has been accessed more frequently than one or more other files stored within the storage device and then tracking the number of times that at least one data block associated with the file is accessed in the storage device. The computer-implemented method may further include determining that the number of times that the data block associated with the file has been accessed in the storage device is above a predetermined threshold. In addition, the computer-implemented method may include caching the data block associated with the file in a caching mechanism to decrease the amount of time required to access the data block. Various other methods, systems, and computer-readable media are also disclosed.",BANERJEE ANINDYA;;JAMBURE AMIT;;PATWARDHAN KEDAR;;PENDHARKAR NIRANJAN;;SYMANTEC CORP,BANERJEE ANINDYA;;JAMBURE AMIT;;PATWARDHAN KEDAR;;PENDHARKAR NIRANJAN,VERITAS US IP HOLDINGS LLC (2016-01-29);;SYMANTEC CORPORATION (2011-02-17);;VERITAS TECHNOLOGIES LLC (2016-03-29),https://lens.org/112-137-934-022-413,Granted Patent,yes,10,9,1,1,0,G06F12/122;;G06F12/122;;G06F12/0804;;G06F12/0804;;G06F12/0868;;G06F12/0868;;G06F2212/463;;G06F2212/463,G06F12/00,711/133;;711/118,0,0,,,,INACTIVE
38,US,A1,US 2018/0050131 A1,158-264-520-180-340,2018-02-22,2018,US 201715663221 A,2017-07-28,US 201715663221 A;;US 201662377313 P,2016-08-19,IMPLANTABLE MEDICINE DELIVERY SYSTEMS,"Implantable medicine delivery systems, devices, and associated methods are disclosed herein. In one embodiment, a method of enhancing bone regeneration in a human or animal body includes implanting a three-dimensional scaffold in the human or animal body. The three-dimensional scaffold is constructed from a porous ceramic material, a ceramic-polymer composite of a biodegradable ceramic material and a polymer, or a ceramic-polymer-metal composite of a biodegradable ceramic material, a polymer, and a metal and embedded with curcumin in the porous ceramic material, the curcumin at least partially coating an exterior surface of the porous ceramic material. The method also includes directly and controllably releasing the embedded curcumin into a circulatory system of the human or animal body according to a release profile, thereby achieving enhanced bone regeneration in the human or animal body.",UNIV WASHINGTON STATE,BOSE SUSMITA;;BANDYOPADHYAY AMIT;;BANERJEE DISHARY;;SARKAR NABONEETA,WASHINGTON STATE UNIVERSITY (2017-08-01),https://lens.org/158-264-520-180-340,Patent Application,yes,0,1,1,1,0,A61L27/54;;A61L27/54;;A61L27/12;;A61L27/12;;A61L27/18;;A61L27/18;;A61L27/34;;A61L27/34;;A61L27/44;;A61L27/56;;A61L27/56;;A61L27/58;;A61L27/58;;A61L2300/216;;A61L2300/216;;A61L2300/416;;A61L2300/416;;A61L2430/02;;A61L2430/02;;A61M31/002;;A61M2205/04;;A61M2207/10;;A61M2210/02;;B28B1/001;;B28B1/001;;B28B11/04;;B33Y10/00;;B33Y80/00;;B33Y80/00,A61L27/54;;A61L27/12;;A61L27/18;;A61L27/34;;A61L27/44;;A61L27/56;;A61L27/58;;A61M31/00;;B33Y10/00;;B33Y80/00,,0,0,,,,DISCONTINUED
39,US,A1,US 2010/0322480 A1,133-647-514-270-789,2010-12-23,2010,US 81821510 A,2010-06-18,US 81821510 A;;US 26931709 P,2009-06-22,Systems and Methods for Remote Tagging and Tracking of Objects Using Hyperspectral Video Sensors,Detection and tracking of an object by exploiting its unique reflectance signature. This is done by examining every image pixel and computing how closely that pixel's spectrum matches a known object spectral signature. The measured radiance spectra of the object can be used to estimate its intrinsic reflectance properties that are invariant to a wide range of illumination effects. This is achieved by incorporating radiative transfer theory to compute the mapping between the observed radiance spectra to the object's reflectance spectra. The consistency of the reflectance spectra allows for object tracking through spatial and temporal gaps in coverage. Tracking an object then uses a prediction process followed by a correction process.,BANERJEE AMIT;;BURLINA PHILLIPPE M;;BROADWATER JOSHUA B,BANERJEE AMIT;;BURLINA PHILLIPPE M;;BROADWATER JOSHUA B,JOHNS HOPKINS UNIVERSITY (2010-06-23),https://lens.org/133-647-514-270-789,Patent Application,yes,19,47,2,2,0,G06T2207/10036;;G06T2207/20081;;G06T7/246;;G06T7/277;;G06V10/143;;G06V10/60;;G06T2207/10036;;G06T2207/20081;;G06T7/246;;G06T7/277;;G06V10/143;;G06V10/60,G06V10/143;;G06V10/60,382/103,0,0,,,,ACTIVE
40,US,H,US H0001679 H,077-384-433-082-216,1997-09-02,1997,US 74832496 A,1996-11-13,US 74832496 A,1996-11-13,Process for preparing an optically pure intermediate for a phosphonosulfonate soualene synthetase inhibitor,"A process is provided for preparing a substantially optically pure phosphonate ester or phosphonate thioester intermediate via an enzymatically catalyzed enantioselective reaction, which intermediate is employed in preparing phosphonosulfonate squalene synthetase inhibitors.",BRISTOL MYERS SQUIBB CO,BANERJEE AMIT;;PATEL RAMESH N;;SZARKA LASZLO J,BRISTOL-MYERS SQUIBB COMPANY (1996-11-08),https://lens.org/077-384-433-082-216,Statutory Invention Registration,yes,0,0,1,1,0,C07F9/4056;;C12P9/00;;C12P41/004;;C07F9/4056;;C12P9/00;;C12P41/004,C07F9/40;;C12P9/00;;C12P41/00,435/280,0,0,,,,EXPIRED
41,EP,A1,EP 4321738 A1,030-926-058-300-653,2024-02-14,2024,EP 23173090 A,2023-05-12,IN 202211030308 A,2022-05-26,SYSTEM AND METHOD FOR HYDRAULICALLY ACTUATING MAIN AND BYPASS VALVES OF A STEAM TURBINE,"A system (10) includes a hydraulic power unit (18) having a tank (222), a pump assembly (300), an accumulator assembly (306), and a header (304). The tank (222) is configured to store a common hydraulic fluid. The pump assembly (300) is configured to pump the common hydraulic fluid from the tank (222) to provide a pressurized hydraulic fluid. The accumulator assembly (306) is configured to store the pressurized hydraulic fluid. The header (304) is coupled to the pump assembly (300) and the accumulator assembly (306), wherein the header (304) is configured to supply the pressurized hydraulic fluid to one or more main valves (142, 166, 196) and one or more bypass valves (150, 174, 204) of a steam turbine system (16).
",GENERAL ELECTRIC TECHNOLOGY GMBH,KHAMKAR AMIT LAXMANRAO;;ANSARI ARSHAD AMIN;;BANERJEE SHAURABH,,https://lens.org/030-926-058-300-653,Patent Application,yes,6,0,5,5,0,F01K13/02;;F01K23/101;;F01K23/106;;F01D17/105;;F01D17/26;;F01D17/145;;F01D21/16;;C10M2223/04;;F01D17/105;;F05D2220/31;;F05D2260/606,F01K13/02;;F01K23/10,,0,0,,,,PENDING
42,US,B1,US 9069992 B1,007-616-805-724-533,2015-06-30,2015,US 53393209 A,2009-07-31,US 53393209 A,2009-07-31,System and method for reducing data loss prevention scans,"A computing device receives a file. The computing device determines whether the file has previously been scanned for violations of a data loss prevention policy. If the file was previously scanned, a result of the previous scan is used to decide whether or not the file violates the data loss prevention policy. If the file was not previously scanned, the file is scanned to decide whether or not the file violates the data loss prevention policy.",VAIKAR AMOL;;BANERJEE ANINDYA;;KABRA NAVIN;;VERMA AMIT;;SYMANTEC CORP,VAIKAR AMOL;;BANERJEE ANINDYA;;KABRA NAVIN;;VERMA AMIT,SYMANTEC CORPORATION (2009-07-31);;CA INC (2019-11-04),https://lens.org/007-616-805-724-533,Granted Patent,yes,13,43,1,1,0,G06F21/6218;;G06F21/88;;G06F21/6218,G06F21/10;;G06F21/88,,0,0,,,,INACTIVE
43,US,A1,US 2005/0009151 A1,028-358-386-981-369,2005-01-13,2005,US 87516104 A,2004-06-22,US 87516104 A;;US 48603203 P;;US 49962203 P,2003-07-10,Methods for the stereospecific and enantiomeric enrichment of beta-amino acids,"The present invention relates to methods for the stereospecific synthesis and for the enantiomeric enrichment of β-amino acids. A novel D-β-aminotransferase, which exhibits stereoselectivity for D-β-phenylalanine, (D-3 amino-3-phenylpropinine acid) was purified from a newly-isolated strain of Variouorax paradoxus . A novel L-β-aminotransferase was purified from a newly-isolated strain of Alcaligenes eutrophus . The D- and L-β-aminotransferases can be used to facilitate the stereoselective biosynthesis of β-D-phenylalanine or β-L-phenylalanine, from a mixture of L-glutamic acid or L-alanine, respectively, and 3-keto-3-phenylpropionic acid in the presence of the cofactor pyridoxal phosphate.",PHARMACIA CORP,CHASE MATTHEW;;CLAYTON ROBERT;;LANDIS BRYAN;;BANERJEE AMIT,,https://lens.org/028-358-386-981-369,Patent Application,yes,9,5,8,8,2,C12P13/04;;C12P13/04;;C12N9/1096;;C12N9/1096;;C12P13/22;;C12P13/22;;C12P41/006;;C12P41/006,C12N9/10;;C12P13/04;;C12P13/22;;C12P41/00,435/106,0,0,,,,DISCONTINUED
44,WO,A1,WO 2024/025712 A1,074-121-291-585-745,2024-02-01,2024,US 2023/0026969 W,2023-07-06,US 202263392631 P,2022-07-27,CAPTURING MULTI-SPECTRAL IMAGES,A method for performing a screening includes illuminating a sample with light from a screen of a system at a first wavelength while the system is at a predetermined position with respect to the sample. The method also includes capturing a first image of the sample using a camera of the system while the system is at the predetermined position and the sample is illuminated with the light at the first wavelength. The method also includes illuminating the sample with the light from the screen at a second wavelength while the system is at the predetermined position. The method also includes capturing a second image of the sample using the camera while the system is at the predetermined position and the sample is illuminated with the light at the second wavelength. The method also includes combining the first and second images to produce a multi spectral image.,UNIV JOHNS HOPKINS,BROADWATER JOSHUA;;BANERJEE AMIT;;MATHEWS SIMON;;PASRICHA PANKAJ,,https://lens.org/074-121-291-585-745,Patent Application,yes,5,0,1,1,0,E03D11/13;;G01N33/50;;G06T7/00;;G01N21/31,G01N21/31;;E03D11/13;;G01N33/50;;G06T7/00,,0,0,,,,PENDING
45,US,A1,US 2013/0114868 A1,129-051-503-375-903,2013-05-09,2013,US 201213626301 A,2012-09-25,US 201213626301 A;;US 201161557708 P,2011-11-09,Hyperspectral Imaging for Detection of Skin Related Conditions,"A method of detecting a skin condition may include employing a multiband hyperspectral sensor to obtain multi-spectral data, employing the multi-spectral data to map constitutive skin parameters to corresponding spectral signatures via a forward model that enables generation of a set of samples including a plurality of parameters mapped to a plurality of spectral signatures, utilizing the set of samples to employ machine learning to generate an inverse model to enable mapping of a spectral signature of skin of a patient to corresponding skin parameters, estimatingconstitutive skin parameters of the skin of the patient based on the inverse model, and determining a distribution of the constitutive parameters for one or more skin locations.",BURLINA PHILIPPE M;;BANERJEE AMIT;;VYAS SAURABH;;GARZA LUIS;;UNIV JOHNS HOPKINS,BURLINA PHILIPPE M;;BANERJEE AMIT;;VYAS SAURABH;;GARZA LUIS,JOHNS HOPKINS UNIVERSITY (2012-09-24),https://lens.org/129-051-503-375-903,Patent Application,yes,1,9,2,2,0,G06T7/0012;;G06T2207/10048;;G06T2207/20081;;G06T2207/30088;;A61B5/0075;;A61B5/444;;G06V10/58;;A61B5/0075;;G06T7/0012;;G06T2207/10048;;G06T2207/30088;;G06T2207/20081;;A61B5/444;;G06V10/58,G06V10/58,382/128,2,2,037-985-948-746-125;;139-410-286-897-370,10.1364/ao.46.000357;;17228381;;10.1109/tgrs.2008.2005993,"Nakariyakul, Songyot, and David Casasent. ""Fusion algorithm for poultry skin tumor detection using hyperspectral data."" Applied optics 46.3 (2007): 357-364.;;Moser, Gabriele, and Sebastiano B. Serpico. ""Automatic parameter optimization for support vector regression for land and sea surface temperature estimation from remote sensing data."" Geoscience and Remote Sensing, IEEE Transactions on 47.3 (2009): 909-921.",ACTIVE
46,US,B2,US 8761476 B2,005-279-793-952-944,2014-06-24,2014,US 201213626301 A,2012-09-25,US 201213626301 A;;US 201161557708 P,2011-11-09,Hyperspectral imaging for detection of skin related conditions,"A method of detecting a skin condition may include employing a multiband hyperspectral sensor to obtain multi-spectral data, employing the multi-spectral data to map constitutive skin parameters to corresponding spectral signatures via a forward model that enables generation of a set of samples including a plurality of parameters mapped to a plurality of spectral signatures, utilizing the set of samples to employ machine learning to generate an inverse model to enable mapping of a spectral signature of skin of a patient to corresponding skin parameters, estimating constitutive skin parameters of the skin of the patient based on the inverse model, and determining a distribution of the constitutive parameters for one or more skin locations.",UNIV JOHNS HOPKINS,BURLINA PHILIPPE M;;BANERJEE AMIT;;VYAS SAURABH;;GARZA LUIS,JOHNS HOPKINS UNIVERSITY (2012-09-24),https://lens.org/005-279-793-952-944,Granted Patent,yes,14,4,2,2,0,G06T7/0012;;G06T2207/10048;;G06T2207/20081;;G06T2207/30088;;A61B5/0075;;A61B5/444;;G06V10/58;;A61B5/0075;;G06T7/0012;;G06T2207/10048;;G06T2207/30088;;G06T2207/20081;;A61B5/444;;G06V10/58,G06V10/58,382/128,2,2,037-985-948-746-125;;139-410-286-897-370,10.1364/ao.46.000357;;17228381;;10.1109/tgrs.2008.2005993,"Nakariyakul, Songyot, and David Casasent. ""Fusion algorithm for poultry skin tumor detection using hyperspectral data."" Applied optics 46.3 (2007): 357-364.;;Moser, Gabriele, and Sebastiano B. Serpico. ""Automatic parameter optimization for support vector regression for land and sea surface temperature estimation from remote sensing data."" Geoscience and Remote Sensing, IEEE Transactions on 47.3 (2009): 909-921.",ACTIVE
47,US,A1,US 2017/0013029 A1,012-292-033-493-79X,2017-01-12,2017,US 201514792190 A,2015-07-06,US 201514792190 A,2015-07-06,ACTUATION USING COLLABORATION MODELS IN AN INTERNET OF THINGS SETTING,"Methods and arrangements for determining one or more actions needed to execute a task communicated to a first device in an Internet of Things. At a first device in the Internet of Things, there is received a communication associated with a task. A data store is consulted for data associated with the task, and thereupon there is determined the present capability of the first device for executing the task collaboratively with at least one other device in the Internet of Things. The at least one other device is communicated with, to assess capability for executing the task collaboratively with the at least one other device. There are thereupon determined one or more actions of the first device that need to be taken to execute the task. Other variants and embodiments are broadly contemplated herein.",IBM,BANERJEE NILANJAN;;KOTHARI RAVI;;NANAVATI AMIT ANIL;;SINGH RAGHAVENDRA,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-05-13),https://lens.org/012-292-033-493-79X,Patent Application,yes,12,4,2,2,0,H04L65/403;;H04L67/12;;H04L67/303;;H04L69/24;;H04W4/70,H04L29/06,,0,0,,,,ACTIVE
48,US,A1,US 2017/0005874 A1,048-662-805-620-990,2017-01-05,2017,US 201514789458 A,2015-07-01,US 201514789458 A,2015-07-01,DISCOVERING CAPABILITIES OF ENTITIES IN AN INTERNET OF THINGS SETTING,"Methods and arrangements for data-driven discovery of collaborative models in an internet of things. At a device in the internet of things setting, data are collected on ambient conditions, and the collected data are stored at the device. At least one other device in the internet of things is communicated with to create and record collaborative states relative to the device and the at least one other device. Other variants and embodiments are broadly contemplated herein.",IBM,BANERJEE NILANJAN;;KOTHARI RAVI;;NANAVATI AMIT ANIL;;SINGH RAGHAVENDRA,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-04-28),https://lens.org/048-662-805-620-990,Patent Application,yes,7,12,2,2,0,H04L67/125;;H04L67/51;;H04L67/125;;H04L67/51,H04L12/24;;H04L12/26,,0,0,,,,ACTIVE
49,AU,A4,AU 2021/100741 A4,101-233-316-750-30X,2021-04-29,2021,AU 2021/100741 A,2021-02-06,AU 2021/100741 A,2021-02-06,A HEAT TREATMENT METHOD FOR SYNTHESIZING NANOCRYSTALLINE HYDROXYAPATITE FROM LABEO ROHITA FISH SCALES,"The present disclosure relates to a heat treatment method for synthesizing nanocrystalline hydroxyapatite from Labeo Rohita fish scales. The nanocrystalline hydroxyapatite (nHAp) is synthesized from Labeo Rohita fish scales by calcination of raw scales at temperatures ranges from 400 to 1000degree Celsius. The synthesized powders are characterized using, X ray diffraction (XRD), Thermogravimetric/Differential Thermal Analyzer (TG-DTA), Fourier transform infrared spectroscopy (FT-IR), Scanning and high-resolution transmission Electron Microscope (SEM, HRTEM) and Energy-dispersive X-ray analysis (EDX), respectively. Crystallite size, crystallinity, lattice parameters of HAp are evaluated from XRD and it is shown that the average crystallite sizes are significantly get enhanced with the calcination temperature attending its maximum value at ~ 40 nm. TG-DTA analysis predicts the thermal stability of the samples and it has been observed that the thermal stability increases with the calcination temperature. (N ( C0 co C) C C C C) 0) x E r0 C: m (0 -~ 0)0 C (0 2( O CC 'n Co0 0 0i- 0 -LU u o0 a. i cU 00> 0 Q( > 0 ) 0) -C -p4f 0) c) 0)> 0 u D to 0i 00 E0 E. (D 00 (04-~- 0wi ( 00 Ln 0) 0 0 0) U> C0) -~0 (0 (0 (0D x -X UL 0 c0 a. E c to) -0~ (0 C)C T(0",BANERJEE DIPTONIL DR;;CHOWDHURY AMIT ROY;;PAL ANINDYA;;SINHA ARIJIT,BANERJEE DIPTONIL;;SINHA ARIJIT;;PAL ANINDYA;;CHOWDHURY AMIT ROY,,https://lens.org/101-233-316-750-30X,Limited Patent,no,0,0,1,1,0,C01B25/32;;C01P2002/85;;C01P2002/82;;C01P2002/74;;A61L27/12;;C01P2004/04;;C01P2004/64;;C01P2004/03,C01B25/32;;A61L27/12,,0,0,,,,INACTIVE
50,WO,A3,WO 2005/005633 A3,000-168-043-433-009,2005-05-12,2005,IB 2004002183 W,2004-06-30,US 48603203 P;;US 49962203 P,2003-07-10,METHODS FOR THE STEREOSELECTIVE SYNTHESIS AND ENANTIOMERIC ENRICHMENT OF B-AMINO ACIDS,"The present invention relates to methods for the stereospecific synthesis and for the enantiomeric enrichment of Beta-amino acids. A novel D-Beta-aminotransferase, which exhibits stereoselectivity for D-Beta phenyalanine D-3-amino-3-phenylpropanoic acid, was purified from a newly-isolated strain of Variovorax paradoxus. A novel L-Beta- aminotransferase was purified from a newly-isolated strain of Alcaligenes eutrophus. The D- and L-Beta-aminotransferases can be used to facilitate the stereoselective biosynthesis of Beta-D-phenylalanine or Beta-L-phenylalanine, from a mixture of L-glutamic acid or L-alanine, respectively, and 3-keto-3-phenypropanoic acid in the presence of the cofactor pyridoxal photephate.",PHARMACIA CORP;;BANERJEE AMIT;;CHASE MATTHEW;;CLAYTON ROBERT A;;LANDIS BRYAN,BANERJEE AMIT;;CHASE MATTHEW;;CLAYTON ROBERT A;;LANDIS BRYAN,,https://lens.org/000-168-043-433-009,Search Report,yes,4,0,8,8,0,C12P13/04;;C12P13/04;;C12N9/1096;;C12N9/1096;;C12P13/22;;C12P13/22;;C12P41/006;;C12P41/006,C12N9/10;;C12P13/04;;C12P13/22;;C12P41/00,,15,11,019-655-774-230-043;;013-207-795-385-848;;054-153-055-876-808;;059-786-641-171-028;;005-720-447-621-40X;;104-211-101-705-722;;052-564-087-828-521;;077-404-411-991-131;;116-017-383-219-947;;050-974-754-957-642;;004-355-132-886-180,10989446;;10.1016/s0076-6879(00)24247-x;;10.1016/0003-9861(79)90240-6;;44448;;13712439;;10.1016/s0021-9258(18)64309-1;;10.1271/bbb.65.1782;;11577718;;10.1021/jo9613500;;10.1016/0957-4166(95)00204-3;;10.1055/s-1993-22447;;10.1016/s0040-4039(00)00222-7;;10.1016/s0040-4020(02)00991-2;;10.1139/w01-062;;11547884;;10.1139/cjm-47-7-642;;pmc383019;;10.1128/aem.70.4.2529-2534.2004;;15066855,"""EC 2.6.1.18"", XP002296512, Retrieved from the Internet <URL:http://www.brenda.uni-koeln.de/php/result_flat.php4?ecno=2.6.1.18> [retrieved on 20040915];;""EC 2.6.1.19"", XP002296513, Retrieved from the Internet <URL:http://www.brenda.uni-koeln.de/php/result_flat.php4?ecno=2.6.1.19> [retrieved on 20040915];;""EC 2.6.1.22"", XP002296514, Retrieved from the Internet <URL:http://www.brenda.uni-koeln.de/php/result_flat.php4?ecno=2.6.1.22> [retrieved on 20040915];;STIRLING D I: ""The use of aminotransferases for the production of chiral amino acids and amines"", CHIRALITY IND. EDITOR(S): COLLINS, ANDREW N.; SHELDRAKE, G. N.; CROSBY, J. PUBLISHER: WILEY, CHICHESTER, UK., 1992, pages 209 - 222, XP008035258;;TAMAKI N ET AL: ""Purification, properties, and sequencing of aminoisobutyrate aminotransferases from rat liver."", METHODS IN ENZYMOLOGY. 2000, vol. 324, 2000, pages 376 - 389, XP008035446, ISSN: 0076-6879;;BOZLER G ET AL: ""Metabolism of L-beta-lysine in a Pseudomonas: conversion of 6-N-acetyl-L-beta-lysine to 3-keto-6-acetamidohexanoate and of 4-aminobutyrate to succinic semialdehyde by different transaminases."", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 197, no. 1, 1 October 1979 (1979-10-01), pages 226 - 235, XP008035384, ISSN: 0003-9861;;HAYAISHI O ET AL: ""Enzymatic studies on the metabolism of beta-alanine"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 236, no. 3, March 1963 (1963-03-01), pages 781 - 790, XP002296515;;SHIN J-S ET AL: ""Comparison of the omega-transaminases from different microorganisms and application to production of chiral amines"", BIOSCIENCE BIOTECHNOLOGY BIOCHEMISTRY, vol. 65, no. 8, August 2001 (2001-08-01), pages 1782 - 1788, XP009010899, ISSN: 0916-8451;;CARDILLO G ET AL: ""Enzymatic resolution of alpha-alkyl beta-amino acids using immobilized penicillin G acylase"", JOURNAL OF ORGANIC CHEMISTRY, vol. 61, no. 24, 1996, pages 8651 - 8654, XP002072500, ISSN: 0022-3263;;SOLOSHONOK V A ET AL: ""Biocatalytic Approach to Enantiomerically Pure beta-Amino Acids"", TETRAHEDRON: ASYMMETRY, vol. 6, no. 7, 1 July 1995 (1995-07-01), pages 1601 - 1610, XP004048135, ISSN: 0957-4166;;SOLOSHONOK V A ET AL: ""An enzymatic entry to enantiopure .beta.-amino acids"", SYNLETT, vol. 5, 1993, pages 339 - 341, XP001194878;;FAULCONBRIDGE S J ET AL: ""Preparation of enantiomerically enriched aromatic beta-amino acids via enzymatic resolution"", TETRAHEDRON LETTERS, vol. 41, no. 15, April 2000 (2000-04-01), pages 2679 - 2681, XP004194578, ISSN: 0040-4039;;LIU M ET AL: ""Recent advances in the stereoselective synthesis of beta-amino acids"", TETRAHEDRON, vol. 58, no. 40, 30 September 2002 (2002-09-30), pages 7991 - 8035, XP004383841, ISSN: 0040-4020;;BELIMOV A A ET AL: ""Characterization of plant growth promoting rhizobacteria isolated from polluted soils and containing 1-aminocyclopropane-1-carboxylate deaminase"", CANADIAN JOURNAL OF MICROBIOLOGY, vol. 47, no. 7, July 2001 (2001-07-01), pages 642 - 652, XP008035482, ISSN: 0008-4166;;YUN H ET AL: ""Omega-amino acid:pyruvate transaminase from Alcaligenes denitrificans Y2k-2: a new catalyst for kinetic resolution of beta-amino acids and amines"", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 70, no. 4, April 2004 (2004-04-01), pages 2529 - 2534, XP009029815, ISSN: 0099-2240",PENDING
51,US,B2,US 10938910 B2,155-886-223-067-584,2021-03-02,2021,US 201514789458 A,2015-07-01,US 201514789458 A,2015-07-01,Discovering capabilities of entities in an internet of things setting,"Methods and arrangements for data-driven discovery of collaborative models in an internet of things. At a device in the internet of things setting, data are collected on ambient conditions, and the collected data are stored at the device. At least one other device in the internet of things is communicated with to create and record collaborative states relative to the device and the at least one other device. Other variants and embodiments are broadly contemplated herein.",IBM,BANERJEE NILANJAN;;KOTHARI RAVI;;NANAVATI AMIT ANIL;;SINGH RAGHAVENDRA,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-04-28),https://lens.org/155-886-223-067-584,Granted Patent,yes,21,0,2,2,0,H04L67/125;;H04L67/51;;H04L67/125;;H04L67/51,H04L29/08,,2,0,,,"mathworks.com, Anatomy of a Lookup Table, Apr. 18, 2014 (1 page).;;en.wikipedia.org, Lookup table, Jun. 18, 2013 (7 pages).",ACTIVE
52,US,B1,US 8495705 B1,058-509-856-070-310,2013-07-23,2013,US 76359310 A,2010-04-20,US 76359310 A,2010-04-20,Systems and methods for reputation-based application of data-loss prevention policies,"A computer-implemented method for data-loss prevention may include: 1) identifying data associated with a user, 2) determining that the data is subject to a data-loss-prevention scan, 3) identifying a data-loss-prevention reputation associated with the user, and then 4) performing a data-loss-prevention operation based at least in part on the data-loss-prevention reputation associated with the user. Various other methods, systems, and computer-readable media are also disclosed.",VERMA AMIT;;BANERJEE ANINDYA;;CHOUDHURY RAJORSHI GHOSH;;JAISWAL SUMESH;;SYMANTEC CORP,VERMA AMIT;;BANERJEE ANINDYA;;CHOUDHURY RAJORSHI GHOSH;;JAISWAL SUMESH,SYMANTEC CORPORATION (2010-04-20);;CA INC (2019-11-04),https://lens.org/058-509-856-070-310,Granted Patent,yes,3,33,1,1,0,G06Q10/06;;G06Q10/06;;G06Q10/10;;G06Q10/10,G06F7/04;;G06F17/30,726/2;;726/1;;726/16;;726/17;;726/18;;726/19;;726/21;;726/26;;726/30;;726/33;;713/182;;713/185;;711/163;;711/164,1,0,,,"ThreatSeeker Network-Foundation of the Websense Technology; www.websense.com/content/ThreatSeeker.aspx; taken from site on Feb. 22, 2010.",ACTIVE
53,CA,A1,CA 2529509 A1,119-519-634-902-193,2005-01-20,2005,CA 2529509 A,2004-06-30,US 48603203 P;;US 49962203 P;;IB 2004002183 W,2003-07-10,METHODS FOR THE STEREOSELECTIVE SYNTHESIS AND ENANTIOMERIC ENRICHMENT OF B-AMINO ACIDS,"The present invention relates to methods for the stereospecific synthesis an d for the enantiomeric enrichment of Beta-amino acids. A novel D-Beta- aminotransferase, which exhibits stereoselectivity for D-Beta phenyalanine D -3- amino-3-phenylpropanoic acid, was purified from a newly-isolated strain of Variovorax paradoxus. A novel L-Beta- aminotransferase was purified from a newly-isolated strain of Alcaligenes eutrophus. The D- and L-Beta- aminotransferases can be used to facilitate the stereoselective biosynthesis of Beta-D-phenylalanine or Beta-L-phenylalanine, from a mixture of L-glutami c acid or L-alanine, respectively, and 3-keto-3-phenypropanoic acid in the presence of the cofactor pyridoxal photephate.",PHARMACIA CORP,CHASE MATTHEW;;LANDIS BRYAN;;CLAYTON ROBERT A;;BANERJEE AMIT,,https://lens.org/119-519-634-902-193,Patent Application,no,0,0,8,8,2,C12P13/04;;C12P13/04;;C12N9/1096;;C12N9/1096;;C12P13/22;;C12P13/22;;C12P41/006;;C12P41/006,C12N15/11;;C12N9/10;;C12P13/04;;C12P13/22;;C12P41/00;;C12Q1/68,,0,0,,,,DISCONTINUED
54,WO,A2,WO 2005/005633 A2,139-084-655-166-282,2005-01-20,2005,IB 2004002183 W,2004-06-30,US 48603203 P;;US 49962203 P,2003-07-10,METHODS FOR THE STEREOSELECTIVE SYNTHESIS AND ENANTIOMERIC ENRICHMENT OF B-AMINO ACIDS,"The present invention relates to methods for the stereospecific synthesis and for the enantiomeric enrichment of Beta-amino acids. A novel D-Beta-aminotransferase, which exhibits stereoselectivity for D-Beta phenyalanine D-3-amino-3-phenylpropanoic acid, was purified from a newly-isolated strain of Variovorax paradoxus. A novel L-Beta- aminotransferase was purified from a newly-isolated strain of Alcaligenes eutrophus. The D- and L-Beta-aminotransferases can be used to facilitate the stereoselective biosynthesis of Beta-D-phenylalanine or Beta-L-phenylalanine, from a mixture of L-glutamic acid or L-alanine, respectively, and 3-keto-3-phenypropanoic acid in the presence of the cofactor pyridoxal photephate.",PHARMACIA CORP;;BANERJEE AMIT;;CHASE MATTHEW;;CLAYTON ROBERT A;;LANDIS BRYAN,BANERJEE AMIT;;CHASE MATTHEW;;CLAYTON ROBERT A;;LANDIS BRYAN,,https://lens.org/139-084-655-166-282,Patent Application,yes,0,31,8,8,2,C12P13/04;;C12P13/04;;C12N9/1096;;C12N9/1096;;C12P13/22;;C12P13/22;;C12P41/006;;C12P41/006,C12N9/10;;C12P13/04;;C12P13/22;;C12P41/00,,0,0,,,,PENDING
55,US,B2,US 10812541 B2,080-146-537-751-271,2020-10-20,2020,US 201514792190 A,2015-07-06,US 201514792190 A,2015-07-06,Actuation using collaboration models in an internet of things setting,"Methods and arrangements for determining one or more actions needed to execute a task communicated to a first device in an Internet of Things. At a first device in the Internet of Things, there is received a communication associated with a task. A data store is consulted for data associated with the task, and thereupon there is determined the present capability of the first device for executing the task collaboratively with at least one other device in the Internet of Things. The at least one other device is communicated with, to assess capability for executing the task collaboratively with the at least one other device. There are thereupon determined one or more actions of the first device that need to be taken to execute the task. Other variants and embodiments are broadly contemplated herein.",IBM,BANERJEE NILANJAN;;KOTHARI RAVI;;NANAVATI AMIT ANIL;;SINGH RAGHAVENDRA,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-05-13),https://lens.org/080-146-537-751-271,Granted Patent,yes,21,0,2,2,0,H04L65/403;;H04L67/12;;H04L67/303;;H04L69/24;;H04W4/70,H04L29/06,,0,0,,,,ACTIVE
56,US,B1,US 6191963 B1,128-568-205-387-899,2001-02-20,2001,US 48806900 A,2000-01-19,US 48806900 A,2000-01-19,Charge pump with no diode drop at output stage,"An integrated circuit-based charge pump generates an output voltage having a greater magnitude than a power supply voltage. The charge pump has a charge pump section having a plurality of alternating stages driven by first and second alternating, non-overlapping clock signals, said plurality of alternating stages including an input stage for receiving the power supply voltage and an output stage for generating at a last stage node a last stage voltage having a greater magnitude than the power supply voltage. A gating transistor is coupled at a drain terminal to the last stage node, wherein the gating transistor is clocked by one of said clock signals and is biased so that the gating transistor, during a boost phase, gates the last stage voltage to a load coupled to the source terminal of the gating transistor without a voltage drop and, at other times, turns off to prevent charge from flowing from the load into the last stage node of the charge pump section.",LUCENT TECHNOLOGIES INC,MCPARTLAND RICHARD JOSEPH;;BANERJEE AMIT KUMAR;;LOEPER DUANE J,AVAGO TECHNOLOGIES GENERAL IP (SINGAPORE) PTE. LTD (2014-08-04);;AVAGO TECHNOLOGIES INTERNATIONAL SALES PTE. LIMITED (2018-05-09);;LUCENT TECHNOLOGIES INC (2000-01-18),https://lens.org/128-568-205-387-899,Granted Patent,yes,6,19,1,1,0,H02M3/073;;H02M3/073,H02M3/07,363/60;;307/111;;307/390;;307/536,1,1,002-415-685-920-536,10.1109/4.663564,"Jieh-Tsorng Wu, et al., ""MOS Charge Pumps for Low-Voltage Operation,"" IEEE Journal of Solid-State Circuits, vol. 33, No. 4, Apr. 1998, pp. 592-597.",EXPIRED
57,BR,A,BR PI0412308 A,055-162-961-267-706,2006-06-20,2006,BR PI0412308 A,2004-06-30,US 48603203 P;;US 49962203 P;;IB 2004002183 W,2003-07-10,métodos para a sìntese estereosseletiva e enriquecimento enantiomérico de ß-aminoácidos,"""MéTODOS PARA A SìNTESE ESTEREOSSELETIVA E ENRIQUECIMENTO ENANTIOMéRICO DE <225>-AMINOáCIDOS"". A presente invenção refere-se a métodos para a síntese estereoespecífica e para o enriquecimento enantiomérico de beta-aminoácidos. Uma nova D-beta-aminotransferase, que apresenta estereosseletividade para D-beta-fenilalanina, (ácido D-3-amino-3-fenilpropanóico) , foi purificada a partir de uma nova cepa isolada de Variovorax paradoxus. uma nova L-beta-aminotransferase foi purificada a partir de uma nova cepa isolada de Alcaligenes eutrophus. As D- e L-beta-aminotransferases podem ser utilizadas para facilitar a biossíntese estereosseletiva de beta-D-fenilalanina ou beta-L-fenilalanina, a partir de uma mistura de ácido L-glutâmico ou L-alanina, respectivamente, e ácido 3-ceto-3-fenilpropanóico na presença do cofator piridoxal fosfato.",PHARMACIA CORP,BANERJEE AMIT;;CHASE MATTHEW;;CLAYTON ROBERT A;;LANDIS BRYAN,,https://lens.org/055-162-961-267-706,Patent Application,no,0,0,8,8,0,C12P13/04;;C12P13/04;;C12N9/1096;;C12N9/1096;;C12P13/22;;C12P13/22;;C12P41/006;;C12P41/006,C12N9/10;;C12P13/04;;C12P13/22;;C12P41/00,,0,0,,,,DISCONTINUED
58,CN,A,CN 114258325 A,154-969-674-493-475,2022-03-29,2022,CN 202080057151 A,2020-08-18,GB 201912400 A;;IB 2020057759 W,2019-08-29,Cyclone separator,"A cyclone separator (10) includes a separation chamber (14), a feed inlet (16) leading to the separation chamber, and an underflow outlet (18) leading from the separation chamber. The cyclone separator further includes an eddy current probe (20) having an inlet end positioned in the separation chamber, an outlet end defining an overflow outlet, and a discharge opening (48) defined by the inlet end and the outlet end of the eddy current probe, and a portion of the overflow may be discharged from the eddy current detector through the discharge opening to remove overlarge particles from the overflow.",WEER MINERAL AFRICAN PRIVATE CO LTD,BANERJEE CHANDRANATH;;CEPEDA EDUARDO;;JOSHI NIAMH BALACHANDRA;;MURALIDHARA AMIT TIRUMALLE,,https://lens.org/154-969-674-493-475,Patent Application,no,7,0,15,15,0,B04C5/00;;B04C5/04;;B04C5/12;;B04C11/00;;B04C5/13;;B04C11/00;;B04C2005/133;;B04C5/181;;B04C5/13;;B04C5/04;;B04C5/103;;B04C5/28;;B04C2005/133,B04C5/00;;B04C5/04;;B04C5/12;;B04C11/00,,0,0,,,,PENDING
59,WO,A1,WO 2018/075679 A1,199-015-106-484-111,2018-04-26,2018,US 2017/0057249 W,2017-10-18,US 201662409769 P,2016-10-18,HYPERSPECTRAL IMAGING FOR PASSIVE DETECTION OF COLORECTAL CANCERS,"A method of detecting colorectal cancers using a hyperspectral sensor system includes receiving a training set of hyperspectral data from colorectal tissue that includes known normal and known cancerous tissue using the hyperspectral sensor system, applying a machine learning algorithm to the training set of hyperspectral data to provide predictor parameters for one of cancerous tissue or non-cancerous tissue, receiving measurement hyperspectral data from colorectal tissue of interest, and using the predictor parameters to classify the colorectal tissue of interest as one of cancerous tissue or non-cancerous tissue. The training set of hyperspectral data and the measurement hyperspectral data include reflection spectra across wavelength bands of light that include at least visible, near infrared and short-wave infrared regions of the electromagnetic spectrum.",UNIV JOHNS HOPKINS,BEAULIEU ROBERT;;GOLDSTEIN SETH;;SAFAR BASHAR;;BANERJEE AMIT;;AHUJA NITA,,https://lens.org/199-015-106-484-111,Patent Application,yes,5,9,2,2,0,A61B5/0084;;A61B5/4255;;A61B5/0071;;A61B5/0071;;A61B5/0075;;A61B5/0075;;A61B5/0084;;A61B5/4255;;A61B5/7267;;A61B5/7267;;A61B5/7275;;G16H50/70,A61B5/00,,0,0,,,,PENDING
60,US,A1,US 2018/0311241 A1,044-013-375-243-05X,2018-11-01,2018,US 201615771334 A,2016-10-20,IN 4103MU2015 A;;IB 2016056311 W,2015-10-29,PHARMACEUTICAL SYNERGISTIC COMBINATION,The present invention describes a synergistic composition comprising of Fimasartan or pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof for the treatment of cardiovascular and related disease. The present invention is directed to a synergistic combination comprising combinations of Fimasartan or suitable pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The present invention is further directed to combinations of Fimasartan or a pharmaceutically effective salt thereof and a NEP inhibitor or a pharmaceutically effective salt thereof. The invention also relates to combining separate pharmaceutical compositions of Fimasartan and a NEP inhibitor in kit form. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.,CADILA HEALTHCARE LTD,JAIN MUKUL;;BANERJEE KAUSHIK;;JOHARAPURKAR AMIT;;PANDYA ARTI;;PATEL VISHAL,CADILA HEALTHCARE LIMITED (2018-04-24),https://lens.org/044-013-375-243-05X,Patent Application,yes,0,0,4,4,0,A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61P9/00;;A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61K2300/00,A61K31/513,,0,0,,,,DISCONTINUED
61,FI,A0,FI 934874 A0,111-034-932-802-776,1993-11-04,1993,FI 934874 A,1993-11-04,US 97228692 A,1992-11-05,Stereoselektiv reducering av ketoner,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;SZARKA LASZLO J,,https://lens.org/111-034-932-802-776,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;A61K31/18;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,PENDING
62,AR,A1,AR 106477 A1,087-577-533-604-433,2018-01-17,2018,AR P160103263 A,2016-10-26,IN 4102MU2015 A,2015-10-29,COMBINACIÓN FARMACÉUTICA DE ANTAGONISTA DEL RECEPTOR NK3 Y BIGUANIDAS,"Una composición sinérgica conformada por antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas, para el tratamiento de PCOS y trastornos relacionados. Combinación sinérgica que comprende combinaciones de un antagonista del receptor NK3 o sus sales farmacéuticamente efectivas, y biguanidas o sus sales farmacéuticamente efectivas en una composición farmacéutica en una sola unidad. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con dicha composición. Reivindicación 2: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque el antagonista del receptor NK3 se selecciona entre Talnetant (SB223412), AZD-4901 y AZD-2624. Reivindicación 3: La composición sinérgica de acuerdo con la reivindicación 1, caracterizada porque las biguanidas son Metformina.",CADILA HEALTHCARE LTD,SAMADHAN KSHIRSAGAR;;ARTI PANDYA;;AMIT JOHARAPURKAR;;KAUSHIK BANERJEE;;MUKUL JAIN,,https://lens.org/087-577-533-604-433,Patent Application,no,0,0,3,3,0,A61K31/155;;A61K31/47;;A61P13/08;;A61P15/08;;A61P17/10;;A61P17/14;;A61P5/00;;A61P5/28,A61K31/155;;A61K31/47;;A61P5/00,,0,0,,,,PENDING
63,EP,A3,EP 0538693 A3,062-189-717-787-244,1994-08-17,1994,EP 92117282 A,1992-10-09,US 78162891 A,1991-10-23,STEREOSELECTIVE PREPARATION OF HALOPHENYL ALCOHOLS,"A process is described for selectively preparing a compound of the formula
  
 wherein:
 R¹ is halogen; R² is halogen, alkyl, cycloalkyl, aryl or
   and R³ is hydrogen, alkyl, cycloalkyl, aryl, or  
 wherein the process comprises treating the associated ketone with an oxido-reductase or a microorganism comprising an oxidoreductase. Compounds prepared by this process are useful antipsychotic agents or useful intermediates therefor.",SQUIBB & SONS INC,PATEL RAMESH N;;LIU MARK;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/062-189-717-787-244,Search Report,yes,5,0,5,5,0,C12P17/165;;C12P17/165;;C12P7/22;;C12P7/22;;C12P17/12;;C12P17/12,C07D239/42;;C12P7/22;;C12P17/12;;C12P17/16;;C12R1/01;;C12R1/06;;C12R1/365;;C12R1/645;;C12R1/72;;C12R1/78;;C12R1/865,,0,0,,,,DISCONTINUED
64,AR,A1,AR 106478 A1,079-772-082-742-821,2018-01-17,2018,AR P160103264 A,2016-10-26,IN 4103MU2015 A,2015-10-29,COMBINACIÓN SINÉRGICA FARMACÉUTICA,"Composición sinérgica conformada por Fimasartán o sus sales farmacéuticamente efectivas, y un inhibidor de NEP o sus sales farmacéuticamente efectivas, para el tratamiento de enfermedades cardiovasculares y enfermedades relacionadas. Combinación sinérgica que comprende combinaciones de Fimasartán o sus sales farmacéuticamente efectivas adecuadas, y un inhibidor de NEP o sus sales farmacéuticamente efectivas, en una composición farmacéutica en una sola unidad. Combinar las composiciones farmacéuticas separadas de Fimasartán y un inhibidor de NEP en forma de kit. Métodos para preparar dichas composiciones farmacéuticas por separado en forma de kit que contiene ambos agentes activos, y con métodos para tratar un sujeto con las mismas. Reivindicación 2: La composición farmacéutica de acuerdo con la reivindicación 1, caracterizada porque el inhibidor de NEP es ácido (4-[[(2S,4R)-5-etoxi-4-metil-5-oxo-1-(4-fenilfenil)pentan-2-il]amino]-4-oxobutanoico o una sal farmacéuticamente aceptable del mismo.",CADILA HEALTHCARE LTD,VISHAL PATEL;;ARTI PANDYA;;AMIT JOHARAPURKAR;;KAUSHIK BANERJEE;;MUKUL JAIN,,https://lens.org/079-772-082-742-821,Patent Application,no,0,0,4,4,0,A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61P9/00;;A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61K2300/00,A61K31/513;;A61K31/216;;A61P9/00,,0,0,,,,PENDING
65,TW,A,TW 201729801 A,070-018-037-620-604,2017-09-01,2017,TW 105134674 A,2016-10-27,IN 4103MU2015 A,2015-10-29,Pharmaceutical synergistic combination,The present invention describes a synergistic composition comprising of Fimasartan or pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof for the treatment of cardiovascular and related disease. The present invention is directed to a synergistic combination comprising combinations of Fimasartan or suitable pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The present invention is further directed to combinations of Fimasartan or a pharmaceutically effective salt thereof and a NEP inhibitor or a pharmaceutically effective salt thereof. The invention also relates to combining separate pharmaceutical compositions of Fimasartan and a NEP inhibitor in kit form. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.,CADILA HEALTHCARE LTD,JAIN MUKUL;;BANERJEE KAUSHIK;;JOHARAPURKAR AMIT;;PANDYA ARTI;;PATEL VISHAL,,https://lens.org/070-018-037-620-604,Patent of Addition,no,0,0,4,4,0,A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61P9/00;;A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61K2300/00,A61K31/216;;A61K31/506,,0,0,,,,PENDING
66,WO,A1,WO 2017/072636 A1,171-064-627-655-275,2017-05-04,2017,IB 2016056311 W,2016-10-20,IN 4103MU2015 A,2015-10-29,PHARMACEUTICAL SYNERGISTIC COMBINATION,The present invention describes a synergistic composition comprising of Fimasartan or pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof for the treatment of cardiovascular and related disease. The present invention is directed to a synergistic combination comprising combinations of Fimasartan or suitable pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The present invention is further directed to combinations of Fimasartan or a pharmaceutically effective salt thereof and a NEP inhibitor or a pharmaceutically effective salt thereof. The invention also relates to combining separate pharmaceutical compositions of Fimasartan and a NEP inhibitor in kit form. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.,CADILA HEALTHCARE LTD,JAIN MUKUL;;BANERJEE KAUSHIK;;JOHARAPURKAR AMIT;;PANDYA ARTI;;PATEL VISHAL,,https://lens.org/171-064-627-655-275,Patent Application,yes,25,0,4,4,0,A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61P9/00;;A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12;;A61K31/513;;A61K2300/00,A61K31/216;;A61K31/506;;A61K45/06;;A61P9/12,,27,14,056-406-340-097-34X;;024-078-737-015-049;;058-822-332-718-80X;;095-334-296-537-065;;020-568-941-300-732;;033-354-342-407-317;;021-582-017-358-389;;007-046-885-438-606;;022-769-848-132-213;;016-811-716-559-046;;001-193-187-110-197;;019-285-181-579-666;;028-626-720-362-730;;035-974-608-405-926,10.1016/j.clinthera.2014.07.004;;25092393;;10.1517/13543784.2013.797963;;23663006;;10.1016/s0895-7061(97)00101-5;;9231889;;12186794;;10.1161/01.cir.0000029801.86489.50;;10.1111/j.1742-4658.2011.08082.x;;21375692;;pmc4495883;;10.1111/j.1476-5381.1994.tb16194.x;;pmc1510039;;7812611;;9260978;;10.1161/01.hyp.30.2.184;;7895362;;10.1161/01.cir.91.7.2036;;7581258;;10.3109/10641969509033640;;pmc3427981;;22937486;;10.1016/s0031-3955(05)70115-2;;10218072;;10645931;;10.1161/01.cir.101.3.329;;21366845;;pmc8673364;;10.1111/j.1751-7176.2010.00397.x;;pmc3025398;;10.1155/2011/729497;;21274403,"YOUN JONG-CHAN ET AL: ""Efficacy and Safety of 30-Mg Fimasartan for the Treatment of Patients With Mild to Moderate Hypertension: An 8-Week, Multicenter, Randomized, Double-Blind, Phase III Clinical Study"", CLINICAL THERAPEUTICS, vol. 36, no. 10, 3 August 2014 (2014-08-03), EXCERPTA MEDICA, PRINCETON, NJ, US, pages 1412 - 1421, XP029082032, ISSN: 0149-2918, DOI: 10.1016/J.CLINTHERA.2014.07.004;;VOORS A A ET AL: ""The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure"", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 22, no. 8, 1 January 2013 (2013-01-01), INFORMA HEALTHCARE, UK, pages 1041 - 1047, XP009173461, ISSN: 1354-3784, DOI: 10.1517/13543784.2013.797963;;DATABASE WPI Week 201667, Derwent World Patents Index; AN 2016-41575S, XP002766281;;WABER B, AMERICAN JOURNAL OF HYPERTENSION, vol. 10, no. 7.2, 1997, pages 131S - 137S;;J HUM HYPERTENS, vol. 9, no. 5, November 1995 (1995-11-01), pages 19 - 24;;DRUGS, vol. 39, no. 2, 1990, pages 11 - 6;;J SURG RES, vol. 128, no. 1, 2005, pages 21 - 27;;J CARDIOVASC PHARMACOL, vol. 46, no. 3, 2005, pages 390 - 397;;CIRCULATION, vol. 106, no. 8, 2002, pages 920 - 926;;JOURNAL OF CARDIOLOGY, vol. 57, 2011, pages 131 - 140;;FEBS JOURNAL, vol. 278, 2011, pages 1808 - 1817;;BR J PHARMACOL, vol. 113, pages 204 - 208;;HYPERTENSION, vol. 30, pages 184 - 190;;PHYSIOL, vol. 271, pages R373 - R380;;CIRCULATION, vol. 91, pages 2036 - 2042;;CLIN EXP HYPERTENS, vol. 17, pages 861 - 876;;BR J PHARMACOL., vol. 107, no. 1, September 1992 (1992-09-01), pages 50 - 7;;AM J CARDIOVASC DIS, vol. 2, no. 3, 2012, pages 160 - 170;;PEDIATR CLIN NORTH AM, vol. 46, no. 2, 1999, pages 235 - 252;;CIRCULATION, vol. 101, no. 3, 2000, pages 329 - 335;;ENVIRON HEALTH PERSPECT, vol. 108, no. 3, 2000, pages 545 - 553;;J CLIN HYPERTENS (GREENWICH, vol. 13, 2011, pages 146 - 154;;CURR OPIN NEPHROL HYPERTENS, vol. 21, no. 5, September 2012 (2012-09-01), pages 486 - 91;;LEE SE, CLIN THER., vol. 34, no. 3, 2012, pages 552 - 68,68 EL-9;;J BIOMED BIOTECHNOL. 2011, 2011, pages 729497;;APMIS, vol. 100, no. 12, December 1992 (1992-12-01), pages 1097 - 105;;INTERNATIONAL JOURNAL OF UROLOGY, vol. 22, 2015, pages 797 - 804",PENDING
67,WO,A1,WO 2017/072629 A1,171-212-089-513-166,2017-05-04,2017,IB 2016056271 W,2016-10-19,IN 4102MU2015 A,2015-10-29,PHARMACEUTICAL COMBINATION OF NK3 RECEPTOR ANTAGONIST AND BIGUANIDES,The present invention describes a synergistic composition comprising of NK3 receptor antagonist or a pharmaceutically effective salts thereof and biguanides or a pharmaceutically effective salts thereof for the treatment of PCOS and related diseases. The present invention is directed to a synergistic combination comprising combinations of a NK3 receptor antagonist or pharmaceutically effective salts thereof and biguanides or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.,CADILA HEALTHCARE LTD,JAIN MUKUL;;BANERJEE KAUSHIK;;JOHARAPURKAR AMIT;;PANDYA ARTI;;KSHIRSAGAR SAMADHAN,,https://lens.org/171-212-089-513-166,Patent Application,yes,16,1,3,3,0,A61K31/155;;A61K31/47;;A61P13/08;;A61P15/08;;A61P17/10;;A61P17/14;;A61P5/00;;A61P5/28,A61K31/155;;A61K31/47;;A61P5/00,,11,5,050-931-814-183-846;;042-821-576-710-796;;099-534-446-411-903;;179-351-083-477-441;;047-123-922-042-983,15941616;;10.1016/j.ejogrb.2004.09.015;;10.2165/00003495-199958001-00010;;10576524;;24151290;;10.1210/jc.2013-2350;;pmc5399492;;10352920;;10.1016/s0889-8529(05)70071-2;;26117684;;10.1093/humupd/dmv029,"MARCA A L ET AL: ""Metformin treatment of PCOS during adolescence and the reproductive period"", EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, ELSEVIER IRELAND LTD, IE, vol. 121, no. 1, 1 July 2005 (2005-07-01), pages 3 - 7, XP027604613, ISSN: 0301-2115, [retrieved on 20050701];;PUGEAT M ET AL: ""INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME AND METFORMIN"", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 58, no. SUPPL. 01, 1 January 1999 (1999-01-01), pages 41 - 46, XP009012355, ISSN: 0012-6667, DOI: 10.2165/00003495-199958001-00010;;RICHARD S. LEGRO ET AL: ""Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline"", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 98, no. 12, 1 December 2013 (2013-12-01), US, pages 4565 - 4592, XP055343755, ISSN: 0021-972X, DOI: 10.1210/jc.2013-2350;;SEMIN REPROD MED., vol. 20, no. 4, November 2002 (2002-11-01), pages 317 - 26;;ENDOCRINOL METAB CLIN NORTH AM., vol. 28, no. 2, June 1999 (1999-06-01), pages 295 - 324;;HUM REPROD UPDATE, vol. 21, no. 5, September 2015 (2015-09-01), pages 575 - 92;;SYST REV., vol. 4, no. 1, 23 September 2015 (2015-09-23), pages 125;;J CLIN ENDOCRINOL METAB., vol. 98, no. 12, December 2013 (2013-12-01), pages 4565 - 92;;AM. J. TRANSL. RES., vol. 5, no. 1, 2013, pages 15 - 20;;J AM SCI, vol. 9, no. 12, 2013, pages 54 - 62;;ENDOCRINE REVIEWS, vol. 36, no. 5, October 2015 (2015-10-01), pages 487 - 525",PENDING
68,TW,A,TW 201729808 A,026-124-112-590-913,2017-09-01,2017,TW 105134672 A,2016-10-27,IN 4102MU2015 A,2015-10-29,Pharmaceutical combination of NK3 receptor antagonist and biguanides,The present invention describes a synergistic composition comprising of NK3 receptor antagonist or a pharmaceutically effective salts thereof and biguanides or a pharmaceutically effective salts thereof for the treatment of PCOS and related diseases. The present invention is directed to a synergistic combination comprising combinations of a NK3 receptor antagonist or pharmaceutically effective salts thereof and biguanides or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.,CADILA HEALTHCARE LTD,JAIN MUKUL;;BANERJEE KAUSHIK;;JOHARAPURKAR AMIT;;PANDYA ARTI;;KSHIRSAGAR SAMADHAN,,https://lens.org/026-124-112-590-913,Patent of Addition,no,0,0,3,3,0,A61K31/155;;A61K31/47;;A61P13/08;;A61P15/08;;A61P17/10;;A61P17/14;;A61P5/00;;A61P5/28,A61K31/47;;A61K31/155;;A61P5/28;;A61P13/08;;A61P15/08;;A61P17/10;;A61P17/14,,0,0,,,,PENDING
69,CA,A1,CA 2081069 A1,067-136-925-849-326,1993-04-24,1993,CA 2081069 A,1992-10-21,US 78162891 A,1991-10-23,STEREOSELECTIVE PREPARATION OF HALOPHENYL ALCOHOLS,"HA583 ABSTRACT STEREOSELECTIVE PREPARATION OF HALOPHENYL ALCOHOLS A process is described for selectively preparing a compound of the formula wherein: R1 is halogen; R2 is halogen, alkyl, cycloalkyl, aryl or ; and R3 is hydrogen, alkyl, cycloalkyl, aryl, or halogen; wherein the process comprises treating the associated ketone with an oxido-reductase or a microorganism comprising an oxidoreductase. Compounds prepared by this process are useful antipsychotic agents or useful intermediates therefor.",PATEL RAMESH N;;LIU MARK;;BANERJEE AMIT;;SZARKA LASZLO J,PATEL RAMESH N;;LIU MARK;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/067-136-925-849-326,Patent Application,no,0,0,5,5,0,C12P7/22;;C12P17/12;;C12P17/165;;C12P17/165;;C12P7/22;;C12P17/12,C07D239/42;;C12P7/22;;C12P17/12;;C12P17/16;;C12R1/01;;C12R1/06;;C12R1/365;;C12R1/645;;C12R1/72;;C12R1/78;;C12R1/865,,0,0,,,,DISCONTINUED
70,EP,A2,EP 0538693 A2,069-950-079-117-001,1993-04-28,1993,EP 92117282 A,1992-10-09,US 78162891 A,1991-10-23,Stereoselective preparation of halophenyl alcohols.,"A process is described for selectively preparing a compound of the formula
  
 wherein:
 R¹ is halogen; R² is halogen, alkyl, cycloalkyl, aryl or
   and R³ is hydrogen, alkyl, cycloalkyl, aryl, or 
  
 wherein the process comprises treating the associated ketone with an oxido-reductase or a microorganism comprising an oxidoreductase. Compounds prepared by this process are useful antipsychotic agents or useful intermediates therefor.",SQUIBB & SONS INC,PATEL RAMESH N;;LIU MARK;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/069-950-079-117-001,Patent Application,yes,0,2,5,5,0,C12P17/165;;C12P17/165;;C12P7/22;;C12P7/22;;C12P17/12;;C12P17/12,C07D239/42;;C12P7/22;;C12P17/12;;C12P17/16;;C12R1/01;;C12R1/06;;C12R1/365;;C12R1/645;;C12R1/72;;C12R1/78;;C12R1/865,,0,0,,,,DISCONTINUED
71,FI,A,FI 934874 A,095-768-757-000-462,1994-05-06,1994,FI 934874 A,1993-11-04,US 97228692 A,1992-11-05,Stereoselektiv reducering av ketoner,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;SZARKA LASZLO J,,https://lens.org/095-768-757-000-462,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;C07C311/21;;A61K31/18;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,PENDING
72,US,A,US 5393663 A,036-298-495-075-144,1995-02-28,1995,US 4688493 A,1993-04-14,US 4688493 A;;US 78162891 A,1991-10-23,Stereoselective preparation of halophenyl alcohols from ketones,"A process is described for selectively preparing a compound of the formula ##STR1## wherein: R.sup.1 is halogen; R.sup.2 is halogen, alkyl, cycloalkyl, aryl or ##STR2## and R.sup.3 hydrogen, alkyl, cycloalkyl, aryl, ##STR3## wherein the process comprises treating the associated ketone with an oxido-reductase or a microorganism comprising an oxidoreductase. Compounds prepared by this process are useful antipsychotic agents or useful intermediates therefor.",SQUIBB & SONS INC,PATEL RAMESH N;;LIU MARK;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/036-298-495-075-144,Granted Patent,yes,17,11,5,5,0,C12P17/165;;C12P17/165;;C12P7/22;;C12P7/22;;C12P17/12;;C12P17/12,C07D239/42;;C12P7/22;;C12P17/12;;C12P17/16;;C12R1/01;;C12R1/06;;C12R1/365;;C12R1/645;;C12R1/72;;C12R1/78;;C12R1/865,435/118;;435/280;;435/156;;435/122,17,11,028-511-009-578-177;;024-238-313-553-687;;058-820-558-166-906;;059-899-847-922-115;;092-464-744-140-229;;033-322-049-189-772;;034-224-293-558-653;;050-768-064-075-215;;076-141-018-289-209;;020-237-463-773-159;;071-998-720-866-02X,10.1080/00021369.1987.10868385;;10.1021/jo01304a044;;10.1016/s0040-4020(01)87306-3;;10.1016/s0957-4166(00)80531-5;;10.1016/s0040-4039(00)95250-x;;10.1021/jo00258a024;;10.1039/c39890000148;;10.1021/ja00321a033;;10.1016/s0040-4039(00)97076-x;;10.1021/jo00297a073;;10.1002/ange.19840960806,"Christen, M et al., J. Chem. Soc. Chem. Commun. 264 266 (1988).;;Shen, G. et al., J. Chem. Soc. Chem Commun. 677 679 (1990).;;Hummel, W., Appl. Microbiol. Biotechnol 34:15 19 (1990).;;Ohta, H., Agrig. Biol. Chem. 51:2421 2427 (1987).;;Imuta, M., J. Org. Chem. 45:3352 3355 (1980).;;Jones J., Tetrahedron 42:3351 3403 (1986).;;Nieduzak et al., Tetrahedron: Assymetry 2 (1991), 113 to 122.;;Lauman et al., J. Chem. Soc. Chem. Commun. (1988), 598 to 600.;;Sih et al., Developments in Industrial Microbiology, vol. 29, (1988) 221 to 229.;;Feichter et al., Tetrahedron Letters 30 (5) 1989, 551 552.;;Bianchi et al., J. Org. Chem. 53 (1988) 5531 5534.;;Laumen et al., J. Chem. Soc., Chem. Commun. 3 (1989), 148 150.;;Nakamura et al., Agric. Biol. Chem. 54 (6) (1990), 1569 1570.;;Cambou et al., J. Am. Chem. Soc. 106 (1984) 2687 to 2692.;;Hsu et al., Tet. Lett. 31 (1990), 6403 to 6406.;;Babiak et al., J. Org. Chem. 55 (1990), 3377 to 3381.;;Sih et al., Angew. Chem. 96 (1984), 556 564.",EXPIRED
73,US,B2,US 9516033 B2,133-294-138-252-85X,2016-12-06,2016,US 201414512634 A,2014-10-13,US 201414512634 A,2014-10-13,Providing restricted access to given devices by constructing abstract devices,"Methods, systems, and computer program products for providing restricted access to given devices by constructing abstract devices are provided herein. A method includes generating a virtual device based on one or more physical devices; mapping multiple device actions of the one or more physical devices to multiple device actions of the virtual device exposed by the virtual device; incorporating (i) discretionary access control techniques, (ii) policy-based access control techniques, and (iii) a physical device-level partial ordering of actions to determine a resolution in response to a set of multiple user access requests for two or more of the multiple device actions of the virtual device; and executing the two or more device actions of the virtual device on the virtual device for one or more given users in accordance with said resolution by coordinating the execution of two or more corresponding device actions of the one or more physical devices on the one or more physical devices based on said mapping.",IBM,BANERJEE NILANJAN;;DESHPANDE PRALHAD;;KAPOOR SHALINI;;KODESWARAN PALANIVEL;;KUMAR RAJAN;;MANGALVEDKAR AMIT M;;NANAVATI AMIT A,INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-06),https://lens.org/133-294-138-252-85X,Granted Patent,yes,13,0,2,2,0,H04L63/102;;H04L63/102;;H04L63/105;;H04L63/105,H04L29/06,,0,0,,,,ACTIVE
74,US,A1,US 2016/0105441 A1,146-099-254-989-021,2016-04-14,2016,US 201414512634 A,2014-10-13,US 201414512634 A,2014-10-13,Providing Restricted Access to Given Devices by Constructing Abstract Devices,"Methods, systems, and computer program products for providing restricted access to given devices by constructing abstract devices are provided herein. A method includes generating a virtual device based on one or more physical devices; mapping multiple device actions of the one or more physical devices to multiple device actions of the virtual device exposed by the virtual device; incorporating (i) discretionary access control techniques, (ii) policy-based access control techniques, and (iii) a physical device-level partial ordering of actions to determine a resolution in response to a set of multiple user access requests for two or more of the multiple device actions of the virtual device; and executing the two or more device actions of the virtual device on the virtual device for one or more given users in accordance with said resolution by coordinating the execution of two or more corresponding device actions of the one or more physical devices on the one or more physical devices based on said mapping.",IBM,BANERJEE NILANJAN;;DESHPANDE PRALHAD;;KAPOOR SHALINI;;KODESWARAN PALANIVEL;;KUMAR RAJAN;;MANGALVEDKAR AMIT M;;NANAVATI AMIT A,INTERNATIONAL BUSINESS MACHINES CORPORATION (2014-10-06),https://lens.org/146-099-254-989-021,Patent Application,yes,10,0,2,2,0,H04L63/102;;H04L63/102;;H04L63/105;;H04L63/105,H04L29/06,,0,0,,,,ACTIVE
75,AU,A,AU 1993/050443 A,052-813-317-124-656,1994-05-19,1994,AU 1993/050443 A,1993-11-04,US 97228692 A,1992-11-05,Stereoselective reduction of ketones,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;SZARKA LASZLO J;;BANERJEE AMIT;;MCNAMEE CLYDE G,,https://lens.org/052-813-317-124-656,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61K31/18;;A61P9/00;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,PENDING
76,DE,T2,DE 69329719 T2,047-759-512-245-984,2001-07-05,2001,DE 69329719 T,1993-05-14,US 88373292 A,1992-05-15,"Stereoselektive mikrobielle oder enzymatische Reduktion von 3,5-Dioxoestern zu 3,5-Dihydroxyestern","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/047-759-512-245-984,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
77,US,H,US H0001893 H,167-188-021-033-025,2000-10-03,2000,US 68531896 A,1996-07-23,US 68531896 A,1996-07-23,Enzymatic reduction method for the preparation of halohydrins,"An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of halohydrins from haloketones. The halohydrin products are particularly useful in the preparation of epoxides, which may be employed as intermediates in the preparation of protease inhibitors such as retroviral protease inhibitors.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;SZARKA LASZLO J;;BANERJEE AMIT;;MCNAMEE CLYDE G,BRISTOL-MYERS SQUIBB COMPANY (1996-10-01),https://lens.org/167-188-021-033-025,Statutory Invention Registration,yes,1,6,1,1,0,C12P13/02;;C12P13/02,C12P13/02,435/129;;435/280;;435/822,1,0,,,"Christen M. et al., Biotransformation in Organic Synthesis: Applications of Yeast Reduction in the Synthesis of 3,5 Dihydroxy Esters of High Optical Plurity, J. Chem. Soc. Chem. Comm. 1988: 264 266.",EXPIRED
78,EP,A3,EP 0596490 A3,043-999-361-176-72X,1995-04-26,1995,EP 93117899 A,1993-11-04,US 97228692 A,1992-11-05,Stereoselective reduction of ketones.,"The present invention concerns a process for the stereoselective enzymatic reduction of keto group-containing compounds such as N-(4-(2-chloroacetyl)phenyl)methanesulfonamido to form the corresponding hydroxyl-group containing compound. The process is selective for the D(+) enantiomer and is catalyzed by enzymes such as oxido-reductase or dehydrogense, or by microorganisms such as Hansenula, Rhodococcus, or Norcardia species.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;SZARKA LASZLO J,,https://lens.org/043-999-361-176-72X,Search Report,yes,1,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;A61K31/18;;C12R1/645,,5,2,084-004-024-301-736;;048-825-817-030-211,14230208;;10.1038/2031283a0;;10.1007/bf00170373,"A.A.LARSEN ET AL.: ""A new bio-isostere:Alkylsulphonamidophenethanolamines."", NATURE., vol. 203, no. 4951, 19 September 1964 (1964-09-19), LONDON GB, pages 1283 - 1284;;CHEMICAL ABSTRACTS, vol. 64, no. 4, 14 February 1966, Columbus, Ohio, US; abstract no. 4980c, R.H.ULOTH ET AL.: ""Monoalkane-and arenesulfonamidophenethanolamines."";;CHEMICAL ABSTRACTS, vol. 70, no. 3, 20 January 1969, Columbus, Ohio, US; abstract no. 10254v, SOMANI, PITAMBAR ET AL.: ""Antiarrhythmic activity of the dextro- and levorotatory isomers of 4-(2-isopropylamino-1-hydroxyethyl)methanesulfoanilide."" page 146;;CHEMICAL ABSTRACTS, vol. 72, no. 7, 16 February 1970, Columbus, Ohio, US; abstract no. 30014m, SOMANI, PITAMBAR ET AL.: ""Blockade of cardiac effects of isoproterenol by the stereoisomers of sotalol."" page 156;;R.PATEL ET AL.: ""Stereoselective microbial reduction of N-(4-(1-oxo-2-chloroacetyl ethyl) phenyl methane sulfonamide."", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY., vol. 40, no. 2/3, November 1993 (1993-11-01), pages 241 - 245, XP035171623, DOI: doi:10.1007/BF00170373",DISCONTINUED
79,US,A,US 5324662 A,194-005-389-338-518,1994-06-28,1994,US 88373292 A,1992-05-15,US 88373292 A,1992-05-15,"Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to 3-hydroxy-5-oxo, 3-oxo-5-hydroxy, and 3,5-dihydroxy esters","Microorganisms or reductases derived therefrom reduce a diketo ester ##STR1## to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers ##STR2## which can be used to prepare antihypercholesterolemic agents such as ##STR3##",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,E. R. SQUIBB & SONS INC. A DE CORP (1992-05-08),https://lens.org/194-005-389-338-518,Granted Patent,yes,14,2,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,435/280;;435/121;;435/135;;435/822;;435/872;;435/938,16,11,059-899-847-922-115;;092-464-744-140-229;;157-222-977-596-117;;033-322-049-189-772;;034-224-293-558-653;;050-768-064-075-215;;076-141-018-289-209;;020-237-463-773-159;;071-998-720-866-02X;;054-937-854-617-242;;058-820-558-166-906,10.1016/s0957-4166(00)80531-5;;10.1016/s0040-4039(00)95250-x;;10.1021/jo00261a033;;10.1021/jo00258a024;;10.1039/c39890000148;;10.1021/ja00321a033;;10.1016/s0040-4039(00)97076-x;;10.1021/jo00297a073;;10.1002/ange.19840960806;;10.1111/j.1432-1033.1990.tb15384.x;;2180695;;10.1016/s0040-4020(01)87306-3,"Nieduzak et al., Tetrahedron: Assymetry 2 (1991), 113 to 122.;;Lauman et al., J. Chem. Soc. Chem. Commun. (1988), 598 to 600.;;Sih et al., Developments in Industrial Microbiology, vol. 29, (1988), 221 to 229.;;Feichter et al., Tetrahedron Letters 30 (5) 1989, 551 552.;;Hiratake et al., J. Org. Chem. 53 (26) (1988), 6130 6133.;;Bianchi et al., J. Org. Chem. 53 (1988) 5531 5534.;;Laumen et al., J. Chem. Soc., Chem. Commun. 3 (1989), 148 150.;;Nakamura et al., Agric. Biol. Chem. 54 (6) (1990), 1569 1570.;;Cambou et al., J. Am. Chem. Soc. 106 (1984) 2687 to 2692.;;Hsu et al., Tet. Lett. 31 (1990), 6403 to 6406.;;Babiak et al., J. Org. Chem. 55 (1990), 3377 to 3381.;;Sih et al., Angew. Chem. 96 (1984), 556 564.;;Hummel W., Appl Microbiol Biotechnol 34:15 19 (1990).;;Christen M. et al, J. Chem Soc Chem Commun 264 6 (1988).;;Heidlas J. et al, Eur J. Biochem 188:165 174 (1990).;;Jones J. B., Tetrahedron 42:3351 3403 (1986).",EXPIRED
80,WO,A2,WO 2005/014649 A2,016-678-421-509-949,2005-02-17,2005,IB 2004002529 W,2004-07-29,US 49374003 P,2003-08-08,METHOD FOR THE PREPARATION OF MOLECULES HAVING ANTIBODY ACTIVITY,"The present invention provides a process for the preparation of an antibody, wherein the method comprises: fermenting a cell mixture comprising the cells and a supernatant solution, wherein the cells are capable of expressing the light chain and the heavy chain; separating the cells from the supernatant solution to form a cell pellet; allowing the cell pellet to stand for a hold time; and extracting the cell pellet with an extracting solution; thereby producing the antibody.",PHARMACIA CORP;;BANERJEE AMIT;;GUSTAFSON MARK;;HO SA V;;MCLAUGHLIN JOSEPH;;THOMAS KRISTIN,BANERJEE AMIT;;GUSTAFSON MARK;;HO SA V;;MCLAUGHLIN JOSEPH;;THOMAS KRISTIN,,https://lens.org/016-678-421-509-949,Patent Application,yes,0,1,3,3,115,C07K16/241;;C07K16/241;;C07K16/00;;C07K16/00;;C07K16/065;;C07K16/065;;C07K2317/24;;C07K2317/24;;C07K2317/55;;C07K2317/55;;C07K2317/565;;C07K2317/565,C07K16/00;;C07K16/06;;C07K16/24,,0,0,,,,PENDING
81,CA,A1,CA 3152878 A1,022-258-223-435-826,2022-09-18,2022,CA 3152878 A,2022-03-17,US 202117205335 A,2021-03-18,METHODS AND SYSTEMS FOR ASSESSING COMPLIANCE OF AIRCRAFT ENGINES,"ABSTRACT Methods and systems for assessing compliance of aircraft engines are described. The method comprises selecting a test population from a set of deployed aircraft engines based on one or more selection criteria, each of the deployed aircraft engines having associated thereto design requirements and field data; selecting at least one parameter that is present in both the design requirements and the field data of the test population, the design requirements comprising design time-series profiles, the field data comprising field time-series profiles; comparing the field time-series profiles to the design time-series profiles for the at least one parameter using a similarity metric to obtain field statistics; comparing the field statistics to expected statistics from the design requirements; and generating a compliance assessment output of the test population based on a difference between the field statistics and the expected statistics. Date Recue/Date Received 2022-03-17",PRATT & WHITNEY CANADA,WIGNY ROBERT;;BANERJEE AVISEKH;;ZHU HONGYU;;DE ANTONI ANDREA;;SURANA AMIT,,https://lens.org/022-258-223-435-826,Patent Application,no,0,0,3,3,0,G06F30/15;;G06F18/22;;G06F18/2433;;B64F5/60;;G06F2111/08;;G06F30/27;;G06F2119/20;;G06F18/10;;G06F18/22;;G06F18/2193,G01M15/00,,0,0,,,,PENDING
82,CA,C,CA 2094191 C,152-910-840-325-647,2003-09-23,2003,CA 2094191 A,1993-04-16,US 88373292 A,1992-05-15,"STEREOSELECTIVE MICROBIAL OR ENZYMATIC REDUCTION OF 3,5-DIOXO ESTERS TO 3-HYDROXY-5-OXO, 3-OXO-5-HYDROXY, AND 3,5-DIHYDROXY ESTERS","Microorganisms or reductases derived therefrom reduce a diketo ester (see formula I) to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers (see formula II, III, IV) which can be used to prepare antihypercholesterolemic agents such as (see formula V)",PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/152-910-840-325-647,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
83,CA,A1,CA 2094191 A1,040-567-823-820-308,1993-11-16,1993,CA 2094191 A,1993-04-16,US 88373292 A,1992-05-15,"STEREOSELECTIVE MICROBIAL OR ENZYMATIC REDUCTION OF 3,5-DIOXO ESTERS TO 3-HYDROXY-5-OXO, 3-OXO-5-HYDROXY, AND 3,5-DIHYDROXY ESTERS","HX54 STEREOSELECTIVE MICROBIAL OR ENZYMATIC REDUCTION OF 3,5-DIOXO ESTERS TO 3-HYDROXY-5-OXO, 3-OXO-5-HYDROXY, AND 3,5-DIHYDROXY ESTERS Microorganisms or reductases derived therefrom reduce a diketo ester to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers which can be used to prepare antihypercholesterolemic agents such as",PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/040-567-823-820-308,Patent Application,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
84,WO,A3,WO 2005/014649 A3,113-224-392-352-232,2005-04-14,2005,IB 2004002529 W,2004-07-29,US 49374003 P,2003-08-08,METHOD FOR THE PREPARATION OF MOLECULES HAVING ANTIBODY ACTIVITY,"The present invention provides a process for the preparation of an antibody, wherein the method comprises: fermenting a cell mixture comprising the cells and a supernatant solution, wherein the cells are capable of expressing the light chain and the heavy chain; separating the cells from the supernatant solution to form a cell pellet; allowing the cell pellet to stand for a hold time; and extracting the cell pellet with an extracting solution; thereby producing the antibody.",PHARMACIA CORP;;BANERJEE AMIT;;GUSTAFSON MARK;;HO SA V;;MCLAUGHLIN JOSEPH;;THOMAS KRISTIN,BANERJEE AMIT;;GUSTAFSON MARK;;HO SA V;;MCLAUGHLIN JOSEPH;;THOMAS KRISTIN,,https://lens.org/113-224-392-352-232,Search Report,yes,4,0,3,3,0,C07K16/241;;C07K16/241;;C07K16/00;;C07K16/00;;C07K16/065;;C07K16/065;;C07K2317/24;;C07K2317/24;;C07K2317/55;;C07K2317/55;;C07K2317/565;;C07K2317/565,C07K16/00;;C07K16/06;;C07K16/24,,2,2,010-340-295-705-917;;054-481-611-060-715,1368228;;10.1038/nbt0292-163;;8749852;;10.1002/prot.340230411,"CARTER P ET AL: ""HIGH LEVEL ESCHERICHIA COLI EXPRESSION AND PRODUCTION OF A BIVALENT HUMANIZED ANTIBODY FRAGMENT"", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 10, no. 2, February 1992 (1992-02-01), pages 163 - 167, XP001182085, ISSN: 0733-222X;;SCHIWECK WOLFRAM AND ARNE SKERRA: ""Fermenter production of an artificial Fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling"", PROTEINS STRUCTURE FUNCTION AND GENETICS, vol. 23, no. 4, 1995, pages 561 - 565, XP002317106, ISSN: 0887-3585",PENDING
85,GR,T3,GR 3035316 T3,058-800-836-729-433,2001-04-30,2001,GR 20010400142 T,2001-01-30,US 88373292 A,1992-05-15,"Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to 3-hydroxy-5-oxo, 3-oxo-5-hydroxy, and 3,5-dihydroxy esters.","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/058-800-836-729-433,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
86,AT,T1,AT E197963 T1,152-668-205-530-120,2000-12-15,2000,AT 93107876 T,1993-05-14,US 88373292 A,1992-05-15,"STEREOSELEKTIVE MIKROBIELLE ODER ENZYMATISCHE REDUKTION VON 3,5-DIOXOESTERN ZU 3,5- DIHYDROXYESTERN","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/152-668-205-530-120,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,DISCONTINUED
87,DK,T3,DK 0569998 T3,064-365-662-134-256,2001-01-08,2001,DK 93107876 T,1993-05-14,US 88373292 A,1992-05-15,"Stereoselektiv mikrobiel eller enzymatisk reduktion af 3,5-dioxo-estere til 3,5-dihydroxy-estere","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;BANERJEE AMIT;;SZARKA LASZLO J;;MCNAMEE CLYDE G,,https://lens.org/064-365-662-134-256,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
88,EP,A3,EP 0569998 A3,120-247-931-441-353,1995-04-05,1995,EP 93107876 A,1993-05-14,US 88373292 A,1992-05-15,"Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to 3-hydroxy-5-oxo, 3-oxo-5-hydroxy, and 3,5-dihydroxy esters.","Microorganisms or reductases derived therefrom reduce a diketo ester
  
 to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers
  
 which can be used to prepare antihypercholesterolemic agents such as
 ",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/120-247-931-441-353,Search Report,yes,5,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
89,MX,A,MX 9306727 A,109-117-104-638-618,1994-06-30,1994,MX 9306727 A,1993-10-28,US 97228692 A,1992-11-05,PROCESO PARA LA PREPARACION DE UN COMPUESTO ALCANOL OPTICAMENTE ACTIVO.,"La presente invención se relaciona con un proceso para la reducción enzimática estereoselectiva de compuestos que contienen el grupo ceto tales como N-(4-(2-cloroacetil)fenil)metansulfonamido para formar el grupo hidroxilo correspondiente que contiene el compuesto. El proceso es selectivo para el enantiómero D(+) y es catalizado por las enzimas tales como la óxido-reductasa o deshidrogenasa, o por microorganismos tales como la especies Hansenula, Rhodococcus o Norcardia.",BRISTOL MYERS SQUIBB CO,SZARKA LASZLO J;;PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G,,https://lens.org/109-117-104-638-618,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;A61K31/18;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,PENDING
90,HU,A,HU T67410 A,114-979-995-924-377,1995-04-28,1995,HU 9303130 A,1993-11-04,US 97228692 A,1992-11-05,METHOD FOR PRODUCING OPTICALLY ACTIVE ALCANOLS,,BRISTOL MYERS SQUIBB CO,SZARKA LASZLO J;;PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G,,https://lens.org/114-979-995-924-377,Unknown,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;A61K31/18;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,DISCONTINUED
91,US,A,US 5391495 A,096-952-083-701-487,1995-02-21,1995,US 14397693 A,1993-10-27,US 14397693 A;;US 97228692 A,1992-11-05,Stereoselective reduction of ketones,"The present invention concerns a process for the stereoselective enzymatic reduction of keto group-containing compounds such as N-(4-(2-chloroacetyl)phenyl)methanesulfonamido to form the corresponding hydroxyl-group containing compound. The process is selective for the D(+) enantiomer and is catalyzed by enzymes such as oxido-reductase or dehydrogense, or by microorganisms such as Hansenula, Rhodococcus, or Norcardia species.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;SZARKA LASZLO J,,https://lens.org/096-952-083-701-487,Granted Patent,yes,3,32,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;C07C311/21;;A61K31/18;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,435/280;;435/911;;435/156;;435/931;;435/872;;435/254.1;;435/255.1;;435/252.1,19,14,062-013-109-693-149;;089-218-659-555-161;;084-004-024-301-736;;054-138-337-158-374;;030-255-809-323-035;;029-555-901-100-562;;077-512-970-597-294;;023-461-171-857-321;;038-621-915-140-126;;048-486-591-380-177;;142-648-288-228-689;;101-940-701-289-241;;124-744-777-073-902;;026-832-093-715-852,10.1021/jo00031a036;;10.1021/jo00031a037;;14230208;;10.1038/2031283a0;;10.1021/ja00294a052;;10.1002/chin.198435352;;10.1021/ja00317a046;;4378558;;10.1016/0014-2999(69)90087-9;;4390869;;10.1248/cpb.32.1342;;10.1007/bf01024393;;10.1111/j.1749-6632.1984.tb29827.x;;10.1016/s0040-4039(00)80112-4;;10.1002/chin.198818169;;3160564;;10.1002/9780470720929.ch3,"Bradshaw, et al. A Pseudomonas sp. Alcohol Dehydrogenase With Broad Substrate Specificity and Unusual Stereospecificity for Organic Synthesis, J. Org. Chem., 57, 1526 1532, 1992.;;Bradshaw, et al., Lactobacillus kefir Alcohol Dehydrogenase: A Useful Catalyst for Synthesis, J. Org. Chem., 57, 1532 1536, 1992.;;Larsen, A. A. and Lish, P. M., A New Bio Isostere: Alkylsulphonamidophenethanolamines, Nature, 203, 1283 1284, 1964.;;Lok, K. P., et al., Enzymes in Organic Synthesis. 34. Preparations of Enantiomerically Pure Exo and Endo Bridged Bicyclic 2.2.1 and 2.2.2 Chiral Lactones via Sterospecific Horse Liver Alcohol Dehydrogenase Catalyzed Oxidations of Meso Diols, J. Am. Chem. Soc. 107(8), 2521 2526, 1985.;;Ng. G. S. Y, et al., Enzymes in Organic Synthesis 29. Preparations of Enantiomerically Pure cis 2,3 and 2,4 Dimethyl Lactones via Horse Liver Alcohol Dehydrogenase catalyzed Oxidations, Tetrahedron 40(8), 1235 1243, 1984.;;Bridges, A. J. et al., Preparations of Enantiomerically Pure Bicyclic 3.2.1 and 3.3.1 Chiral Lactones via Stereospecific Horse Liver Alcohol Dehydrogenase Catalyzed Oxidations of Meso Diols, J. Am. Chem. Soc. 106(5), 1461 1467, 1984.;;Fischli, A., Chiral Building Blocks in Enantiomer Synthesis Using Enzymatic Transformations, Mod. Synth. Methods, Conf. Pap. Int. Semin., 2nd., Rolf Scheffold (Ed), 269 350, 1980.;;Lish, et al., Pharmacological and toxicological Properties of Two New Adrenergic Receptor Antagonists, J. Pharma. Exper. Ther., 149, 161 173, 1965.;;Somani, P. and Bachand, T., Blockade of Cardiac Effects of Isoproterenol by the Stereoisomers of Sotalol, European Journal of Pharmacology, 7, 239 247, 1969.;;Akita, H., et al., The Use of Microorganisms in Organic Synthesis.IV. Microbiological Asymmetric Reduction of Methyl 3 Phenyl 2 Oxybutyrate, Chem. Pharm. Bull. 32(4), 1342 1348, 1984.;;Hummel, W., Enzyme catalyzed Synthesis of Optically Pure R( ) phenylethanol, Biotechnol. Lett. 12(6), 403 408, 1990.;;Hummel, et al., New Enzymes for the Synthesis of Chiral Compounds, Ann. N.Y. Acad. Sci., 434, 194 205, 1984.;;Whitlock, H. W., Jr., Enzymatic Versus Chemical Synthesis of Molecules Labeled with Heavy Isotopes, Tech. Chem. (N.Y.), 10, 1045 1065, 1976.;;Whitesides, et al., The Use of Enzymes as Catalysts for Synthesis in Medicinal Chemistry: Chiral Synthons and Carbohydrates, New Methods in Drug Research, 2, 1 15, 1988.;;Flynn, G. A. and Beight, D. W., An Efficient Synthesis of Ethyl (R) 2 Hydroxy 4 Phenylbutyrate: A Useful Intermediate in the Synthesis of Converting Enzyme Inhibitors, Tetrahedron Lett. 29(4), 423 426, 1988.;;Fuganti, C. and Servi, S., Enzyme Mediated Synthesis of Pheromones, Bioflavour 87, Proc. Int. Conf., Peter Schreier (Ed), 555 569, 1988.;;Sonnet, P. E., Enzymes for Chiral Synthesis, Chemtech, 18(2), 94 98, 1988.;;Dodds, et al., Enzymes in Organic Synthesis. 38. Preparations of Enantiometerically Pure Chiral Hydroxydecalones via Stereospecific Horse Liver Alcohol Dehydrogenase Catalyzed Reductions of Decalindiones, J. Am. Chem. Soc. 110(2), 577 583, 1988.;;Battersby, A. R., Enzymic Synthesis of Labeled Chiral Substances, Ciba Found. Symp., 111, 22 30, 1985.",EXPIRED
92,US,A1,US 2022/0300682 A1,117-329-284-724-269,2022-09-22,2022,US 202117205335 A,2021-03-18,US 202117205335 A,2021-03-18,METHODS AND SYSTEMS FOR ASSESSING COMPLIANCE OF AIRCRAFT ENGINES,"Methods and systems for assessing compliance of aircraft engines are described. The method comprises selecting a test population from a set of deployed aircraft engines based on one or more selection criteria, each of the deployed aircraft engines having associated thereto design requirements and field data; selecting at least one parameter that is present in both the design requirements and the field data of the test population, the design requirements comprising design time-series profiles, the field data comprising field time-series profiles; comparing the field time-series profiles to the design time-series profiles for the at least one parameter using a similarity metric to obtain field statistics; comparing the field statistics to expected statistics from the design requirements; and generating a compliance assessment output of the test population based on a difference between the field statistics and the expected statistics.",PRATT & WHITNEY CANADA,WIGNY ROBERT;;BANERJEE AVISEKH;;ZHU HONGYU;;DE ANTONI ANDREA;;SURANA AMIT,PRATT & WHITNEY CANADA CORP (2021-02-26),https://lens.org/117-329-284-724-269,Patent Application,yes,0,1,3,3,0,G06F30/15;;G06F18/22;;G06F18/2433;;B64F5/60;;G06F2111/08;;G06F30/27;;G06F2119/20;;G06F18/10;;G06F18/22;;G06F18/2193,G06F30/27;;B64F5/60;;G06K9/62,,0,0,,,,PENDING
93,PT,E,PT 569998 E,125-964-773-717-345,2001-03-30,2001,PT 93107876 T,1993-05-14,US 88373292 A,1992-05-15,"REDUCAO ESTEREOSSELECTIVA MICROBIANA OU ENZIMATICA DE ESTERES DE GRUPO 3,5-DIOXO PARA SE OBTER ESTERES DE GRUPOS 3-HIDROXI-5-OXO-5-HIDROXI E 3,5-DI-HIDROXI","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;SZARKA LASZLO J;;MCNAMEE CLYDE G;;BANERJEE AMIT,,https://lens.org/125-964-773-717-345,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
94,CA,A1,CA 2103932 A1,111-367-704-097-273,1994-05-06,1994,CA 2103932 A,1993-08-12,US 97228692 A,1992-11-05,STEREOSELECTIVE REDUCTION OF KETONES,"The present invention concerns a process for the stereoselective enzymatic reduction of keto group-containing compounds such as N-(4-(2-chloroacetyl)phenyl)methanesulfon-amido to form the corresponding hydroxyl-group containing compound. The process is selective for the D(+) enantiomer and is catalyzed by enzymes such as oxido-reductase or dehydrogense, or by microorganisms such as Hansenula, Rhodococcus, or Norcardia species.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;SZARKA LASZLO J,,https://lens.org/111-367-704-097-273,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;A61K31/18;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,DISCONTINUED
95,EP,A2,EP 0596490 A2,132-303-621-744-366,1994-05-11,1994,EP 93117899 A,1993-11-04,US 97228692 A,1992-11-05,Stereoselective reduction of ketones.,"The present invention concerns a process for the stereoselective enzymatic reduction of keto group-containing compounds such as N-(4-(2-chloroacetyl)phenyl)methanesulfonamido to form the corresponding hydroxyl-group containing compound. The process is selective for the D(+) enantiomer and is catalyzed by enzymes such as oxido-reductase or dehydrogense, or by microorganisms such as Hansenula, Rhodococcus, or Norcardia species.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;SZARKA LASZLO J,,https://lens.org/132-303-621-744-366,Patent Application,yes,0,9,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61P9/00;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;A61K31/18;;C12R1/645,,0,0,,,,DISCONTINUED
96,EP,B1,EP 0569998 B1,050-868-066-257-758,2000-12-06,2000,EP 93107876 A,1993-05-14,US 88373292 A,1992-05-15,"Stereoselective microbial or enzymatic reduction of 3,5-dioxoesters to 3,5-dihydroxyesters","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/050-868-066-257-758,Granted Patent,yes,5,1,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
97,EP,A1,EP 4060310 A1,057-213-529-775-939,2022-09-21,2022,EP 22163086 A,2022-03-18,US 202117205335 A,2021-03-18,METHOD AND SYSTEM FOR ASSESSING COMPLIANCE OF AIRCRAFT ENGINES,"Methods and systems for assessing compliance of aircraft engines are described. The method comprises selecting a test population (301) from a set of deployed aircraft engines (300) based on one or more selection criteria, each of the deployed aircraft engines (300) having associated thereto design requirements (303) and field data (305); selecting at least one parameter that is present in both the design requirements (303) and the field data (305) of the test population (302), the design requirements (303) comprising design time-series profiles (402...806), the field data comprising field time-series profiles (404...802); comparing the field time-series profiles (404...802) to the design time-series profiles (402...806) for the at least one parameter using a similarity metric to obtain field statistics; comparing the field statistics to expected statistics from the design requirements (303); and generating a compliance assessment output of the test population (301) based on a difference between the field statistics and the expected statistics.
",PRATT & WHITNEY CANADA,WIGNY ROBERT;;BANERJEE AVISEKH;;ZHU HONYU;;DE ANTONI ANDREA;;SURANA AMIT,,https://lens.org/057-213-529-775-939,Patent Application,yes,2,0,3,3,0,G06F30/15;;G06F18/22;;G06F18/2433;;B64F5/60;;G06F2111/08;;G06F30/27;;G06F2119/20;;G06F18/10;;G06F18/22;;G06F18/2193,G01M15/14,,1,0,,,"FEDERAL AVIATION ADMINISTRATION: ""Aviation Safety Organization Changes"", FEDERAL REGISTER PUBLIC LAW, 31 December 2012 (2012-12-31), pages 1 - 13, XP055942260, Retrieved from the Internet <URL:https://www.govinfo.gov/content/pkg/FR-2012-12-31/pdf/2012-31109.pdf> [retrieved on 20220713]",PENDING
98,DE,D1,DE 69329719 D1,106-171-389-932-666,2001-01-11,2001,DE 69329719 T,1993-05-14,US 88373292 A,1992-05-15,"Stereoselektive mikrobielle oder enzymatische Reduktion von 3,5-Dioxoestern zu 3,5-Dihydroxyestern","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/106-171-389-932-666,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
99,ES,T3,ES 2152234 T3,036-009-084-593-576,2001-02-01,2001,ES 93107876 T,1993-05-14,US 88373292 A,1992-05-15,"REDUCCION ESTEREOSELECTIVA MICROBIANA O ENZIMATICA DE 3,5-DIOXOESTERES EN 3,5-DIHIDROXIESTERES.","Microorganisms or reductases derived therefrom reduce a diketo ester <CHEM> to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers <CHEM> which can be used to prepare antihypercholesterolemic agents such as <CHEM>",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/036-009-084-593-576,Granted Patent,no,0,0,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
100,HU,D0,HU 9303130 D0,038-291-631-921-474,1994-01-28,1994,HU 9303130 A,1993-11-04,US 97228692 A,1992-11-05,METHOD FOR PRODUCING OPTICALLY ACTIVE ALKANOLS,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;SZARKA LASZLO J,,https://lens.org/038-291-631-921-474,Patent Application,no,0,0,14,14,0,C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/931;;Y10S435/872;;A61P9/00;;C12P41/00;;C12P11/00;;C07C311/08;;C07C311/21;;C12P13/02;;Y10S435/911;;Y10S435/872;;Y10S435/931,A61K31/18;;A61P9/00;;C07C311/08;;C07C311/21;;C12P13/02;;C12P41/00;;C12R1/01;;C12R1/645,,0,0,,,,DISCONTINUED
101,EP,A2,EP 0569998 A2,168-213-444-168-94X,1993-11-18,1993,EP 93107876 A,1993-05-14,US 88373292 A,1992-05-15,"Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to 3-hydroxy-5-oxo, 3-oxo-5-hydroxy, and 3,5-dihydroxy esters.","Microorganisms or reductases derived therefrom reduce a diketo ester
  
 to form the associated 3-hydroxy, 5-hydroxy, or 3,5-dihydroxy esters. Selected microorganisms produce the preferred stereoisomers
  
 which can be used to prepare antihypercholesterolemic agents such as
 ",SQUIBB & SONS INC,PATEL RAMESH N;;MCNAMEE CLYDE G;;BANERJEE AMIT;;SZARKA LASZLO J,,https://lens.org/168-213-444-168-94X,Patent Application,yes,2,28,15,15,0,C07D319/06;;C07D405/06;;C12P7/62;;Y10S435/822;;Y10S435/872;;Y10S435/938;;C07D405/06;;C07D319/06;;C12P7/62;;Y10S435/872;;Y10S435/822;;Y10S435/938,C07D319/06;;C07D405/06;;C12P7/62;;C12P17/16;;C12R1/01;;C12R1/365;;C12R1/645;;C12R1/78;;C12R1/84;;C12R1/865,,0,0,,,,EXPIRED
102,EP,A1,EP 2804130 A1,032-157-548-643-391,2014-11-19,2014,EP 14168763 A,2014-05-19,IN 1769MU2013 A,2013-05-17,Identifications of individuals using multiple skeleton recording devices,"Method(s) and system(s) for identification of an unknown person are disclosed. The method includes receiving skeleton data comprises data of multiple skeleton joints of the unknown person from skeleton recording devices. The method further includes extracting G gait feature vectors from the skeleton data. Further, the method includes classifying each gait feature vector into one of N classes based on a training dataset for N known persons and computing a classification score for each class. The method also includes clustering the training dataset into M clusters based on M predefined characteristic attributes of the known persons, tagging each gait feature vector with one of the M clusters based on a distance between a respective gait feature vector and cluster centers of M clusters, and determining a clustering score for each M cluster. The method further includes identifying the unknown person based on clustering scores and classification scores.
",TATA CONSULTANCY SERVICES LTD,CHAKRAVARTY KINGSHUK;;SINHA ANIRUDDHA;;DAS DIPTESH;;BANERJEE ROHAN;;KONAR AMIT;;DUTTA SUDEEPTO,,https://lens.org/032-157-548-643-391,Patent Application,yes,0,1,3,3,0,G06V40/25;;G06V10/34;;G06F18/2413;;G06V40/25;;G06V10/34;;G06F18/2413,G06V10/34,,3,2,024-264-977-616-352;;002-357-429-977-645,10.1109/ipta.2008.4743792;;10.1145/2157689.2157767,"ANIRUDDHA SINHA ET AL: ""Person Identification using Skeleton Information from Kinect"", ACHI 2013 : THE SIXTH INTERNATIONAL CONFERENCE ON ADVANCES IN COMPUTER-HUMAN INTERACTIONS, 24 February 2013 (2013-02-24), Nice, France, pages 101 - 108, XP055140883, ISBN: 978-1-61-208250-9, Retrieved from the Internet <URL:http://www.thinkmind.org/download.php?articleid=achi_2013_4_50_20187> [retrieved on 20140917];;JANG-HEE YOO ET AL: ""Automated Human Recognition by Gait using Neural Network"", IMAGE PROCESSING THEORY, TOOLS AND APPLICATIONS, 2008. IPTA 2008. FIRST WORKSHOPS ON, IEEE, PISCATAWAY, NJ, USA, 23 November 2008 (2008-11-23), pages 1 - 6, XP031404063, ISBN: 978-1-4244-3321-6;;ADRIAN BALL ET AL: ""Unsupervised clustering of people from skeleton data"", HUMAN-ROBOT INTERACTION (HRI), 2012 7TH ACM/IEEE INTERNATIONAL CONFERENCE ON, IEEE, 5 March 2012 (2012-03-05), pages 225 - 226, XP032212000, ISBN: 978-1-4503-1063-5",DISCONTINUED
103,EP,A3,EP 0629702 A3,087-558-406-011-72X,1997-06-04,1997,EP 94109407 A,1994-06-17,US 7971293 A;;US 19291894 A,1993-06-18,Enzymatic preparation of chiral epoxide or hydroxy compounds by stereoselective epoxidation or hydroxylation.,"An enzymatic process for the preparation of chiral epoxides, monohydroxy or dihydroxy compounds of formula
   by the stereoselective epoxidation or hydroxylation of benzopyrans of formula
   or resolution of compounds of formula
   The compounds of formula I and II are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LAZSLO J,,https://lens.org/087-558-406-011-72X,Search Report,yes,7,0,5,5,0,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P17/181;;C12P41/004;;C07D493/04;;C07D311/22;;C07D311/70;;C12P41/004;;C12P17/181;;C12P17/18,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P41/00,,0,0,,,,DISCONTINUED
104,CN,A,CN 103596543 A,175-457-164-677-752,2014-02-19,2014,CN 201280029074 A,2012-05-15,EP 2012059031 W;;EP 11176118 A;;IN 1761MU2011 A,2011-06-17,An oral care composition,"The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the colour of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the colour of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to oxidation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the colour of the toothpaste, and also, when stored, are able to deliver green tea catechins.",UNILEVER NV,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,,https://lens.org/175-457-164-677-752,Patent Application,no,5,1,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61Q11/00,,0,0,,,,ACTIVE
105,SA,B1,SA 112330609 B1,034-312-216-945-182,2015-07-29,2015,SA 112330609 A,2012-06-13,IN 1761MU2011 A;;EP 11176118 A,2011-06-17,An oral care composition,"AN ORAL CARE COMPOSITION ABSTRACT The present invention relates to an oral care composition comprising catechins. We ‎have found that the catechins tend to darken the colour of the chalk based toothpaste ‎due to its oxidation which happens at the high pH of the toothpaste. Once the catechins ‎are oxidized and darken the colour of the toothpaste it is no longer available as such for ‎providing anti-inflammatory benefits. It is an object of the invention to provide a chalk ‎based toothpaste formulation which does not turn substantially dark due to oxidation of ‎catechins. The present inventors while working with oral care compositions comprising ‎catechins preferably green tea catechins for providing anti-inflammatory benefits, ‎surprisingly found that some selected zinc salts when added in particular quantities do ‎not result in darkening the colour of the toothpaste, and also, when stored, are able to ‎deliver green tea catechins.‎",UNILEVER PLC,AMIT KUMAR GHOSH;;PRASUN BANDYOPADHYAY;;GAUTAM BANERJEE;;RESHMEE MUKHOPADHYAY;;SMITHA ASHOK UPADHYAYA,,https://lens.org/034-312-216-945-182,Granted Patent,no,0,0,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,,,0,0,,,,ACTIVE
106,CA,A1,CA 2124733 A1,095-996-767-247-498,1994-12-19,1994,CA 2124733 A,1994-05-31,US 7971293 A;;US 19291894 A,1993-06-18,ENZYMATIC PREPARATION OF CHIRAL EPOXIDE OR HYDROXY COMPOUNDS BY STEROSELECTIVE EPOXIDATION OR HYDROXYLATION,"Abstract ENZYMATIC PREPARATION OF CHIRAL EPOXIDE OR HYDROXY COMPOUNDS BY STEREOSELECTIVE EPOXIDATION OR HYDROXYLATION An enzymatic process for the preparation of chiral epoxides, monohydroxy or dihydroxy compounds of formula I ; and II by the stereoselective epoxidation or hydroxylation of benzopyrans of formula III or resolution of compounds of formula IIa . The compounds of formula I and II are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.",PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LASZLO J,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LASZLO J,,https://lens.org/095-996-767-247-498,Patent Application,no,0,0,5,5,0,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P17/181;;C12P41/004;;C07D493/04;;C07D311/22;;C07D311/70;;C12P41/004;;C12P17/181;;C12P17/18,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P41/00,,0,0,,,,DISCONTINUED
107,MX,A,MX 2013015008 A,110-958-196-086-444,2014-03-26,2014,MX 2013015008 A,2012-05-15,IN 1761MU2011 A;;EP 11176118 A;;EP 2012059031 W,2011-06-17,AN ORAL CARE COMPOSITION.,"The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the colour of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the colour of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to oxidation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the colour of the toothpaste, and also, when stored, are able to deliver green tea catechins.",UNILEVER NV,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,,https://lens.org/110-958-196-086-444,Patent Application,no,0,0,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61Q11/00,,0,0,,,,DISCONTINUED
108,EP,A2,EP 0629702 A2,017-017-172-910-835,1994-12-21,1994,EP 94109407 A,1994-06-17,US 7971293 A;;US 19291894 A,1993-06-18,Enzymatic preparation of chiral epoxide or hydroxy compounds by stereoselective epoxidation or hydroxylation.,"An enzymatic process for the preparation of chiral epoxides, monohydroxy or dihydroxy compounds of formula
   by the stereoselective epoxidation or hydroxylation of benzopyrans of formula
   or resolution of compounds of formula
   The compounds of formula I and II are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LAZSLO J,,https://lens.org/017-017-172-910-835,Patent Application,yes,0,0,5,5,0,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P17/181;;C12P41/004;;C07D493/04;;C07D311/22;;C07D311/70;;C12P41/004;;C12P17/181;;C12P17/18,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P41/00,,0,0,,,,DISCONTINUED
109,US,A1,US 2019/0261913 A1,094-588-668-131-482,2019-08-29,2019,US 201716342805 A,2017-10-18,US 201716342805 A;;US 201662409769 P;;US 2017/0057249 W,2016-10-18,HYPERSPECTRAL IMAGING FOR PASSIVE DETECTION OF COLORECTAL CANCERS,"A method of detecting colorectal cancers using a hyperspectral sensor system includes receiving a training set of hyperspectral data from colorectal tissue that includes known normal and known cancerous tissue using the hyperspectral sensor system, applying a machine learning algorithm to the training set of hyperspectral data to provide predictor parameters for one of cancerous tissue or non-cancerous tissue, receiving measurement hyperspectral data from colorectal tissue of interest, and using the predictor parameters to classify the colorectal tissue of interest as one of cancerous tissue or non-cancerous tissue. The training set of hyperspectral data and the measurement hyperspectral data include reflection spectra across wavelength bands of light that include at least visible, near infrared and short-wave infrared regions of the electromagnetic spectrum.",UNIV JOHNS HOPKINS,BEAULIEU ROBERT J;;GOLDSTEIN SETH D;;SAFAR BASHAR;;BANERJEE AMIT;;AHUJA NITA,THE JOHNS HOPKINS UNIVERISTY (2017-02-15),https://lens.org/094-588-668-131-482,Patent Application,yes,7,9,2,2,0,A61B5/7267;;A61B5/0071;;A61B5/0075;;A61B5/0084;;A61B5/4255;;G16H50/70;;A61B5/0075;;A61B5/4255;;A61B5/7267;;A61B5/7275;;A61B5/0084;;A61B5/0071,A61B5/00,,1,1,010-335-918-151-687,20460203;;10.1109/tbme.2010.2049110,"Akbari et al., ""Detection and analysis of the intestinal ischemia using visible and invisible hyperspectral imaging"", IEEE Trans. Biomed. Eng. 57, 2011-7 (2010). (Year: 2010)",DISCONTINUED
110,US,B2,US 9439846 B2,041-235-110-666-510,2016-09-13,2016,US 201214125323 A,2012-05-15,IN 1761MU2011 A;;EP 11176118 A;;EP 2012059031 W,2011-06-17,Oral care composition,"The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the color of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the color of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to oxidation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the color of the toothpaste, and also, when stored, are able to deliver green tea catechins.",BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK;;CONOPCO INC,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,CONOPCO INC. D/B/A UNILEVER (2013-12-17),https://lens.org/041-235-110-666-510,Granted Patent,yes,11,0,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61Q11/00;;A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61K33/06;;A61K33/10;;A61K33/30;;A61K36/82,,6,0,,,"IPRP2 in PCTEP2012059031, May 17, 2013.;;Search Report in EP11176118, Jan. 10, 2012.;;Written Opinion in EP11176118, Aug. 11, 2011.;;Written Opinion in PCTEP2012059031, Jun. 19, 2012.;;International Search Report, PCT/EP2012/059031, mailed Jun. 19, 2012, 4 pp.;;European Search Report, EP 11 17 6118, dated Jan. 10, 2012, 2 pp.",ACTIVE
111,WO,A1,WO 2012/171738 A1,054-412-535-522-535,2012-12-20,2012,EP 2012059031 W,2012-05-15,IN 1761MU2011 A;;EP 11176118 A,2011-06-17,AN ORAL CARE COMPOSITION,"The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the colour of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the colour of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to oxidation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the colour of the toothpaste, and also, when stored, are able to deliver green tea catechins.",UNILEVER NV;;UNILEVER PLC;;UNILEVER HINDUSTAN;;BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,,https://lens.org/054-412-535-522-535,Patent Application,yes,5,2,11,11,0,A61K8/19;;A61K8/27;;A61Q11/00;;A61K8/498;;A61K8/9789;;A61K8/19;;A61K8/27;;A61Q11/00;;A61K8/9789;;A61K8/498,A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61Q11/00,,2,0,,,"DATABASE WPI Week 200960, Derwent World Patents Index; AN 2009-N15084, XP002666718;;DATABASE WPI Week 200953, Derwent World Patents Index; AN 2009-M21347, XP002666719",PENDING
112,US,A1,US 2014/0341439 A1,042-313-971-368-731,2014-11-20,2014,US 201414280353 A,2014-05-16,IN 1769MU2013 A,2013-05-17,Identification of People Using Multiple Skeleton Recording Devices,"Method(s) and system(s) for identification of an unknown person are disclosed. The method includes receiving skeleton data comprises data of multiple skeleton joints of the unknown person from skeleton recording devices. The method further includes extracting G gait feature vectors from the skeleton data. Further, the method includes classifying each gait feature vector into one of N classes based on a training dataset for N known persons and computing a classification score for each class. The method also includes clustering the training dataset into M clusters based on M predefined characteristic attributes of the known persons, tagging each gait feature vector with one of the M clusters based on a distance between a respective gait feature vector and cluster centers of M clusters, and determining a clustering score for each M cluster. The method further includes identifying the unknown person based on clustering scores and classification scores.",TATA CONSULTANCY SERVICES LTD,CHAKRAVARTY KINGSHUK;;SINHA ANIRUDDHA;;DAS DIPTESH;;BANERJEE ROHAN;;KONAR AMIT;;DUTTA SUDEEPTO,,https://lens.org/042-313-971-368-731,Patent Application,yes,4,5,3,3,0,G06V40/25;;G06V10/34;;G06F18/2413;;G06V40/25;;G06V10/34;;G06F18/2413,G06V10/34,382/115,2,1,068-317-451-317-991,10.1109/tpami.2003.1251144,"Lee et al: ""Gait analysis for recognition and classification"", proc. of IEEE, 2002.;;Wang et al: ""Silhouette analysis-based gait recognition for human identification"", PAMI-IEEE, 2003.",ACTIVE
113,WO,A2,WO 2010/127244 A2,097-994-589-521-880,2010-11-04,2010,US 2010/0033166 W,2010-04-30,US 77048310 A;;US 17484009 P;;US 24580509 P;;US 23423009 P,2009-05-01,STAGED TRANSACTION TOKEN FOR MERCHANT RATING,"An e-wallet service allows a consumer to retrieve a list of merchants selling goods and services specified by the consumer, see reviews by other consumers who conducted transactions with the merchants on the retrieved list; select a merchant from the retrieved list and an account to pay for a staged transaction and a corresponding token for the staged transaction with the selected merchant, conduct the staged transaction with the merchant by the submission of the token to the merchant as form of payment; and use the token, after conducting the staged transaction with the selected merchant, to gain access to a social media portal and input the consumer's opinion about the selected merchant's performance of the staged transaction.",TSYS ACQUIRING SOLUTIONS L L C;;BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,,https://lens.org/097-994-589-521-880,Patent Application,no,0,10,3,3,0,G06Q30/06;;G06Q30/06,G06Q20/00;;G06Q30/00,,0,0,,,,PENDING
114,US,A,US 5478734 A,154-226-178-531-56X,1995-12-26,1995,US 19291894 A,1994-02-07,US 19291894 A;;US 7971293 A,1993-06-18,Method of chiral epoxidation of benzopyran or pyranopyridine derivatives using microorganisms,"An enzymatic process for the preparation of chiral epoxides, monohydroxy or dihydroxy compounds of formula ##STR1## by the stereoselective epoxidation or hydroxylation of benzopyrans of formula ##STR2## or resolution of compounds of formula ##STR3## The compounds of formula I and II are intermediates useful in the preparation of pyranyl cyanoguanidine derivatives.",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LASZLO J,BRISTOL-MYERS SQUIBB COMPANY (1994-02-04),https://lens.org/154-226-178-531-56X,Granted Patent,yes,2,4,5,5,0,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P17/181;;C12P41/004;;C07D493/04;;C07D311/22;;C07D311/70;;C12P41/004;;C12P17/181;;C12P17/18,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P41/00,435/119;;435/125;;435/280,13,12,137-234-283-604-736;;025-429-791-424-298;;059-777-084-486-101;;009-101-905-382-657;;048-013-121-287-904;;073-817-959-331-454;;072-122-646-083-608;;080-837-333-678-386;;002-664-980-850-072;;104-529-331-157-207;;058-820-558-166-906;;004-502-652-501-835,10.1039/c39920000234;;10.1016/s0021-9258(17)39235-9;;4019509;;1447132;;pmc207472;;10.1128/jb.174.23.7613-7619.1992;;10.1021/jo00012a010;;1368499;;10.1007/bf00174198;;10.1007/bf00174197;;pmc203998;;3116933;;10.1128/aem.53.8.1780-1784.1987;;10.1039/c39930000049;;3144975;;10.1016/s0006-291x(88)81033-7;;10.1016/0031-9422(90)85203-r;;10.1016/s0040-4020(01)87306-3;;10.1016/s0960-894x(00)80437-0,"H. A. J. Carless, Enantiospecific and Stereoselective Synthesis of ( ) Conduritol C from Chlorobenzene via Microbial Oxidation and Epoxidation , J. Chem. Soc. Chem. Commun., (1992), pp. 234 235.;;K. Furuhashi, A Fermentation Process for the Production of Optically Active Epoxides , Chem. Econo. & Eng. Review, Jul./Aug. (1986), 18:7 8 (No. 200), pp. 21 26.;;P. J. van Bladeren et al., Differential Stereoselectivity of Cytochromes P 450b and P 405c in the Formation of Naphthalene and Anthracene 1,2 Oxides , The J. of Biological Chem., Aug. 25, (1985), 260:18, pp. 10226 10235.;;T. Nakamura et al., Resolution and Some Properties of Enzymes Involved in Enantioselective Transformation of 1,3 Dichloro 2 Propanol to (R) 3 Chloro 1,2 Propanediol by Corynebacterium sp. Strain N 1074 , J. of Bacteriology, Dec. (1992), 174:23, pp. 7613 7619.;;X. M. Zhang et al., Microbiological Transformations, 19. Asymmetric Dihydroxylation of the Remote Double Bond of Geraniol: A Unique Stereochemical Control Allowing Easy Access to Both Enantiomers of Geraniol 6,7 diol , J. Org. Chem., (1991), 56, pp. 3814 3817.;;M. Mahmoudian et al., Stereoselective epoxidation of phenyl allyl either by alkene utilizing bacteria , Appl. Microbiol Biotechnol, (1992), 37, pp. 28 31.;;M. Mahmoudian et al., Biocatalysts for production of chiral epoxides , Appl. Microbiol Biotechnol, (1992), 37, pp. 23 27.;;F. S. Sariaslani et al., Microbial Transformation of Precocene II: Oxidative Reactions by Streptomyces griseus , Appl. and Environ. Microbiology, (1987), 53:8, pp. 1780 1784.;;D. R. Boyd et al., Biotransformation of Unsaturated Heterocyclic Rings by Pseudomonas putida to Yield cis Diols , J. Chem. Soc. Chem. Commun, (1993), pp. 49 51.;;M. K. Trower et al., Xenobiotic Oxidation by Cytochrome P 450 Enriched Extracts of Streptomyces Griseus , BBRC, (1988), 157:3, pp. 1417 1422.;;W. R. Abraham et al., Hydroxy (Methylbutenynyl) Benzoic Acid and Derivatives from Curvularia Fallax , Phytochem, (1990) 29:8, pp. 2641 2644.;;J. B. Jones, Enzymes in Organic Synthesis , Tetrahedron, (1986) 42:13, pp. 3351 3403.;;D. G. Smith et al., Pyrrole Analogues of the Pyrrolidinone Moiety of the Potassium Channel Activator Cromakalim as Relaxants of Guinea Pig Trachealis , Bioorg. & Med. Chem. Lett., (1992) 2:12, pp. 1595 1598.",EXPIRED
115,BR,A2,BR 112013032266 A2,014-653-054-288-967,2016-09-06,2016,BR 112013032266 A,2012-05-15,EP 2012059031 W;;IN 1761MU2011 A;;EP 11176118 A,2011-06-17,composição de cuidado bucal e uso de sal de zinco selecionado,,UNILEVER NV,GHOSH AMIT KUMAR;;BANERJEE GAUTAM;;BANDYOPADHYAY PRASUN;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,UNILEVER IP HOLDINGS B.V. (PB) (2021-02-09),https://lens.org/014-653-054-288-967,Patent Application,no,0,0,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61Q11/00;;A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97,,0,0,,,,DISCONTINUED
116,US,B2,US 9208376 B2,165-457-291-029-763,2015-12-08,2015,US 201414280353 A,2014-05-16,IN 1769MU2013 A,2013-05-17,Identification of people using multiple skeleton recording devices,"Method(s) and system(s) for identification of an unknown person are disclosed. The method includes receiving skeleton data comprises data of multiple skeleton joints of the unknown person from skeleton recording devices. The method further includes extracting G gait feature vectors from the skeleton data. Further, the method includes classifying each gait feature vector into one of N classes based on a training dataset for N known persons and computing a classification score for each class. The method also includes clustering the training dataset into M clusters based on M predefined characteristic attributes of the known persons, tagging each gait feature vector with one of the M clusters based on a distance between a respective gait feature vector and cluster centers of M clusters, and determining a clustering score for each M cluster. The method further includes identifying the unknown person based on clustering scores and classification scores.",TATA CONSULTANCY SERVICES LTD;;TATA CONSULTANCY SERVICES,CHAKRAVARTY KINGSHUK;;SINHA ANIRUDDHA;;DAS DIPTESH;;BANERJEE ROHAN;;KONAR AMIT;;DUTTA SUDEEPTO,,https://lens.org/165-457-291-029-763,Granted Patent,yes,4,0,3,3,0,G06V40/25;;G06V10/34;;G06F18/2413;;G06V40/25;;G06V10/34;;G06F18/2413,G06V10/34,,3,1,068-317-451-317-991,10.1109/tpami.2003.1251144,"Lee et al: ""Gait analysis for recognition and classification"", proc. of IEEE, 2002.;;Wang et al: ""Silhouette analysis-based gait recognition for human identification"", PAMI-IEEE, 2003.;;Wittenberg, ""Performance and Motion Capture using Multiple Xbox Kinects"", Rochester Institute of Technology, Dec. 2013, 18 pages.",ACTIVE
117,US,A1,US 2010/0276484 A1,115-046-845-777-414,2010-11-04,2010,US 77048310 A,2010-04-29,US 77048310 A;;US 17484009 P;;US 23423009 P;;US 24580509 P,2009-05-01,STAGED TRANSACTION TOKEN FOR MERCHANT RATING,"An e-wallet service allows a consumer to retrieve a list of merchants selling goods and services specified by the consumer, see reviews by other consumers who conducted transactions with the merchants on the retrieved list; select a merchant from the retrieved list and an account to pay for a staged transaction and a corresponding token for the staged transaction with the selected merchant, conduct the staged transaction with the merchant by the submission of the token to the merchant as form of payment; and use the token, after conducting the staged transaction with the selected merchant, to gain access to a social media portal and input the consumer's opinion about the selected merchant's performance of the staged transaction.",BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,TSYS ACQUIRING SOLUTIONS L.L.C (2010-04-21),https://lens.org/115-046-845-777-414,Patent Application,yes,64,244,3,3,0,G06Q30/06;;G06Q30/06,G06K5/00;;G06Q30/00,235/379,0,0,,,,DISCONTINUED
118,EP,B1,EP 2720669 B1,038-163-239-099-715,2017-08-23,2017,EP 12720530 A,2012-05-15,IN 1761MU2011 A;;EP 11176118 A;;EP 2012059031 W,2011-06-17,AN ORAL CARE COMPOSITION,,UNILEVER NV;;UNILEVER PLC,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,"UNILEVER GLOBAL IP LIMITED, WIRRAL, GB (2021-08-24)",https://lens.org/038-163-239-099-715,Granted Patent,yes,3,0,11,11,0,A61K8/19;;A61K8/27;;A61Q11/00;;A61K8/498;;A61K8/9789;;A61K8/19;;A61K8/27;;A61Q11/00;;A61K8/9789;;A61K8/498,A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61Q11/00,,2,0,,,"DATABASE WPI Week 200960 Thomson Scientific, London, GB; AN 2009-N15084 XP002666718, & JP 2009 196986 A (KAO CORP) 3 September 2009 (2009-09-03);;DATABASE WPI Week 200953 Thomson Scientific, London, GB; AN 2009-M21347 XP002666719, & JP 2009 173572 A (KAO CORP) 6 August 2009 (2009-08-06)",ACTIVE
119,US,A1,US 2014/0170084 A1,084-117-207-196-626,2014-06-19,2014,US 201214125323 A,2012-05-15,IN 1761MU2011 A;;EP 11176118 A;;EP 2012059031 W,2011-06-17,ORAL CARE COMPOSITION,"The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the colour of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the colour of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to ox illation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the colour of the toothpaste, and also, when stored, are able to deliver green tea catechins.",BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,CONOPCO INC. D/B/A UNILEVER (2013-12-17),https://lens.org/084-117-207-196-626,Patent Application,yes,3,3,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61K8/49;;A61K8/27;;A61K8/97;;A61Q11/00,424/58;;424/49,0,0,,,,ACTIVE
120,AU,A,AU 1994/064780 A,098-832-342-600-856,1994-12-22,1994,AU 1994/064780 A,1994-06-17,US 7971293 A;;US 19291894 A,1993-06-18,Enzymatic preparation of chiral epoxide or hydroxy compounds by stereoselective epoxidation or hydroxylation,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE;;BRZOZOWSKI DAVID;;SZARKA LASZLO J,,https://lens.org/098-832-342-600-856,Patent Application,no,0,0,5,5,0,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P17/181;;C12P41/004;;C07D493/04;;C07D311/22;;C07D311/70;;C12P41/004;;C12P17/181;;C12P17/18,C07D311/22;;C07D311/70;;C07D493/04;;C12P17/18;;C12P41/00,,0,0,,,,PENDING
121,WO,A3,WO 2010/127244 A3,102-570-579-963-415,2011-02-03,2011,US 2010/0033166 W,2010-04-30,US 77048310 A;;US 17484009 P;;US 24580509 P;;US 23423009 P,2009-05-01,STAGED TRANSACTION TOKEN FOR MERCHANT RATING,"An e-wallet service allows a consumer to retrieve a list of merchants selling goods and services specified by the consumer, see reviews by other consumers who conducted transactions with the merchants on the retrieved list; select a merchant from the retrieved list and an account to pay for a staged transaction and a corresponding token for the staged transaction with the selected merchant, conduct the staged transaction with the merchant by the submission of the token to the merchant as form of payment; and use the token, after conducting the staged transaction with the selected merchant, to gain access to a social media portal and input the consumer's opinion about the selected merchant's performance of the staged transaction.",TSYS ACQUIRING SOLUTIONS L L C;;BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,BANERJEE ASHIM;;HAPITAS DIMITRIOS;;SCHMUCK ANGELA M;;LUDWIG CRAIG S;;BHATNAGAR AMIT,,https://lens.org/102-570-579-963-415,Search Report,no,4,0,3,3,0,G06Q30/06;;G06Q30/06,G06Q20/00;;G06Q30/00,,0,0,,,,PENDING
122,EP,A1,EP 2720669 A1,069-999-159-602-557,2014-04-23,2014,EP 12720530 A,2012-05-15,IN 1761MU2011 A;;EP 11176118 A;;EP 2012059031 W,2011-06-17,AN ORAL CARE COMPOSITION,,UNILEVER NV;;UNILEVER PLC,BANDYOPADHYAY PRASUN;;BANERJEE GAUTAM;;GHOSH AMIT KUMAR;;MUKHOPADHYAY RESHMEE;;UPADHYAYA SMITHA ASHOK,"UNILEVER GLOBAL IP LIMITED, WIRRAL, GB (2021-08-24)",https://lens.org/069-999-159-602-557,Patent Application,yes,0,0,11,11,0,A61K8/498;;A61K8/498;;A61K8/19;;A61K8/19;;A61K8/27;;A61K8/27;;A61K8/9789;;A61K8/9789;;A61Q11/00;;A61Q11/00,A61K8/19;;A61K8/27;;A61K8/49;;A61K8/97;;A61Q11/00,,1,0,,,See references of WO 2012171738A1,ACTIVE
123,US,A1,US 2022/0198089 A1,068-548-846-972-382,2022-06-23,2022,US 202017126147 A,2020-12-18,US 202017126147 A,2020-12-18,METHODS AND SYSTEMS FOR DEFINING MISSION PROFILES FOR A NEW ENGINE,"Systems and methods for defining mission profiles for a new engine are described. The method comprises selecting deployed engines from a set of existing engines based on components of the new engine using a first similarity metric; collecting field data associated with the deployed engines, the field data comprising usage and operating conditions for the deployed engines creating representative mission profiles from the field data using a second similarity metric; and defining the mission profiles for the new engine using the representative mission profiles.",PRATT & WHITNEY CANADA,SMITH FABRIZIO;;DE ANTONI ANDREA;;BANERJEE AVISEKH;;RUCCO MATTEO;;SURANA AMIT;;ZHU HONGYU,,https://lens.org/068-548-846-972-382,Patent Application,yes,19,0,3,3,0,G06F30/15;;G06F2111/10;;G06F16/24578;;G06F30/15;;G06F9/30003;;G06F9/30007,G06F30/15;;G06F16/2457,,3,2,018-426-932-441-802;;059-042-958-323-219,10.1016/j.cja.2019.10.004;;10.2514/6.2012-841,"José ALEXANDRE, et al, ""An innovative approach for integrated airline network and aircraft family optimization"", Chinese Journal of Aeronautics, Volume 33, Issue 2, 2020, Pages 634-663, Available online 16 November 2019 (Year: 2020);;RIOS ALEJANDRO et al., Identification of the Actual Mission Profiles and Their Impact on the Integrated Aircraft and Airline Network Optimization, Technological Institute of Aeronautics, November 1, 2020, Brazil, (Cited by applicant on IDS 8/7/22) (Year: 2020);;Brian K. Kestner et al, ""Integrated Engine and Aircraft Mission Performance Analysis Using NPSS"" 50th AIAA Aerospace Sciences Meeting including the New Horizons Forum and Aerospace Exposition 09 - 12 January 2012, Nashville, Tennessee; Pgs.10 (Year: 2012)",PENDING
124,EP,A1,EP 4016362 A1,171-082-761-886-786,2022-06-22,2022,EP 21215202 A,2021-12-16,US 202017126147 A,2020-12-18,METHODS AND SYSTEMS FOR DEFINING MISSION PROFILES FOR A NEW ENGINE,"Systems and methods (24, 30) for defining mission profiles for a new engine (10) are described. The method (30) comprises: selecting (32) deployed engines from a set of existing engines based on components of the new engine (10) using a first similarity metric; collecting (34) field data (402A, 402B,...402N) associated with the deployed engines, the field data (402A, 402B,...402N) comprising usage and operating conditions for the deployed engines; creating (36) representative mission profiles from the field data (402A, 402B,...402N) using a second similarity metric; and defining (38) the mission profiles for the new engine (10) using the representative mission profiles.
",PRATT & WHITNEY CANADA,SMITH FABRIZIO;;DE ANTONI ANDREA;;BANERJEE AVISEKH;;RUCCO MATTEO;;SURANA AMIT;;ZHU HONGYU,,https://lens.org/171-082-761-886-786,Patent Application,yes,0,0,3,3,0,G06F30/15;;G06F2111/10;;G06F16/24578;;G06F30/15;;G06F9/30003;;G06F9/30007,G06F30/15;;G06F111/10,,4,2,033-983-667-595-928;;116-582-811-425-598,10.2514/6.2021-2453;;10.2514/1.i010329,"RIOS ALEJANDRO ET AL: ""Identification of the Actual Mission Profiles and Their Impact on the Integrated Aircraft and Airline Network Optimization"", 1 November 2020 (2020-11-01), XP055917405, Retrieved from the Internet <URL:https://www.researchgate.net/publication/346030583_Identification_of_the_Actual_Mission_Profiles_and_Their_Impact_on_the_Integrated_Aircraft_and_Airline_Network_Optimization/link/60ba9074458515218f8f9133/download> [retrieved on 20220503];;KIM DAJUNG ET AL: ""Data-driven Operation-based Aircraft Design Optimization"", 25 June 2020 (2020-06-25), pages 2020 - 3156, XP055917735, Retrieved from the Internet <URL:https://hal-enac.archives-ouvertes.fr/hal-02868096/document> [retrieved on 20220503], DOI: 10.2514/6.2020-3156ï¿¿;;LI LISHUAI ET AL: ""Analysis of Flight Data Using Clustering Techniques for Detecting Abnormal Operations"", JOURNAL OF AEROSPACE INFORMATION SYSTEMS, vol. 12, no. 9, 1 September 2015 (2015-09-01), pages 587 - 598, XP055917840, Retrieved from the Internet <URL:https://www.researchgate.net/publication/282891656_Analysis_of_Flight_Data_Using_Clustering_Techniques_for_Detecting_Abnormal_Operations/link/5c9180a2a6fdccd4602bf069/download> [retrieved on 20220503], DOI: 10.2514/1.I010329;;PELT MAURICE ET AL: ""DATA MINING IN MRO"", 1 February 2019 (2019-02-01), XP055917836, Retrieved from the Internet <URL:https://library.oapen.org/bitstream/id/083fcbfb-ac19-4e2e-9ca4-a632c5f23d02/data-mining-in-mro---publication-auas-2019.pdf> [retrieved on 20220503]",PENDING
125,CA,A1,CA 3140500 A1,112-538-567-256-986,2022-06-18,2022,CA 3140500 A,2021-11-25,US 202017126147 A,2020-12-18,METHODS AND SYSTEMS FOR DEFINING MISSION PROFILES FOR A NEW ENGINE,"Systems and methods for defining mission profiles for a new engine are described. The method comprises selecting deployed engines from a set of existing engines based on components of the new engine using a first similarity metric; collecting field data associated with the deployed engines, the field data comprising usage and operating conditions for the deployed engines creating representative mission profiles from the field data using a second similarity metric; and defining the mission profiles for the new engine using the representative mission profiles.",PRATT & WHITNEY CANADA,SMITH FABRIZIO;;DE ANTONI ANDREA;;BANERJEE AVISEKH;;RUCCO MATTEO;;SURANA AMIT;;ZHU HONGYU,,https://lens.org/112-538-567-256-986,Patent Application,no,0,0,3,3,0,G06F30/15;;G06F2111/10;;G06F16/24578;;G06F30/15;;G06F9/30003;;G06F9/30007,,,0,0,,,,PENDING
126,US,A1,US 2005/0048056 A1,134-537-870-886-669,2005-03-03,2005,US 91401504 A,2004-08-06,US 91401504 A;;US 49374003 P,2003-08-08,Method for the preparation of molecules having antibody activity,"The present invention provides a process for the preparation of an antibody, wherein the method comprises: fermenting a cell mixture comprising the cells and a supernatant solution, wherein the cells are capable of expressing the light chain and the heavy chain; separating the cells from the supernatant solution to form a cell pellet; allowing the cell pellet to stand for a hold time; and extracting the cell pellet with an extracting solution; thereby producing the antibody.",PHARMACIA CORP,HO SA V;;MCLAUGHLIN JOSEPH K;;THOMAS KRISTIN;;GUSTAFSON MARK E;;BANERJEE AMIT,PHARMACIA CORPORATION OF PFIZER INC (2004-10-18),https://lens.org/134-537-870-886-669,Patent Application,yes,0,0,3,3,115,C07K16/241;;C07K16/241;;C07K16/00;;C07K16/00;;C07K16/065;;C07K16/065;;C07K2317/24;;C07K2317/24;;C07K2317/55;;C07K2317/55;;C07K2317/565;;C07K2317/565,C07K16/00;;C07K16/06;;C07K16/24,424/145.1;;530/388.23;;435/70.21,0,0,,,,DISCONTINUED
127,US,A1,US 2002/0025566 A1,185-691-663-913-56X,2002-02-28,2002,US 84298701 A,2001-04-26,US 84298701 A;;US 38658899 A;;US 9895698 P,1998-09-03,Enzymatic oxidative deamination process,"
   The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. 
",PATEL RAMESH N.;;BANERJEE AMIT;;NANDURI VENKATA B.;;GOLDBERG STEVEN L.;;JOHNSTON ROBERT M.,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M,,https://lens.org/185-691-663-913-56X,Patent Application,yes,0,0,14,14,6,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N15/09;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,435/119;;435/68.1;;435/252.3;;536/23.2;;562/556,0,0,,,,EXPIRED
128,US,B2,US 6649387 B2,115-366-381-788-520,2003-11-18,2003,US 84298701 A,2001-04-26,US 84298701 A;;US 38658899 A;;US 9895698 P,1998-09-03,Enzymatic oxidative deamination process,"
    The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. 
",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M,,https://lens.org/115-366-381-788-520,Granted Patent,yes,3,9,14,14,6,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N15/09;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,435/193;;435/252.3;;435/320.1;;435/69.1;;435/252.33;;435/254.1;;536/23.2,26,19,086-894-697-374-884;;051-897-864-027-585;;055-792-532-851-126;;066-141-497-990-023;;032-728-154-591-070;;114-619-682-814-274;;028-454-131-133-472;;082-902-765-648-368;;064-397-996-119-618;;013-891-870-160-838;;050-580-471-089-96X;;014-978-026-283-267;;047-294-079-836-486;;070-383-251-783-098;;000-346-919-904-207;;024-841-374-797-219;;020-533-566-973-694;;028-928-148-811-585;;029-259-061-759-228,1991735;;pmc207215;;10.1128/jb.173.3.985-988.1991;;10.1128/jb.173.19.6258-6264.1991;;pmc208378;;1917857;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/0022-2836(70)90057-4;;5420325;;3092189;;pmc311678;;10.1093/nar/14.16.6745;;2672459;;10.1016/0168-9525(89)90073-5;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/oxfordjournals.jbchem.a123388;;1880121;;344137;;344136;;10.1016/0378-1119(77)90000-2;;10.1038/275617a0;;360074;;386136;;10.1038/281544a0;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;6363212;;10.1016/0378-1119(83)90222-6;;6248238;;10.1016/0092-8674(80)90613-3;;10.1073/pnas.74.12.5463;;271968;;pmc431765;;10.1073/pnas.74.2.560;;265521;;pmc392330;;pmc179396;;10.1128/jb.179.17.5300-5308.1997;;9286980;;10.1271/bbb.62.622;;9614692,"Hames et al., Nucleic Acid Hybridization, A Practical Approach, IRL Press, Washington, D.C. (1985), Title and publication pages, and pp. 113-137 (Chapter 5).;;Kern, B. et al., Antimicrobial Agents and Chemotherapy, American Society of Microbiology, vol. 17, No. 4, pp. 679-685 (1986).;;Madduri, K. et al., Journal of Bacteriology, vol. 173, No. 3, pp. 985-988 (1991).;;Coque, J. et al., Journal of Bacteriology, vol. 173, No. 19, pp. 6258-6264 (1991).;;Houghton et al., Proc.Natl Acad.Sci. 82, 5131-5135 (1985).;;Devereux et al., Nucl.Acids Res. 12:387-395 (1984).;;Needleman et al., J. Mol. Biol. 48:443-453 (1970).;;Smith et al., Adv.Appl.Math 2:482 (1981).;;Gribskov et al., Nucl. Acids Res. 14:6745-6763 (1986).;;Schwartz et al., Atlas of Protein Sequence and Structure, National Biomedical Research Foundation, 353-358 (1979).;;White et al., Trends Genet. 5:185-189 (1989).;;Morinaga et al., Nucl. Acids Res. 2:636-639 (1984).;;Taylor et al., Nucl, Acids Res. 13: 8746-8764 (1985).;;Kunkel, Proc. Natl. Acad. Sci USA 82:482-492 (1985).;;Sayers et al., Nucl. Acids Res. 16:791-802 (1988).;;Takada et al., J. Biochem. 109:371-376 (1991).;;Bolivar et al., Gene 2:95-113 (1977).;;Chang et al., Nature, 275:617-624 (1978).;;Goeddel et al., Nature 281:544-548 (1979).;;Goeddel et al., Nucl. Acids Res. 8:4057-4074 (1980).;;Amann et al., Gene 25, 167-178 (1983).;;Siebenlist et al., Cell 20:269-281 (1980).;;Sanger et al., Proc.Natl.Acad.Sci.USA 74:5463-5467 (1977).;;Maxam et al., Proc.Natl.Acad.Sci.USA 74:560-564 (1977).;;Park et al. J. Bacteriol 1997, vol. 179, No. 17, pp. 5300-5308.;;Oku et al. Biosci. Biotech.Biochem. 1998, vol. 62, No. 4, pp. 622-627.",EXPIRED
129,US,A,US 5420337 A,025-102-228-636-991,1995-05-30,1995,US 97545392 A,1992-11-12,US 97545392 A,1992-11-12,Enzymatic reduction method for the preparation of compounds useful for preparing taxanes,"An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of compounds useful as intermediates in the preparation of taxanes.",SQUIBB & SONS INC,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;THOTTATHIL JOHN K;;SZARKA LASZLO J,E.R. SQUIBB & SONS INC (1992-12-04),https://lens.org/025-102-228-636-991,Granted Patent,yes,21,12,2,2,0,C07C231/12;;C07C231/12;;C07C233/87;;C07C233/87,C07C231/12;;C07C233/87,560/41,38,36,016-544-780-833-050;;140-911-139-165-832;;059-899-847-922-115;;116-132-307-121-570;;092-464-744-140-229;;157-222-977-596-117;;033-322-049-189-772;;034-224-293-558-653;;050-768-064-075-215;;076-141-018-289-209;;020-237-463-773-159;;071-998-720-866-02X;;065-645-730-052-328;;117-029-845-120-12X;;100-757-371-383-806;;021-293-141-793-539;;017-298-940-122-182;;170-261-254-330-49X;;024-238-313-553-687;;028-511-009-578-177;;071-306-557-290-795;;052-597-967-121-760;;004-273-809-166-531;;018-939-102-311-471;;107-065-398-558-01X;;083-903-999-026-968;;147-310-192-176-435;;031-255-781-174-213;;161-214-473-702-371;;152-529-155-236-600;;031-009-487-375-002;;138-512-105-122-754;;144-221-067-101-57X;;113-020-900-064-946;;043-426-799-446-802;;132-908-891-179-899,2296008;;10.1021/jm00163a002;;10.1021/jo00356a006;;10.1016/s0957-4166(00)80531-5;;10.1002/chin.198843372;;10.1016/s0040-4039(00)95250-x;;10.1021/jo00261a033;;10.1021/jo00258a024;;10.1039/c39890000148;;10.1021/ja00321a033;;10.1016/s0040-4039(00)97076-x;;10.1021/jo00297a073;;10.1002/ange.19840960806;;10.1016/s0040-4039(00)79708-5;;10.1021/jo00351a008;;10.1016/s0040-4020(01)90519-8;;10.1016/s0021-9258(18)66141-1;;13084604;;10.1021/jo00293a052;;10.1021/jo00005a003;;10.1021/jo01304a044;;10.1080/00021369.1987.10868385;;10.1007/bf00170916;;10.1039/c39900000677;;10.1039/c39880000264;;10.1016/s0040-4039(00)95133-5;;10.1016/0045-2068(88)90011-9;;10.1016/s0040-4039(00)87646-7;;10.1039/p19870001607;;2653423;;10.1021/bi00428a012;;14052896;;10.1021/jo00228a039;;10.1021/jo01261a013;;10.1021/jo00278a051;;10.1055/s-1983-30555;;10.1039/p19800001139;;10.1021/ja00225a063;;10.1021/jo00041a054;;10.1021/ja00227a043,"Angelastro, et al. J. Med. Chem. 33(1) pp. 11 13 (1990).;;Magri et al, J. Org. Chem 51(6), 797 802 (1986).;;Nieduzak, et al., Multigram Lipase Catalyzed Enantioselective Acylation in the Synthesis of the Four Stereoisomers of a New Biologically Active Aryl 4 Piperidinemethanol Derivative, Tetrahedron:Asymmetry, vol. 2, No. 2, pp. 113 122(1991).;;Laumen, et al., A Highly Selective Ester Hydrolase from Pseudomonas Sp. for the Enzymatic Preparation of Enantiomerically Pure Secondary Alcohols; Chiral Auxilaries in Organic Synthesis, J. Chem. Soc. Chem. Commun., pp. 598 600 (1988).;;Sih, et al., The Use of Microbial Enzymes for the Synthesis of Optically Active Pharmaceuticals, J. of Industrial Microbiology, Suppl. No. 3, pp. 221 229 (1988).;;Feichter, et al., Biocatalytic Resolution of Long Chain 3 Hydroxy alkanoic Esters; Tetrahedron Letters, vol. 30, No. 5, pp. 551 552 (1989).;;Hiratake, et al., Irreversible and Highly Enantioselective Acylation of 2 Halo 1 arylethanols in Organic Solvents Catalyzed by a Lipase from Pseudomonas fluorescens; J. Org. Chem., 53, pp. 6130 6133 (1988).;;Bianchi, et al., Anhydrides as Acylating Agents in Lipase Catalyzed Stereoselective Esterification of Racemic Alcohols, J. Org. Chem., 53, pp. 5531 5534 (1988).;;Laumen, et al., Enantiomerically Pure Cyclohexanols and Cyclohexane 1,2 Diol Derivatives; Chiral Auxilaries and Substitutes for ( ) 8 Phenylmenthol. A Facile Enzymatic Route, J. Chem. Soc. Chem. Commun., pp. 148 150 (1989).;;Nakamura, et al., Stereoselective Preparation of (R) 4 Nitro 2 butanol and (R) 5 Nitro 2 pentanol Mediated by a Lipase; Agric Biol. Chem., 54(6), pp. 1569 1570 (1990).;;Cambou, et al., Preparative Production of Optically Active Esters and Alcohols Using Esterase Catalyzed Stereospecific Transesterification in Organic Media; J. Amer. Chem. Soc., 106, pp. 2687 2692 (1984).;;Hsu, et al., Lipase Catalyzed Irreversible Transesterification Using Enol Esters: XAD 8 Immobilized Lipoprotein Lipase Catalyzed Resolution of Secondary Alcohols; Tetrahedron Letters, vol. 31, No. 44, pp. 6403 6406 (1990).;;Babiak, et al., Lipase Catalyzed Irreversible Transesterification Using Enol Esters: Resolution of Prostaglandin Synthons 4 Hydroxy 2 alkyl 2 cyclo pentenones and Inversion of the 4S Enantiomer to the 4R Enantiomer; J. Org. Chem., 55, pp. 3377 3381 (1990).;;Sih, et al., Mikrobielle asymmetrische Katalyze enantioselektive Reduktion von Ketonen; Angew Chem., 96, pp. 556 565 (1984).;;Georg, et al., Asymmetric Synthesis of lactams and N Benzoyl 3 Phenylisoserines via the Staudinger Reaction, Tetrahedron Letters, vol. 32, No. 27, pp. 3151 3154 (1991).;;Denis, et al., An Efficient, Enantioselective Synthesis of the Taxol Side Chain, J. Org. Chem., 51, pp. 46 50 (1986).;;Honig, et al., Chemo Enzymatic Synthesis of All Isomeric 3 Phenylserines and Isoserines, Tetrahedron, vol. 46, No. 11, pp. 3841 3850 (1990).;;Fones, The Isomers of the phenylserines, J. Biol. Chem., 204, pp. 323 328 (1953).;;Denis, et al., An Improved Synthesis of the Taxol Side Chain and of RP 56976; J. Org. Chem., 55, pp. 1957 1959 (1990).;;Ojima, et al., Efficient and Practical Asymmetric Synthesis of the Taxol C 13 Side Chain, N Benzoyl (2R,3S) 3 phenylisoserine, and its Analogues via Chiral 3 Hydroxy 4 aryl lactams through Chiral Ester Enolate Imine Cyclo condensation, J. Org. Chem., 56, pp. 1681 1683 (1991).;;Imuta, et al., Product Stereospecificity in the Microbial Reduction of Haloaryl Ketones, J. Org. Chem., 45, pp. 3352 3355 (1980).;;Ohta, et al., Microbial Reduction of 1,2 Diketones to Optically Active Hydroxyketones; Agric. Biol. Chem., 51(9), pp. 2421 2427 (1987).;;Hummel, Reduction of acetophenone to R( ) phenylethanol by a new alcohol dehydrogenase from Lactobacillus kefir; Appl. Microbial Biotechnol, 34, pp. 15 19 (1990).;;Shen, et al., A New NAD dependent Alcohol Dehydrogenase with Opposite Facial Selectivity useful for Asymmetric Reduction and Cofactor Regeneration, J. Chem. Soc., Chem. Commun., pp. 677 679 (1990).;;Christen, et al., Biotransformation in Organic Synthesis: Applications of Yeast Reduction in the Synthesis of 3,5 Dihydroxy Esters of High Optical Purity, J. Chem. Soc. Chem. Commun., pp. 264 266 (1988).;;Fujisawa, et al., Diastereo and Enantioselective Reduction of , Diketodithiane with the Baker s Yeast, Tetrahedron Letters, vol. 26, No. 49, pp. 6089 6092 (1985).;;Willaert, et al., Enzymatic in Vitro Reduction of Ketones; Bioorganic Chemistry, pp. 223 231 (1988).;;Hoffman, et al., Synthesis of 6S,7S Anhydro Serricornine, Tetrahedron Letters, vol. 23, No. 34, pp. 3479 3482 (1982).;;Bernardi, et al., Production of (R) 1 (1,3 Dithian 2 yl)propan 2 ol by Microbial Reduction; J. Chem. Soc., Perkin Trans. I, pp. 1607 1608 (1987).;;Chunduru, et al., Mechanism of Ketol Acid Reductoisomerase Steady State Analysis and Metal Ion Requirement, Biochemistry, vol. 28, No. 2, pp. 486 493 (1989).;;Utaka, et al., Asymmetric Reduction of a Prochiral Carbonyl Group of Aliphatic and Keto Acids by Use of Fermenting Bakers Yeast, J. Org. Chem., vol. 52, pp. 4363 4368 (1987).;;Dale, et al., Methoxy trifluoromethylphenylacetic Acid, a Versatile Reagent for the Determination of Enantiomeric Composition of Alcohhols and Amines; The J. of Org. Chem., vol. 34, No. 9, pp. 2543 2550 (1969).;;Naoshima, et al., Biotransformation of Some KetoEsters through the Consecutive Reuse of Immobilized Nicotiana tabacum Cells; J. Org. Chem., vol. 54, pp. 4237 4239 (1989).;;Bucciarelli, et al., Asymmetric Reduction of Trifluoromethyl and Methyl Ketones by Yeast; An Improved Method; Synthesis Communications, pp. 897 899 (1983).;;Charles, et al., Bicyclic Heterocycles with Nitrogen at the Ring Junction. Part 2. Application of the Dakin West Reaction to the Synthesis of Imidazo 5,1 f 1,2,4 triazin 4(3H) ones, J.C.S. Perkin I, pp. 1139 1145 (1980).;;Denis, et al., A Highly Efficient, Practical Approach to Natural Taxol, J. Am. Chem. Soc., 110, 5917 5919 (1988).;;Deng et al., A Practical, Highly Enantioselective Synthesis of the Taxol Side Chain via Asymmetric Catalysis; J. Org. Chem., 57, pp. 4320 4323 (1992).;;Holton, et al., A Synthesis of Taxusin, J. Am. Chem. Soc., 110, pp. 6558 6560 (1988).",EXPIRED
130,US,A,US 5686298 A,021-760-965-861-581,1997-11-11,1997,US 38245595 A,1995-02-01,US 38245595 A;;US 97545392 A,1992-11-12,Enzymatic reduction method for the preparation of compounds useful for preparing taxanes,"An enzymatic reduction method, particularly a stereoselective enzymatic reduction method, for the preparation of compounds useful as intermediates in the preparation of taxanes.",SQUIBB & SONS INC,PATEL RAMESH N;;BANERJEE AMIT;;MCNAMEE CLYDE G;;THOTTATHIL JOHN K;;SZARKA LASZLO J,,https://lens.org/021-760-965-861-581,Granted Patent,yes,21,7,2,2,0,C07C231/12;;C07C231/12;;C07C233/87;;C07C233/87,C07C231/12;;C07C233/87,435/280;;435/135;;435/123,43,39,140-911-139-165-832;;100-757-371-383-806;;018-939-102-311-471;;031-255-781-174-213;;059-899-847-922-115;;116-132-307-121-570;;092-464-744-140-229;;157-222-977-596-117;;033-322-049-189-772;;034-224-293-558-653;;050-768-064-075-215;;076-141-018-289-209;;020-237-463-773-159;;071-998-720-866-02X;;065-645-730-052-328;;117-029-845-120-12X;;100-757-371-383-806;;021-293-141-793-539;;017-298-940-122-182;;170-261-254-330-49X;;024-238-313-553-687;;028-511-009-578-177;;071-306-557-290-795;;052-597-967-121-760;;004-273-809-166-531;;018-939-102-311-471;;107-065-398-558-01X;;083-903-999-026-968;;147-310-192-176-435;;031-255-781-174-213;;161-214-473-702-371;;152-529-155-236-600;;031-009-487-375-002;;138-512-105-122-754;;144-221-067-101-57X;;113-020-900-064-946;;043-426-799-446-802;;132-908-891-179-899;;016-544-780-833-050,10.1021/jo00356a006;;10.1016/s0040-4020(01)90519-8;;10.1016/s0040-4039(00)95133-5;;2653423;;10.1021/bi00428a012;;14052896;;10.1016/s0957-4166(00)80531-5;;10.1002/chin.198843372;;10.1016/s0040-4039(00)95250-x;;10.1021/jo00261a033;;10.1021/jo00258a024;;10.1039/c39890000148;;10.1021/ja00321a033;;10.1016/s0040-4039(00)97076-x;;10.1021/jo00297a073;;10.1002/ange.19840960806;;10.1016/s0040-4039(00)79708-5;;10.1021/jo00351a008;;10.1016/s0040-4020(01)90519-8;;10.1016/s0021-9258(18)66141-1;;13084604;;10.1021/jo00293a052;;10.1021/jo00005a003;;10.1021/jo01304a044;;10.1080/00021369.1987.10868385;;10.1007/bf00170916;;10.1039/c39900000677;;10.1039/c39880000264;;10.1016/s0040-4039(00)95133-5;;10.1016/0045-2068(88)90011-9;;10.1016/s0040-4039(00)87646-7;;10.1039/p19870001607;;2653423;;10.1021/bi00428a012;;14052896;;10.1021/jo00228a039;;10.1021/jo01261a013;;10.1021/jo00278a051;;10.1055/s-1983-30555;;10.1039/p19800001139;;10.1021/ja00225a063;;10.1021/jo00041a054;;10.1021/ja00227a043;;2296008;;10.1021/jm00163a002,"ATCC Catalogue of Bacteria, 1992, pp. 270 275.;;Magri et al., J. Org. Chem. 51(6). 797 802 (1986).;;Honig et al., Tetrahedron, vol. 46, No. 11, pp. 3841 3850 (1990).;;Shen et al., J. Chem. Soc. Chem. Commun, pp. 677 679 (1988).;;Fujisawa et al., Tetrahedron Lett., vol. 26, No. 49, pp. 6089 6092, 1985.;;Chunduru et al., Biochemistry, vol. 28, No. 2, pp. 486 493, 1989.;;Nieduzak, et al., Multigram Lipase Catalyzed Enantioselective Acylation in the Synthesis of the Four Stereoisomers of a New Biologically Active Aryl 4 Piperidinemethanol Derivative, Tetrahedron:Asymmetry , vol. 2, No. 2, pp. 113 122 (1991).;;Laumen, et al., A Highly Selective Ester Hydrolase from Pseudomonas Sp. for the Enzymatic Preparation of Enantiomerically Pure Secondary Alcohols; Chiral Auxilaries in Organic Synthesis, J. Chem. Soc., Chem. Commun. , pp. 598 600 (1988).;;Sih, et al., The Use of Microbial Enzymes for the Synthesis of Optically Active Pharmaceuticals, J. of Industrial Microbiology , Suppl. No. 3, pp. 221 229 (1988).;;Feichter, et al., Biocatalytic Resolution of Long Chain 3 Hydroxy alkanoic Esters; Tetrahedron Letters , vol. 30, No. 5, pp. 551 552 (1989).;;Hiratake, et al., Irreversible and Highly Enantioselective Acylation of 2 Halo 1 arylethanols in Organic Solvents Catalyzed by a Lipase from Pseudomonas fluorescens ; J. Org. Chem. , 53, pp. 6130 6133, (1988).;;Bianchi, et al., Anhydrides as Acylating Agents in Lipase Catalyzed Stereoselective Esterification of Racemic Alcohols, J. Org. Chem. , 53, pp. 5531 5534 (1988).;;Laumen, et al., Enantiomerically Pure Cyclohexanols and Cyclohexane 1,2 Diol Derivatives; Chiral Auxilaries and Substitutes for ( ) 8 Phenylmenthol. A Facile Enzymatic Route, J. Chem. Soc., Chem. Commun. , pp. 148 150 (1989).;;Nakamura, et al., Stereoselective Preparation of (R) 4 Nitro 2 butanol and (R) 5 Nitro 2 pentanol Mediated by a Lipase; Agric. Biol. Chem. , 54(6), pp. 1569 1570 (1990).;;Cambou, et al., Preparative Production of Optically Active Esters and Alcohols Using Esterase Catalyzed Stereospecific Transesterification in Organic Media; J. Amer. Chem. Soc. , 106, pp. 2687 2692 (1984).;;Hsu, et al., Lipase Catalyzed Irreversible Transesterification Using Enol Esters: XAD 8 Immobilized Lipoprotein Lipase Catalyzed Resolution of Secondary Alcohols; Tetrahedron Letters , vol. 31, No. 44, pp. 6403 6406 (1990).;;Babiak, et al., Lipase Catalyzed Irreversible Transesterification Using Enol Esters: Resolution of Prostaglandin Synthons 4 Hydroxy 2 alkyl 2 cyclo pentenones and Inversion of the 4S Enantiomer to the 4R Enantiomer; J. Org. Chem. , 55, pp. 3377 3381 (1990).;;Sih, et al., Mikrobielle asymmetrische Katalyze enantioselektive Reduktion von Ketonen; Angew Chem. , 96, pp. 556 565 (1984).;;Georg, et al., Asymmetric Synthesis of lactams and N Benzoyl 3 Phenylisoserines via the Staudinger Reaction, Tetrahedron Letters , vol. 32, No. 27, pp. 3151 3154 (1991).;;Denis, et al., An Efficient, Enantioselective Synthesis of the Taxol Side Chain, J. Org. Chem. , 51, pp. 46 50 (1986).;;Honig, et al., Chemo Enzymatic Synthesis of All Isomeric 3 Phenylserines and Isoserines, Tetrahedron , vol. 46, No. 11, pp. 3841 3850 (1990).;;Fones, The Isomers of the phenylserines, J. Biol. Chem. , 204, pp. 323 328 (1953).;;Denis, et al., An Improved Synthesis of the Taxol Side Chain and of RP 56976; J. Org. Chem , 55, pp. 1957 1959 (1990).;;Ojima, et al., Efficient and Practical Asymmetric Synthesis of the Taxol C 13 Side Chain, N Benzoyl (2R,3S) 3 phenylisoserine, and Its Analogues via Chiral 3 Hydroxy 4 aryl lactams through Chiral Ester Enolate Imine Cyclo condensation, J. Org. Chem. , 56, pp. 1681 1683 (1991).;;Imuta, et al., Product Stereospecificity in the Microbial Reduction of Haloaryl Ketones, J. Org. Chem. , 45, pp. 3352 3355 (1980).;;Ohta, et al., Microbial Reduction of 1,2 Diketones to Optically Active Hydroxyketones; Agric. Biol. Chem. , 51(9), pp. 2421 2427 (1987).;;Hummel, Reduction of acetophenone to R( ) phenylethanol by a new alcohol dehydrogenase from Lactobacillus kefir ; Appl. Microbial Biotechnol , 34, pp. 15 19 (1990).;;Shen, et al., A New NAD dependent Alcohol Dehydrogenase with Opposite Facial Selectivity useful for Asymmetric Reduction and Cofactor Regeneration, J. Chem. Soc., Chem. Commun. , pp. 677 679 (1990).;;Christen, et al., Biotransformation in Organic Synthesis: Applications of Yeast Reduction in the Synthesis of 3,5 Dihydroxy Esters of High Optical Purity, J. Chem. Soc., Chem. Commun. , pp. 264 266 (1988).;;Fujisawa, et al., Diastereo and Enantioselective Reduction of , Diketodithiane with the Baker s Yeast, Tetrahedron Letters , vol. 26, No. 49, pp. 6089 6092 (1985).;;Willaert, et al., Enzymatic in Vitro Reduction of Ketones; Bioorganic Chemistry , pp. 223 231 (1988).;;Hoffman, et al., Synthesis of 6S,7S Anhydro Serricornine, Tetrahedron Letters , vol. 23, No. 34, pp. 3479 3482 (1982).;;Bernardi, et al., Production of (R) 1 (1,3 Dithian 2 yl)propan 2 ol by Microbial Reduction; J. Chem. Soc. , Perkin Trans. I, pp. 1607 1608 (1987).;;Chunduru, et al., Mechanism of Ketol Acid Reductoisomerase Steady State Analysis and Metal Ion Requirement, Biochemistry , vol. 28, No. 2, pp. 486 493 (1989).;;Utaka, et al., Asymmetric Reduction of a Prochiral Carbonyl Group of Aliphatic and Keto Acids by Use of Fermenting Bakers Yeast, J. Org. Chem. , vol. 52, pp. 4363 4368 (1987).;;Dale, et al., Methoxy trifluoromethylphenylacetic Acid, a Versatile Reagent for the Determination of Enantiomeric Composition of Alcohols and Amines; The J. of Org. Chem. , vol. 34, No. 9, pp. 2543 2550 (1969).;;Naoshima, et al., Biotransformation of Some Keto Esters through the Consecutive Reuse of Immobilized Nicotiana tabacum Cells; J. Org. Chem. , vol. 54, pp 4237 4239 (1989).;;Bucciarelli, et al. Asymmetric Reduction of Trifluoromethyl and Methyl Ketones by Yeast; An Improved Method; Synthesis Communications , pp. 897 899 (1983).;;Charles, et al., Bicyclic Heterocycles with Nitrogen at the Ring Junction. Part 2. Application of the Dakin West Reaction to the Synthesis of Imidazo 5,1 f 1,2,4 triazin 4(3H) ones, J.C.S. Perkin I , pp. 1139 1145 (1980).;;Denis, et al., A Highly Efficient, Practical Approach to Natural Taxol, J. Am. Chem. Soc. , 110, 5917 5919 (1988).;;Deng et al., A Practical, Highly Enantioselective Synthesis of the Taxol Side Chain via Asymmetric Catalyst; J. Org. Chem. , 57, pp. 4320 4323 (1992).;;Holton, et al., A Synthesis of Taxusin, J. Am. Chem. Soc. , 110, pp. 6558 6560 (1988).;;Angelastro et al., J. Med. Chem. , 33(1), pp. 11 13 (1990).",EXPIRED
131,US,A1,US 2013/0190256 A1,015-346-445-868-877,2013-07-25,2013,US 201113581020 A,2011-02-25,US 201113581020 A;;US 30836210 P;;US 2011/0026308 W,2010-02-26,Curcumin Derivatives,The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON;;UNIV CITY NEW YORK RES FOUND,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2010-04-09),https://lens.org/015-346-445-868-877,Patent Application,yes,5,3,4,4,0,A61K31/4192;;A61K31/4192;;A61K31/7056;;A61K31/7056;;A61P25/28;;C07H13/04;;C07H13/04;;C07C49/255;;C07C49/255;;C07C69/42;;C07C69/42;;C07C69/716;;C07C69/716;;C07C233/18;;C07C233/18;;C07D249/04;;C07D249/04;;C07H7/06;;C07H7/06;;C07H15/08;;C07H15/08;;C07H15/26;;C07H15/26,C07H13/04;;C07H7/06,514/25;;536/17.4;;536/18.1,4,2,017-292-896-289-34X;;109-982-476-899-495,18201805;;10.1016/j.ejmech.2007.11.027;;10.1021/ol702370m.s002;;10.1021/ol702370m;;18020348,"Dubey et al., ""Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties"" European Journal of Medicinal Chemistry (2008) vol. 43 pp. 1837-1846;;Shi et al., ""Synthesis of Monofunctional Curcumin Derivatives, Clicked Curcumin Dimer, and a PAMAM Dendrimer Curcumin Conjugate for Therapeutic Applications"" Organic Letters (2007) vol. 9 no. 26 pp. 5461 - 5464;;English abstract and machine translation of WO2004/031122 above (2004) downloaded from Chemical Abstracts database HCAPLUS, and espace.net;;English abstract of CN101524546A above, downloaded from Chemical Abstracts database HCAPLUS",INACTIVE
132,WO,A2,WO 2011/106691 A2,053-880-990-476-658,2011-09-01,2011,US 2011/0026308 W,2011-02-25,US 30836210 P,2010-02-26,CURCUMIN DERIVATIVES,The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.,UNIV CITY NEW YORK RES FOUND;;RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,,https://lens.org/053-880-990-476-658,Patent Application,yes,0,1,4,4,0,A61K31/4192;;A61K31/4192;;A61K31/7056;;A61K31/7056;;A61P25/28;;C07H13/04;;C07H13/04;;C07C49/255;;C07C49/255;;C07C69/42;;C07C69/42;;C07C69/716;;C07C69/716;;C07C233/18;;C07C233/18;;C07D249/04;;C07D249/04;;C07H7/06;;C07H7/06;;C07H15/08;;C07H15/08;;C07H15/26;;C07H15/26,C07C49/223;;A61K31/12;;A61P25/28;;C07C49/255;;C07D249/04,,0,0,,,,PENDING
133,WO,A1,WO 2021/200569 A1,107-071-827-956-528,2021-10-07,2021,JP 2021012619 W,2021-03-25,JP 2020063788 A,2020-03-31,SENSOR DEVICE AND METHOD FOR MANUFACTURING SAME,[Problem] To provide: a sensor device by which it is possible to improve the detection accuracy for a gas; and a method for manufacturing the same. [Solution] A sensor device according to one aspect of the present invention comprises: a substrate; a gate electrode; a source electrode; a drain electrode; and an oscillator. The gate electrode is disposed on the substrate. The source electrode is disposed on the substrate and has a first conductive layer and a second conductive layer that is provided on the first conductive layer. The drain electrode is disposed on the substrate and has a third conductive layer and a fourth conductive layer that is provided on the third conductive layer. The oscillator has: a first end part disposed between the first and the second conductive layers; a second end part disposed between the third and the fourth conductive layers; and an oscillating part that opposes the gate electrode.,TAIYO YUDEN KK,MURUGANATHAN MANOHARAN;;AGBONLAHOR GABRIEL;;BANERJEE AMIT;;MIZUTA HIROSHI;;MAKI HISASHI;;ONDA YOSUKE;;HATTORI MASASHI;;SHIMOMAI KENICHI,,https://lens.org/107-071-827-956-528,Patent Application,yes,5,0,2,2,0,G01N27/00;;G01N5/02,G01N5/02;;G01N27/00,,1,1,038-068-598-509-864,25184967;;10.1021/nl502279c,"ZHU ALEXANDER Y ET AL.: ""Optoelectromechanical Multimodal Biosensor with Graphene active Region"", NANO LETTERS, vol. 14, 2014, pages 5641 - 5649, XP055792254, DOI: 10.1021/nl502279c",PENDING
134,WO,A1,WO 2021/200570 A1,111-737-839-018-566,2021-10-07,2021,JP 2021012624 W,2021-03-25,JP 2020063789 A,2020-03-31,"SENSOR DEVICE, PRODUCTION METHOD FOR SENSOR DEVICE, AND GAS DETERMINATION SYSTEM","[Problem] To provide a sensor device, a production method for the sensor device, and a gas determination system that make it possible to increase the sensitivity with which gases are detected. [Solution] The sensor device according to one embodiment of the present invention comprises a gate electrode, an insulating film, a graphene layer, a source electrode and a drain electrode, and a conductive porous layer. The insulating film is formed on the gate electrode. The graphene layer is formed on the insulating film. The source electrode and the drain electrode are arranged on the insulating film so as to be opposite each other with the graphene layer therebetween. The porous layer is formed on the graphene layer.",TAIYO YUDEN KK,MURUGANATHAN MANOHARAN;;AGBONLAHOR GABRIEL;;BANERJEE AMIT;;MIZUTA HIROSHI;;MAKI HISASHI;;ONDA YOSUKE;;HATTORI MASASHI;;SHIMOMAI KENICHI,,https://lens.org/111-737-839-018-566,Patent Application,yes,3,0,2,2,0,G01N27/00;;G01N27/414,G01N27/00;;G01N27/414,,1,1,017-432-099-425-603,10.1080/10408436.2016.1244656,"AKSHAY V. SINGHAL, HEMANT CHARAYA, INDRANIL LAHIRI: ""Noble Metal Decorated Graphene-Based Gas Sensors and Their Fabrication: A Review"", CRITICAL REVIEWS IN SOLID STATE AND MATERIALS SCIENCES, vol. 42, no. 6, 30 November 2016 (2016-11-30), pages 499 - 526, XP009536471, ISSN: 0161-1593, DOI: 10.1080/10408436.2016.1244656",PENDING
135,WO,A1,WO 2020/020535 A1,057-210-179-198-217,2020-01-30,2020,EP 2019065737 W,2019-06-14,IN 201841027903 A,2018-07-25,A METHOD OF CONFIGURING A PLURALITY OF POSITION CO-ORDINATES FOR INDOOR POSITIONING,"The present disclosure discloses a method of configuring a plurality of position co- ordinates for indoor positioning. The method includes retrieving a reference map of an indoor location, establishing a first level relationship between a plurality of first- level sub-locations with respect to the at least one labelled location, establishing a second level relationship between a plurality of second level sub-locations within each of the plurality of first level sub-locations by grouping the plurality of second level sub-locations into at least one cluster, determining at least one position co-ordinate based on the grouping and storing the at least one position co-ordinate in the reference map for enabling the indoor positioning. Therefore the position co-ordinates are configured automatically in real-time without the need for tedious process of getting the training data.",BOSCH GMBH ROBERT;;ROBERT BOSCH ENGINEERING AND BUSINESS SOLUTIONS PRIVATE LTD,BANERJEE ABHIK;;VIJENDRAN GOPALAN VENKOPARAO;;RAGAVENDRA PRABHAKAR;;KHARGHARIA HIMADRI SIKHAR;;BORUNDIYA AMIT PARASMAL;;HEMANTH SHEELVANT MAHALINGESHWARA,,https://lens.org/057-210-179-198-217,Patent Application,yes,5,1,1,1,0,G01C21/206;;G01S5/02521;;G01S5/02524;;G01S5/02524,G01C21/20;;G01S5/02,,1,1,032-334-497-075-391,10.1109/mass.2015.103,"SHEN XINGFA ET AL: ""BarFi: Barometer-Aided Wi-Fi Floor Localization Using Crowdsourcing"", 2015 IEEE 12TH INTERNATIONAL CONFERENCE ON MOBILE AD HOC AND SENSOR SYSTEMS, IEEE, 19 October 2015 (2015-10-19), pages 416 - 424, XP032845683, DOI: 10.1109/MASS.2015.103",PENDING
136,WO,A3,WO 2011/106691 A3,101-848-154-354-400,2011-12-15,2011,US 2011/0026308 W,2011-02-25,US 30836210 P,2010-02-26,CURCUMIN DERIVATIVES,"The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified to comprise (A) triazole and oligo-ethylene glycol (OEG) unit, (B) amide unit, or (C) OEG/carbohydrate structural unit. The water/plasma solubility of curcumin is improved by attaching water-soluble molecules such as polyethylene glycol (PEG) and sugar derivatives.",UNIV CITY NEW YORK RES FOUND;;RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,,https://lens.org/101-848-154-354-400,Search Report,yes,4,0,4,4,0,A61K31/4192;;A61K31/4192;;A61K31/7056;;A61K31/7056;;A61P25/28;;C07H13/04;;C07H13/04;;C07C49/255;;C07C49/255;;C07C69/42;;C07C69/42;;C07C69/716;;C07C69/716;;C07C233/18;;C07C233/18;;C07D249/04;;C07D249/04;;C07H7/06;;C07H7/06;;C07H15/08;;C07H15/08;;C07H15/26;;C07H15/26,C07C49/223;;A61K31/12;;A61P25/28;;C07C49/255;;C07D249/04,,1,1,109-982-476-899-495,10.1021/ol702370m.s002;;10.1021/ol702370m;;18020348,"SHI, WEI ET AL.: ""Synthesis of Monofunctional Curcumin Derivatives, Clicked Curcumin Dimer, and a PAMAM Dendrimer Curcumin Conjugate for Therapeutic Applications"", ORGANIC LETTERS, vol. 9, no. 26, 2007, pages 5461 - 5464",PENDING
137,US,B2,US 9650404 B2,067-138-378-133-482,2017-05-16,2017,US 201113581020 A,2011-02-25,US 201113581020 A;;US 30836210 P;;US 2011/0026308 W,2010-02-26,Curcumin derivatives,The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON;;UNIV CITY NEW YORK RES FOUND,RAJA KRISHNASWAMI;;ALONSO ALEJANDRA;;BANERJEE PROBAL;;DOLAI SUKANTA;;CORBO CHRISTOPHER;;AVERICK SAADYAH;;MOGHA AMIT;;DEBNATH SHAWON,THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (2010-04-09),https://lens.org/067-138-378-133-482,Granted Patent,yes,7,0,4,4,0,A61K31/4192;;A61K31/4192;;A61K31/7056;;A61K31/7056;;A61P25/28;;C07H13/04;;C07H13/04;;C07C49/255;;C07C49/255;;C07C69/42;;C07C69/42;;C07C69/716;;C07C69/716;;C07C233/18;;C07C233/18;;C07D249/04;;C07D249/04;;C07H7/06;;C07H7/06;;C07H15/08;;C07H15/08;;C07H15/26;;C07H15/26,A61K31/4192;;A61K31/7056;;C07C49/255;;C07C69/42;;C07C69/716;;C07C233/18;;C07D249/04;;C07H7/06;;C07H13/04;;C07H15/08;;C07H15/26,,5,3,017-292-896-289-34X;;109-982-476-899-495;;130-398-393-005-415,18201805;;10.1016/j.ejmech.2007.11.027;;10.1021/ol702370m.s002;;10.1021/ol702370m;;18020348;;10.1021/ja964381l,"Dubey et al., “Design, synthesis and characterization of some bioactive conjugates of curcumin with glycine, glutamic acid, valine and demethylenated piperic acid and study of their antimicrobial and antiproliferative properties” European Journal of Medicinal Chemistry (2008) vol. 43 pp. 1837-1846.;;Shi et al., “Synthesis of Monofunctional Curcumin Derivatives, Clicked Curcumin Dimer, and a PAMAM Dendrimer Curcumin Conjugate for Therapeutic Applications” Organic Letters (2007) vol. 9 No. 26 pp. 5461-5464.;;English abstract and machine translation of WO2004/031122 above (2004) downloaded from Chemical Abstracts database HCAPLUS, and espace.net.;;English abstract of CN101524546A above, downloaded from Chemical Abstracts database HCAPLUS.;;DuBois et al., “Novel, Stereoselective Synthesis of 2-Amino Saccharides,” J. Am. Chem. Soc., vol. 119, 3179-3180 (1997).",INACTIVE
138,IN,A,IN 3217DE2013 A,184-615-036-452-02X,2015-05-08,2015,IN 3217DE2013 A,2013-10-30,IN 3217DE2013 A,2013-10-30,FORMULATION FOR REPELLING SNAKES AND METHOD THEREOF,"The present disclosure relates to a formulation comprising of Cedrus deodara, Eugenia caryophyllata, Capsicum chinense, Cinnamomum verum, Allium Sativum, Syzygium aromaticum, and Mentha piperita. The present disclosure further relates to a process for the preparation of the formulation and the use of the formulation for repelling snakes.",DIRECTOR GENERAL DEFENCE RES AND DEV ORGANIZATION,CHATTOPADHYAY PRONOBESH;;BANERJEE SHUBAM;;AGNIHOTRI AMIT;;KARMAKAR SANJEEV;;GOYARY DANSWRANG;;POLICEGOUDRA RUDRAGOUD;;VAIRALE MOHAN G;;CHAURASIA ASSHWINI;;VEER VIJAY,,https://lens.org/184-615-036-452-02X,Patent Application,no,0,0,1,1,0,,A61K/,,0,0,,,,PENDING
139,CA,A1,CA 2862755 A1,037-870-837-891-573,2013-08-15,2013,CA 2862755 A,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A DIBENZOOXAHETEROCYCLE MOIETY,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R -R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.(I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/037-870-837-891-573,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,DISCONTINUED
140,SG,A,SG 11201404475T A,049-209-087-852-105,2014-08-28,2014,SG 11201404475T A,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A DIBENZOOXAHETEROCYCLE MOIETY,,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/049-209-087-852-105,Unknown,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,PENDING
141,WO,A1,WO 2013/118097 A1,010-667-005-570-386,2013-08-15,2013,IB 2013051062 W,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A,2012-02-10,ANTIVIRAL COMPOUNDS WITH A DIBENZOOXAHETEROCYCLE MOIETY,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R -R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.(I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/010-667-005-570-386,Patent Application,yes,88,7,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,15,6,063-649-754-807-196;;016-478-179-197-687;;012-968-144-305-859;;007-364-858-655-289;;019-817-021-691-872;;018-344-144-106-967,10.1007/bf02893380;;14688826;;10.1002/hep.510260703;;9305658;;10.1056/nejmoa020047;;12324553;;10.1002/jps.2600660104;;833720;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6;;1100221,"SZABO E; LOTZ G ET AL., PATHOL. ONCOL. RES., vol. 9, 2003, pages 215 - 221;;HOOFNAGLE JH., HEPATOLOGY, vol. 26, 1997, pages 15S - 20;;FRIED MW ET AL., N. ENGL. J. MED., vol. 347, 2002, pages 975 - 982;;JESUDIAN AB; GAMBARIN-GELWAN M; JACOBSON IM., GASTROENTEROLOGY HEPATOL., vol. 8, 2012, pages 91 - 101;;BERGE S. M. ET AL.: ""Pharmaceutical Salts, a review article"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;P. H. EINRICH; STAHLAND CAMILLE; G. WERMUTH: ""Handbook of Pharmaceutical Salts - Properties, Selection, and Use"", 2002, WILEY- VCH;;""Remington's Pharmaceutical Sciences, 18th ed.,"", 1990, MACK PUBLISHING COMPANY, pages: 1445;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2 - 19;;BANKER AND CHALMERS: ""Pharmaceutics and Pharmacy Practice"", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250;;""ASHP Handbook on Injectable Drugs, 4th ed.,"", 1986, TOISSEL, pages: 622 - 630;;""Remington's Pharmaceutical Science(17th ed.,"", 1985, MACK PUBLISHING COMPANY;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;PHYSICIANS' DESK REFERENCE, 2004;;WASSERMAN ET AL., CANCER, vol. 36, 1975, pages 1258 - 1268;;""Physicians' Desk Reference, 58th ed.,"", 2004, THOMSON PDR",PENDING
142,KR,A,KR 20140129034 A,178-885-597-430-288,2014-11-06,2014,KR 20147023151 A,2013-02-09,IN 1017KO2012 A;;IN 147KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/178-885-597-430-288,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14,,0,0,,,,DISCONTINUED
143,CN,A,CN 104136433 A,104-494-446-262-659,2014-11-05,2014,CN 201380008883 A,2013-02-09,IB 2013051077 W;;IN 147KO2012 A;;IN 1017KO2012 A,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/104-494-446-262-659,Patent Application,no,2,1,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,INACTIVE
144,MX,A,MX 2014009546 A,121-975-766-157-464,2015-10-29,2015,MX 2014009546 A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY.,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR;;RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO,,https://lens.org/121-975-766-157-464,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,PENDING
145,ZA,B,ZA 201405490 B,137-070-256-414-250,2015-10-28,2015,ZA 201405490 A,2014-07-25,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,,LUPIN LTD,PALLE VENKATA P;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;BANERJEE MOLOY MANOJ;;JOSHI ADVAIT ARUN;;RAMDAS VIDYA;;KAMBOJ RAJENDER KUMAR,,https://lens.org/137-070-256-414-250,Granted Patent,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,,,0,0,,,,ACTIVE
146,AU,A1,AU 2013/217229 A1,194-822-945-448-540,2014-08-21,2014,AU 2013/217229 A,2013-02-09,IN 1017KO2012 A;;IN 147KO2012 A;;IB 2013051077 W,2012-02-10,Antiviral compounds with a heterotricycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/194-822-945-448-540,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,ACTIVE
147,NZ,A,NZ 628445 A,031-208-655-416-662,2016-05-27,2016,NZ 62844513 A,2013-02-09,IB 2013051077 W;;IN 147KO2012 A;;IN 1017KO2012 A,2012-02-10,Antiviral compounds with a heterotricycle moiety,"Disclosed are heterocyclic naphtho-thiophen derivative compounds of formula (I) for use as antiviral agents, wherein the variables A, B, U, R1-R7, m, n, and q are as described in the specification. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. These compounds inhibits the replication of HCV by targeting a protein of the viral genome and are suitable for treating or preventing infection caused by an RNA-containing virus, particularly hepatitis C virus.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/031-208-655-416-662,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,DISCONTINUED
148,US,A1,US 2015/0010505 A1,089-566-941-497-218,2015-01-08,2015,US 201314375534 A,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W,2012-02-10,Antiviral Compounds with a Dibenzooxaheterocycle Moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2014-07-21),https://lens.org/089-566-941-497-218,Patent Application,yes,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61K45/06,424/85.5;;548/311.7;;514/397;;424/85.7;;424/85.6;;424/204.1;;435/238,0,0,,,,INACTIVE
149,US,B2,US 9073943 B2,101-863-633-369-138,2015-07-07,2015,US 201314375534 A,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W,2012-02-10,Antiviral compounds with a dibenzooxaheterocycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R-R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. (I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2014-07-21),https://lens.org/101-863-633-369-138,Granted Patent,yes,96,3,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D409/14;;C07D417/14;;C07D495/04,,20,7,012-968-144-305-859;;016-478-179-197-687;;002-570-636-930-551;;035-937-820-850-821;;063-649-754-807-196;;019-817-021-691-872;;018-344-144-106-967,10.1056/nejmoa020047;;12324553;;10.1002/hep.510260703;;9305658;;22485076;;pmc3317517;;22507961;;10.1016/j.bmcl.2012.03.089;;pmc7732024;;10.1007/bf02893380;;14688826;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6;;1100221,"International Search Report in corresponding International Application No. PCT/IB2013/051062, mailed Jun. 27, 2013.;;Avis, Kenneth E., ""Parenteral Preparations,"" Remington's Pharmaceutical Sciences, 17th Edition, Chapter 85, Mack Publishing Company, Easton, PA, pp. 1518-1541 (1985).;;Barnes, E., ""Hepatitis C,"" World Health Organization Fact Sheet No. 164, http://www.who.int/mediacentre/factsheets/fs164/en/ (Apr. 2014).;;Deluca, Patrick P., et al., ""Parenteral Drug-Delivery Systems,"" Pharmaceutics and Pharmacy Practice, Chapter 8, J.B. Lippincott Company, Philadelphia, PA, pp. 238-250 (1982).;;Fried, Michael W., et al., ""Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection,"" The New England Journal of Medicine, vol. 347, No. 13, pp. 975-982 (Sep. 26, 2002).;;Hoofnagle, Jay H., ""Hepatitis C: The Clinical Spectrum of Disease,"" Hepatology, vol. 26, No. 3, suppl. 1, pp. 15S-20S (Sep. 1997).;;Jesudian, Arun B., et al., ""Advances in the Treatment of Hepatitis C Virus Infection,"" Gastroenterology & Hepatology, vol. 8, No. 2, pp. 91-101 (Feb. 2012).;;""Product Identification Guide,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 303-340 (2004).;;""Product Information-Eisai,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 1221-1223 (2004).;;""Product Information-Janssen,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 1759-1764 (2004).;;""Product Information-Novartis Pharmaceuticals,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 2252-2259 (2004).;;""Product Information-Pfizer,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 2570-2573 (2004).;;Remingtons' Pharmaceutical Sciences, 18th Edition, p. 1445 (1990).;;Shi, Junxing, et al., ""Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors,"" Bioorganic & Medicinal Chemistry Letters, vol. 22, pp. 3488-3491 (2012).;;Stahl, P. Heinrich, et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, pp. 1-374 (2002).;;Szabó, Erzsébet, et al., ""Viral Hepatitis: New Data on Hepatitis C Infection,"" Pathology Oncology Research, vol. 9, No. 4, pp. 215-221 (2003).;;Szoka, Jr., Francis, et al., ""Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes),"" Annual Review of Biophysics & Bioengineering, vol. 9, pp. 467-508 (1980).;;Tusco, Salvatore J., et al., ""Intravenous Admixtures,"" Remington's Pharmaceutical Sciences, 17th Edition, Chapter 86, Mack Publishing Company, Easton, PA, pp. 1542-1552 (1985).;;Trissel, Lawrence A., ""Intravenous Infusion Solutions,"" ASHP Handbok on Injectable Drugs, Fourth Edition, American Society of Hospital Pharmacists, Inc., Bethesda, MD, pp. 622-630 (1986).;;Wasserman, Todd H., et al., ""Clinical Comparison of the Nitrosoureas,"" Cancer, vol. 36, pp. 1258-1268 (1975).",INACTIVE
150,AU,B2,AU 2013/217224 B2,078-311-658-544-185,2017-04-06,2017,AU 2013/217224 A,2013-02-08,IN 1017KO2012 A;;IN 147KO2012 A;;IB 2013051062 W,2012-02-10,Antiviral compounds with a dibenzooxaheterocycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R -R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.(I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/078-311-658-544-185,Granted Patent,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,ACTIVE
151,EP,A1,EP 2812327 A1,118-059-211-299-344,2014-12-17,2014,EP 13708912 A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2017-02-22),https://lens.org/118-059-211-299-344,Patent Application,yes,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,DISCONTINUED
152,US,A1,US 2015/0010504 A1,108-985-372-412-336,2015-01-08,2015,US 201314375530 A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,Antiviral Compounds with a Heterotricycle Moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R 1 -R 7 , m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2014-07-22),https://lens.org/108-985-372-412-336,Patent Application,yes,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D495/04;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D409/14;;C07D417/14,424/85.5;;548/311.7;;514/397;;424/85.7;;424/85.6;;424/228.1;;424/85.4;;548/150;;514/366;;548/311.4,0,0,,,,INACTIVE
153,SG,A,SG 11201404365S A,172-304-523-348-568,2014-10-30,2014,SG 11201404365S A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/172-304-523-348-568,Unknown,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,PENDING
154,WO,A1,WO 2013/118102 A1,197-023-379-078-474,2013-08-15,2013,IB 2013051077 W,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R 1 -R 7 , m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/197-023-379-078-474,Patent Application,yes,86,7,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,17,7,035-937-820-850-821;;063-649-754-807-196;;016-478-179-197-687;;012-968-144-305-859;;007-364-858-655-289;;019-817-021-691-872;;018-344-144-106-967,22507961;;10.1016/j.bmcl.2012.03.089;;pmc7732024;;10.1007/bf02893380;;14688826;;10.1002/hep.510260703;;9305658;;10.1056/nejmoa020047;;12324553;;10.1002/jps.2600660104;;833720;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6;;1100221,"JUNXING SHI ET AL: ""Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 22, no. 10, 22 March 2012 (2012-03-22), pages 3488 - 3491, XP028479285, ISSN: 0960-894X, [retrieved on 20120329], DOI: 10.1016/J.BMCL.2012.03.089;;SZABO E; LOTZ G ET AL., PATHOL. ONCOL. RES., vol. 9, 2003, pages 215 - 221;;HOOFNAGLE JH., HEPATOLOGY, vol. 26, 1997, pages 15S - 20;;BARNES E., WHO FACTSHEET, 2010, Retrieved from the Internet <URL:http://www.who.int/vaccine_research/diseases/viral_cancers/en/index2.html>;;FRIED MW ET AL., N. ENGL. J. MED., vol. 347, 2002, pages 975 - 982;;JESUDIAN AB; GAMBARIN-GELWAN; JACOBSON IM., GASTROENTEROLOGY HEPATOL., vol. 8, 2012, pages 91 - 101;;BERGE S. M. ET AL.: ""Pharmaceutical Salts, a review article"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;P. H. EINRICH STAHLAND; CAMILLE G. WERMUTH: ""Handbook of Pharmaceutical Salts - Properties, Selection, and Use"", 2002, WILEY- VCH;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY, pages: 1445;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2 - 19;;""Pharmaceutics and Pharmacy Practice"", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250;;""ASHP Handbook on Injectable Drugs"", 1986, pages: 622 - 630;;""Remington's Pharmaceutical Science"", 1985, MACK PUBLISHING COMPANY;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;PHYSICIANS' DESK REFERENCE, 2004;;WASSERMAN ET AL., CANCER, vol. 36, 1975, pages 1258 - 1268;;THOMSON PDR: ""Physicians' Desk Reference"", 2004",PENDING
155,BR,A8,BR 112014019584 A8,135-711-298-583-671,2017-07-11,2017,BR 112014019584 A,2013-02-09,IB 2013051077 W;;IN 1017KO2012 A;;IN 147KO2012 A,2012-02-10,"COMPOSTO DA FÓRMULA (I), SUA FORMA TAUTOMÉRICA, SEU ISÔMERO, OU SEU SAL FARMACEUTICAMENTE ACEITÁVEL, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE INIBIÇÃO DA REPLICAÇÃO DE UM VÍRUS CONTENDO RNA, MÉTODO DE TRATAMENTO OU PREVENÇÃO DE INFECÇÃO CAUSADA POR UM VÍRUS CONTENDO RNA, E, MÉTODO DE TRATAMENTO DE INFECÇÃO POR HEPATITE C","COMPOSTO DA FÓRMULA (I), SUA FORMA TAUTOMÉRICA, SEU ISÔMERO, OU SEU SAL FARMACEUTICAMENTE ACEITÁVEL, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE INIBIÇÃO DA REPLICAÇÃO DE UM VÍRUS CONTENDO RNA, MÉTODO DE TRATAMENTO OU PREVENÇÃO DE INFECÇÃO CAUSADA POR UM VÍRUS CONTENDO RNA, E, MÉTODO DE TRATAMENTO DE INFECÇÃO POR HEPATITE C. São divulgados compostos da fórmula (I) para uso como agentes antivirais, particularmente como agentes antivírus da hepatite C, em que A, B, U, R1-R7, m, n, e q são como descritos aqui. São também divulgadas composições farmacêuticas e métodos de tratamento ou prevenção de infecção viral em um hospedeiro pelo uso destes compostos, ou sozinhos ou em combinação com outros agentes farmaceuticamente ativos. São adicionalmente divulgados métodos de preparação de tais compostos.",LUPIN LTD,VIDYA RAMDAS;;ADVAIT ARUN JOSHI;;MOLOY MANOJ BANERJEE;;AMIT KUMAR DAS;;DEEPAK SAHEBRAO WALKE;;VENKATA P PALLE;;RAJENDER KUMAR KAMBOJ,,https://lens.org/135-711-298-583-671,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,DISCONTINUED
156,US,B2,US 9073942 B2,138-733-342-611-024,2015-07-07,2015,US 201314375530 A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,Antiviral compounds with a heterotricycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R 1 -R 7 , m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2014-07-22),https://lens.org/138-733-342-611-024,Granted Patent,yes,96,3,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D495/04;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D409/14;;C07D417/14,,21,8,007-364-858-655-289;;012-968-144-305-859;;016-478-179-197-687;;002-570-636-930-551;;035-937-820-850-821;;063-649-754-807-196;;019-817-021-691-872;;018-344-144-106-967,10.1002/jps.2600660104;;833720;;10.1056/nejmoa020047;;12324553;;10.1002/hep.510260703;;9305658;;22485076;;pmc3317517;;22507961;;10.1016/j.bmcl.2012.03.089;;pmc7732024;;10.1007/bf02893380;;14688826;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6;;1100221,"International Search Report in corresponding International Application No. PCT/IB2013/051077, mailed Jun. 24, 2013.;;Avis, Kenneth E., ""Parenteral Preparations,"" Remington's Pharmaceutical Sciences, 17th Edition, Chapter 85, Mack Publishing Company, Easton, PA, pp. 1518-1541 (1985).;;Barnes, E., ""Hepatitis C,"" World Health Organization Fact Sheet No. 164, http://www.who.int/mediacentre/factsheets/fs164/en/ (Apr. 2014).;;Berge, Stephen M., et al., ""Pharmaceutical Salts,"" Review Article from Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19 (Jan. 1977).;;Deluca, Patrick P., et al., ""Parenteral Drug-Delivery Systems,"" Pharmaceutics and Pharmacy Practice, Chapter 8, J.B. Lippincott Company, Philadelphia, PA, pp. 238-250 (1982).;;Fried, Michael W., et al., ""Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection,"" The New England Journal of Medicine, vol. 347, No. 13, pp. 975-982 (Sep. 26, 2002).;;Hoofnagle, Jay H., ""Hepatitis C: The Clinical Spectrum of Disease,"" Hepatology, vol. 26, No. 3, suppl. 1, pp. 15S-20S (Sep. 1997).;;Jesudian, Arun B., et al., ""Advances in the Treatment of Hepatitis C Virus Infection,"" Gastroenterology & Hepatology, vol. 8, No. 2, pp. 91-101 (Feb. 2012).;;""Product Identification Guide,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 303-340 (2004).;;""Product Information-Eisai,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 1221-1223 (2004).;;""Product Information-Janssen,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 1759-1764 (2004).;;""Product Information-Novartis Pharmaceuticals,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 2252-2259 (2004).;;""Product Information-Pfizer,"" Physicians' Desk Reference, 58th Edition, Thomson PDR, Montvale, NJ, pp. 2570-2573 (2004).;;Remingtons' Pharmaceutical Sciences, 18th Edition, p. 1445 (1990).;;Shi, Junxing, et al., ""Synthesis and biological evaluation of new potent and selective HCV NS5A inhibitors,"" Bioorganic & Medicinal Chemistry Letters, vol. 22, pp. 3488-3491 (2012).;;Stahl, P. Heinrich, et al., Handbook of Pharmaceutical Salts: Properties, Selection, and Use, Wiley-VCH, Weinheim, pp. 1-374 (2002).;;Szabó, Erzsébet, et al., ""Viral Hepatitis: New Data on Hepatitis C Infection,"" Pathology Oncology Research, vol. 9, No. 4, pp. 215-221 (2003).;;Szoka, Jr., Francis, et al., ""Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes),"" Annual Review of Biophysics & Bioengineering, vol. 9, pp. 467-508 (1980).;;Tusco, Salvatore J., et al., ""Intravenous Admixtures,"" Remington's Pharmaceutical Sciences, 17th Edition, Chapter 86, Mack Publishing Company, Easton, PA, pp. 1542-1552 (1985).;;Trissel, Lawrence A., ""Intravenous Infusion Solutions,"" ASHP Handbok on Injectable Drugs, Fourth Edition, American Society of Hospital Pharmacists, Inc., Bethesda, MD, pp. 622-630 (1986).;;Wasserman, Todd H., et al., ""Clinical Comparison of the Nitrosoureas,"" Cancer, vol. 36, pp. 1258-1268 (1975).",INACTIVE
157,AU,B2,AU 2013/217229 B2,094-746-577-285-540,2017-03-02,2017,AU 2013/217229 A,2013-02-09,IN 1017KO2012 A;;IN 147KO2012 A;;IB 2013051077 W,2012-02-10,Antiviral compounds with a heterotricycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/094-746-577-285-540,Granted Patent,no,1,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,ACTIVE
158,CA,A1,CA 2862330 A1,131-683-646-444-838,2013-08-15,2013,CA 2862330 A,2013-02-09,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/131-683-646-444-838,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;A61K31/4178;;A61K31/427;;A61P31/12;;C07D417/14;;C07D495/04,,0,0,,,,DISCONTINUED
159,AU,A1,AU 2013/217224 A1,041-644-506-194-633,2014-08-21,2014,AU 2013/217224 A,2013-02-08,IN 1017KO2012 A;;IN 147KO2012 A;;IB 2013051062 W,2012-02-10,Antiviral compounds with a dibenzooxaheterocycle moiety,"Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein R -R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.(I).",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/041-644-506-194-633,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,ACTIVE
160,IN,A,IN 1548MUN2014 A,156-333-933-609-567,2015-05-08,2015,IN 1548MUN2014 A,2014-07-31,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051077 W;;IN 1548MUN2014 A,2012-02-10,ANTIVIRAL COMPOUNDS WITH A HETEROTRICYCLE MOIETY,Disclosed are compounds of formula (I) for use as antiviral agents particularly as anti hepatitis virus C agents wherein A B U R R m n and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/156-333-933-609-567,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D409/14;;C07D417/14;;C07D495/04,,0,0,,,,PENDING
161,EP,A1,EP 2812326 A1,056-356-052-466-136,2014-12-17,2014,EP 13715002 A,2013-02-08,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W,2012-02-10,ANTIVIRAL COMPOUNDS WITH A DIBENZOOXAHETEROCYCLE MOIETY,,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2017-02-22),https://lens.org/056-356-052-466-136,Patent Application,yes,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,DISCONTINUED
162,NZ,A,NZ 628515 A,022-584-839-538-181,2016-06-24,2016,NZ 62851513 A,2013-02-08,IB 2013051062 W;;IN 147KO2012 A;;IN 1017KO2012 A,2012-02-10,Antiviral compounds with a dibenzooxaheterocycle moiety,"Disclosed are heterocyclic dibenzo-dioxonin derivative compounds of formula (I) for use as antiviral agents, wherein the variables R1-R6 and p are as described in the specification. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds. These compounds inhibits the replication of HCV by targeting a protein of the viral genome and are suitable for treating or preventing infection caused by an RNA-containing virus, particularly hepatitis C virus.",LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/022-584-839-538-181,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/4178;;A61P31/12,,0,0,,,,DISCONTINUED
163,WO,A1,WO 2013/021344 A1,031-790-235-135-799,2013-02-14,2013,IB 2012054020 W,2012-08-07,IN 1046KO2011 A,2011-08-08,IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS,"Compounds of the general formula (I) their tautomeric forms, their stereoisomers, their analogs, their prodrugs, their isotopes, their N-oxides, their metabolites, their pharmaceutically acceptable salts, polymorphs, solvates, optical isomers, clathrates, co-crystals, combinations with suitable medicament, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as antiviral candidate, more specifically as anti-HCV are disclosed.",LUPIN LTD;;RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/031-790-235-135-799,Patent Application,yes,16,5,1,1,0,A61P31/00;;C07D403/14;;C07D413/14;;C07D491/044;;C07D498/04,C07D403/14;;A61K31/4178;;A61K31/4184;;A61K31/422;;A61K31/424;;A61P31/00;;C07D413/14;;C07D491/044;;C07D498/04,,26,13,063-649-754-807-196;;016-478-179-197-687;;012-968-144-305-859;;006-821-015-886-593;;081-875-724-386-341;;086-758-996-497-132;;021-342-104-079-748;;028-192-742-417-071;;038-727-069-767-784;;007-364-858-655-289;;019-817-021-691-872;;018-344-144-106-967;;044-700-497-738-506,10.1007/bf02893380;;14688826;;10.1002/hep.510260703;;9305658;;10.1056/nejmoa020047;;12324553;;10.1111/j.1469-0691.2004.01061.x;;15679481;;10.1177/095632020301400601;;14968935;;10.1016/s0040-4039(02)01085-7;;10.1021/ja991185g;;10.1021/jm9906264;;10821717;;10.1021/jm050317f;;16279795;;10.1021/jm050317f.s001;;10.1002/jps.2600660104;;833720;;10.1146/annurev.bb.09.060180.002343;;6994593;;10.1002/1097-0142(197510)36:4<1258::aid-cncr2820360411>3.0.co;2-6;;1100221;;10.1021/jo010279h;;11485497,"SZABO E; LOTZ G ET AL., PATHOL. ONCOL. RES., vol. 9, 2003, pages 215 - 221;;HOOFNAGLE JH., HEPATOLOGY, vol. 26, 1997, pages 15S - 20;;BARNES E., WHO FACTSHEET, 2010, Retrieved from the Internet <URL:http://www.who.int/vaccine_research/diseases/virai_cancers/en/index2.htmi>;;FRIED MW ET AL., N ENGL J MED., vol. 347, 2002, pages 975 - 982;;JESUDIAN AB; GAMBARIN-GELWAN M; JACOBSON IM., GASTROENTEROLOGY HEPATOL., vol. 8, 2012, pages 91 - 101;;THOMSON BJ ET AL., CLIN MICROBIAL INFECT., vol. 11, 2005, pages 86 - 94;;MORIISHI K ET AL., ANTIVIR. CHEM. CHEMOTHER., vol. 14, 2003, pages 285 - 297;;TETRAHEDRON, vol. 56, 2000, pages 5225 - 5240;;TET. LETT., vol. 43, 2002, pages 5401 - 5404;;J. AM. CHEM. SOC., vol. 121, 1999, pages 7574 - 7581;;TET. ASYMM., vol. 19, 2008, pages 2796 - 2803;;J. MED. CHEM., vol. 43, 2000, pages 2049 - 2063;;J. MED. CHEM., vol. 48, 2005, pages 7351 - 7362;;BERGE S.M. ET AL.: ""Pharmaceutical Salts"", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;P.H.EINRICH; STAHLAND; CAMILLE; G.WERMUTH: ""handbook of pharmaceutical salts properties, selection, and use"", 2002, WILEY- VCH;;""Remington's Pharmaceutical Sciences"", 1990, MACK PUBLISHING COMPANY, pages: 1445;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2 - 19;;""Pharmaceutics and Pharmacy Practice"", 1982, J.B. LIPPINCOTT COMPANY, pages: 238 - 250;;TOISSEL: ""ASHP Handbook on Injectable Drugs"", 1986, pages: 622 - 630;;""Remington's Pharmaceutical Science"", 1985, MACK PUBLISHING COMPANY;;SZOKA ET AL., ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467;;PHYSICIANS' DESK REFERENCE, 2004;;WASSERMAN ET AL., CANCER, vol. 36, 1975, pages 1258 - 1268;;""Physicians' Desk Reference"", 2004;;J. ORG. CHEM., vol. 66, no. 16, 2001, pages 5629 - 5632;;TETRAHEDRON: ASYMMETRY, vol. 19, 2008, pages 2796 - 2803",PENDING
164,IN,A,IN 1547MUN2014 A,189-572-046-667-459,2015-05-08,2015,IN 1547MUN2014 A,2014-07-31,IN 147KO2012 A;;IN 1017KO2012 A;;IB 2013051062 W;;IN 1547MUN2014 A,2012-02-10,ANTIVIRAL COMPOUNDS WITH A DIBENZOOXAHETEROCYCLE MOIETY,Disclosed are compounds of formula (I) for use as antiviral agents particularly as anti hepatitis virus C agents wherein R R 6 and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.(I).,LUPIN LTD,RAMDAS VIDYA;;JOSHI ADVAIT ARUN;;BANERJEE MOLOY MANOJ;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/189-572-046-667-459,Patent Application,no,0,0,29,29,0,C07D405/14;;C07D409/14;;C07D417/14;;C07D495/04;;C07D409/14;;C07D417/14;;A61K31/4178;;A61K31/428;;C07D405/14;;C07D495/04;;A61P31/12;;A61P31/14;;Y02A50/30;;C07D409/14;;C07D417/14;;Y02A50/30;;A61K31/4178;;A61K31/428;;A61K45/06;;C07D405/14;;C07D495/04,C07D405/14;;A61K31/417;;A61P31/12,,0,0,,,,PENDING
165,AR,A1,AR 101070 A1,040-351-571-512-102,2016-11-23,2016,AR P150100933 A,2015-03-30,IN 1170MU2014 A,2014-03-29,COMPUESTOS SULFONAMIDA COMO MODULADORES DE CANAL SÓDICO DE VOLTAJE REGULADO,"Uso en un medicamento para el tratamiento de enfermedades, trastornos asociados con la inhibición de canales sódicos de voltaje regulado (CSVR) particularmente NaV1.7. Asimismo se relaciona con los compuestos de la presente y sus sales farmacéuticamente aceptables, composiciones farmacéuticas de los mismos útiles para tratar enfermedades, trastornos, síndromes y/o estados asociados con la inhibición de canales sódicos de voltaje regulado (CSVR) particularmente el NaV1.7. También se relaciona con el proceso para la preparación de los compuestos del presente. Reivindicación 1: Un compuesto que tiene la fórmula (1) donde, Y se selecciona de CH₂, O y NR; L es una unión u O; R es hidrógeno o alquilo sustituido o no sustituido; A¹ y A² son independientemente hidrógeno o alquilo sustituido o no sustituido; o A¹ y A², junto con el átomo de carbono al cual están unidos forman un anillo cicloalquilo sustituido o no sustituido de 3 a 6 miembros o anillo heterociclilo de 4 - 6 miembros; Z se selecciona de CH₂ o -CH₂-CH₂; R¹ se selecciona de hidrógeno, halógeno, ciano, alquilo sustituido o no sustituido y alcoxi sustituido o no sustituido; el anillo B es arilo sustituido o no sustituido o heteroarilo sustituido o no sustituido; R², que podrá ser igual o diferente en cada evento, se selecciona independientemente de halógeno, ciano, alquilo sustituido o no sustituido, haloalquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, hidroxialquilo sustituido o no sustituido, alcoxialquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido y heterociclilo sustituido o no sustituido; W en cada evento se selecciona independientemente de N o CR³; R³ se selecciona de hidrógeno, halógeno, ciano, alquilo sustituido o no sustituido y alcoxi sustituido o no sustituido; m es un entero que oscila de 0 a 3, ambos inclusive; donde los sustituyentes para alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, hidroxialquilo sustituido o no sustituido, alcoxialquilo sustituido o no sustituido, haloalquilo sustituido o no sustituido son uno o más igual o diferente y seleccionados independientemente del grupo que consiste de hidroxi, halógeno, carboxi, ciano, nitro, oxo (=O), tio (=S), alquilo, haloalquilo, hidroxialquilo, alcoxi-alquilo, alquenilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, cicloalquenilo, heteroarilo, anillo heterocíclico, heterociclilalquilo, heteroarilalquilo, -C(O)ORˣ, -C(O)Rʸ, -C(S)Rʸ, -C(O)NRˣRᶻ, -NRˣC(O)NRˣRᶻ, -N(Rˣ)S(O)₂Rʸ, -NRˣRᶻ, -NRˣC(O)Rʸ, -NRˣC(S)Rʸ, -NRˣC(S)NRˣRᶻ, -S(O)₂NRˣRᶻ, -ORˣ, -OC(O)Rʸ, -C(RᵃRᵇ)₁₋₃C₍O₎ORˣ, -C(RᵃRᵇ)₁₋₃C₍O₎NRˣRᶻ, -OC(RᵃRᵇ)₂₋₃-ORˣ, -OC(RᵃRᵇ)₂₋₃-NRˣRᶻ, -OC(RᵃRᵇ)₂₋₃-S(O)₀₋₂Rʸ, -C(RᵃRᵇ)₁₋₃-NRˣRᶻ, -C(RᵃRᵇ)₁₋₃-S(O)₀₋₂Rʸ, -OC(RᵃRᵇ)₁₋₃-C(O)NRˣRᶻ, -OC(RᵃRᵇ)₁₋₃-C(O)ORˣ, y -S(O)₀₋₂Rʸ; Rˣ, que podrá ser igual o diferente en cada evento, se selecciona independientemente de hidrógeno, alquilo, haloalquilo, alquenilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquenilo, heteroarilo, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; Rʸ, que podrá ser igual o diferente en cada evento, se selecciona independientemente de alquilo, haloalquilo, alquenilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquenilo, heteroarilo, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; y Rᶻ, que podrá ser igual o diferente en cada evento se selecciona independientemente de hidrógeno, alquilo, haloalquilo, alquenilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquenilo, heteroarilo, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; o Rˣ y Rᶻ junto con el átomo de nitrógeno al cual están unidos forman un anillo cíclico sustituido o no sustituido, saturado o no saturado de 4 a 8 miembros, donde el anillo cíclico no saturado podrá tener una o dos uniones doble; u óxidos N de los mismos o una sal farmacéuticamente aceptable de los mismos.",LUPIN LTD,RAJENDER KAMBOJ;;VENKATA P PALLE;;MOLOY BANERJEE;;TALHA HUSSAIN KHAN;;AMIT KUMAR DAS;;DEEPAK SAHEBRAO WALKE;;RAJESHKUMAR MAGANLAL LORIYA;;VIDYA RAMDAS,,https://lens.org/040-351-571-512-102,Patent Application,no,0,0,1,8,0,,C07D417/12;;A61K31/427;;A61K31/4523;;A61P29/00;;C07D417/14,,0,0,,,,PENDING
166,US,B2,US 11773360 B2,012-561-519-214-415,2023-10-03,2023,US 201816607139 A,2018-04-30,IN 201621037647 A;;IB 2018052980 W,2017-05-02,Algal cultivation system and a process for biomass production,"The present disclosure relates to an algal cultivation system comprising an algal pond. The algal pond comprises a growth chamber containing algal culture which is exposed to light to enable rapid growth of algae therein, and a regeneration chamber which is substantially devoid of light and configured to provide a residence time to algal culture for repair of damaged proteins of algal cells. The present disclosure also relates to a process for biomass production, comprising circulating algal culture using convection current or forced convection, between the growth chamber and the regeneration chamber. The system and process facilitate in increasing biomass and mitigating salinity and/or temperature variations in the algal culture (A).",RELIANCE INDUSTRIES LTD,MOHAN NATARAJAN;;MAHULKAR AMIT VINOD;;VELUSWAMY GANESH K;;KHOPKAR AVINASH RAMCHANDRA;;MADDIKERI GANESH LAKSHMAN;;KIRDAT NITIN NARAYAN;;BANERJEE ARUN;;YELCHURI RAVIKUMAR,RELIANCE INDUSTRIES LIMITED (2019-12-18),https://lens.org/012-561-519-214-415,Granted Patent,yes,10,0,4,4,0,A01G33/00;;C12M21/02;;C12N1/12;;C12M23/58;;Y02A40/80;;C12M21/02;;C12M23/18;;C12M23/38;;C12M27/20;;C12M29/00;;C12N1/12;;C12M23/58,C12M1/00;;C12N1/12,,3,2,107-801-347-730-10X;;010-499-194-668-381,27584904;;10.1016/j.biortech.2016.08.083;;10.1080/00071618500650161,"Bilanovic et al., Co-cultivation of microalgae and nitrifiers for higher biomass production and better carbon capture, Aug. 25, 2016, Bioresource Technology 220, pp. 282-288 (Year: 2016).;;Gibson, Growth rate, maintenance energy and pigmentation of planktonic Cyanophyta during one-hour light: dark cycles, 1985, Br. phycol. J., 20:155-161 (Year: 1985).;;ISA/IN, PCT International Search Report and Written Opinion dated Aug. 1, 2018 issued in PCT International Application No. PCT/IB2018/052980 filed Apr. 30, 2018.",ACTIVE
167,SA,B1,SA 519410545 B1,067-633-920-718-64X,2022-11-07,2022,SA 519410545 A,2019-10-28,IN 201621037647 A,2017-05-02,AN ALGAL CULTIVATION SYSTEM AND A PROCESS FOR BIOMASS PRODUCTION,"The present disclosure relates to an algal cultivation system comprising an algal pond (202). The algal pond (202) comprises a growth chamber (206a) containing algal culture which is exposed to light to enable rapid growth of algae therein, and a regeneration chamber (206b) which is substantially devoid of light and configured to provide a residence time to algal culture for repair of damaged proteins of algal cells. The present disclosure also relates to a process for biomass production, comprising circulating algal culture using convection current or forced convection, between the growth chamber (206a, 10) and the regeneration chamber (206b, 12). The system and process facilitate in increasing biomass and mitigating salinity and/or temperature variations in the algal culture (A). See fig.3",RELIANCE INDUSTRIES LTD,BANERJEE ARUN;;MAHULKAR AMIT VINOD;;KHOPKAR AVINASH RAMCHANDRA;;VELUSWAMY GANESH K;;MADDIKERI GANESH LAKSHMAN;;YELCHURI RAVIKUMAR;;MOHAN NATARAJAN;;KIRDAT NITIN NARAYAN,,https://lens.org/067-633-920-718-64X,Granted Patent,no,0,0,4,4,0,A01G33/00;;C12M21/02;;C12N1/12;;C12M23/58;;Y02A40/80;;C12M21/02;;C12M23/18;;C12M23/38;;C12M27/20;;C12M29/00;;C12N1/12;;C12M23/58,,,0,0,,,,ACTIVE
168,US,A1,US 2020/0385662 A1,177-388-714-394-885,2020-12-10,2020,US 201816607139 A,2018-04-30,IN 201621037647 A;;IB 2018052980 W,2017-05-02,ALGAL CULTIVATION SYSTEM AND A PROCESS FOR BIOMASS PRODUCTION,"The present disclosure relates to an algal cultivation system comprising an algal pond. The algal pond comprises a growth chamber containing algal culture which is exposed to light to enable rapid growth of algae therein, and a regeneration chamber which is substantially devoid of light and configured to provide a residence time to algal culture for repair of damaged proteins of algal cells. The present disclosure also relates to a process for biomass production, comprising circulating algal culture using convection current or forced convection, between the growth chamber and the regeneration chamber. The system and process facilitate in increasing biomass and mitigating salinity and/or temperature variations in the algal culture (A).",RELIANCE INDUSTRIES LTD,MOHAN NATARAJAN;;MAHULKAR AMIT VINOD;;VELUSWAMY GANESH K;;KHOPKAR AVINASH RAMCHANDRA;;MADDIKERI GANESH LAKSHMAN;;KIRDAT NITIN NARAYAN;;BANERJEE ARUN;;YELCHURI RAVIKUMAR,RELIANCE INDUSTRIES LIMITED (2019-12-18),https://lens.org/177-388-714-394-885,Patent Application,yes,1,0,4,4,0,A01G33/00;;C12M21/02;;C12N1/12;;C12M23/58;;Y02A40/80;;C12M21/02;;C12M23/18;;C12M23/38;;C12M27/20;;C12M29/00;;C12N1/12;;C12M23/58,C12M1/00;;C12N1/12,,2,2,107-801-347-730-10X;;010-499-194-668-381,27584904;;10.1016/j.biortech.2016.08.083;;10.1080/00071618500650161,"Bilanovic et al., Co-cultivation of microalgae and nitrifiers for higher biomass production and better carbon capture, 25 August 2016, Bioresource Technology 220, pp. 282-288 (Year: 2016);;Gibson, Growth rate, maintenance energy and pigmentation of planktonic Cyanophyta during one-hour light: dark cycles, 1985, Br. phycol. J., 20:155-161 (Year: 1985)",ACTIVE
169,MA,A,MA 39778 A,051-241-697-341-689,2017-02-08,2017,MA 39778 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A,2014-03-29,SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,"The present invention relates to the compound of formula (i) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of voltage-gated sodium channels (vgsc) particularly na",LUPIN LTD,BANERJEE MOLOY;;DAS AMIT KUMAR;;KAMBOJ RAJENDER KUMAR;;KHAN TALHA HUSSAIN;;LORIYA RAJESHKUMAR MAGANLAL;;PALLE VENKATA P;;RAMDAS VIDYA;;WALKE DEEPAK SAHEBRAO,,https://lens.org/051-241-697-341-689,Unknown,no,0,0,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,A61K31/427;;A61P39/00;;C07D417/12,,0,0,,,,PENDING
170,TW,A,TW 201623264 A,068-107-724-936-734,2016-07-01,2016,TW 104109916 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A,2014-03-29,Sulfonamide compounds as voltage gated sodium channel modulators,"The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions there of useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/068-107-724-936-734,Patent of Addition,no,0,0,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,C07D277/52;;A61K31/426;;A61K31/427;;A61K31/433;;A61K31/4439;;A61K31/454;;A61K31/506;;A61P25/04;;A61P29/00;;C07D285/08;;C07D417/12;;C07D417/14,,0,0,,,,PENDING
171,AU,A1,AU 2015/242219 A1,147-634-223-367-316,2016-10-06,2016,AU 2015/242219 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A;;IB 2015052273 W,2014-03-29,Sulfonamide compounds as Voltage gated sodium channel modulators,"The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/147-634-223-367-316,Patent Application,no,0,0,7,8,0,C07D417/12;;C07D417/14;;A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/14,C07D417/12;;A61K31/427;;A61P39/00,,0,0,,,,DISCONTINUED
172,US,A1,US 2017/0137415 A1,047-916-947-228-506,2017-05-18,2017,US 201515300337 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A;;IB 2015052273 W,2014-03-29,SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,"The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2016-09-23),https://lens.org/047-916-947-228-506,Patent Application,yes,0,2,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,C07D417/12;;C07D417/14,,6,2,010-830-693-310-162;;039-683-657-155-076,pmc5084288;;19789071;;10.1016/j.nurt.2009.08.001;;25060923;;10.1016/j.bmcl.2014.06.038,"Erythromelalgia, 2017,http://emedicine.medscape.com/article/200071-treatment#d10;;Mexiletine, 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209151/;;Bhattacharya et al., THe Journal of the American Society for Experimental NeuroTherapeutics, 6, 663-678, 2009;;Bagal et al., Bioorganic&Medicinal Chemistry Letters, 24 (2014), 3690-3699;;Erythromelalgia-Cure, https://mnphysicalmedicine.com/2017/06/12/erythrolelalgia-potential-chronic-pain-cure/;;NeuropathicPain, 2017, https://www.spine-health.com/treatment/pain-management/treatment-options-neuropathic-pain",DISCONTINUED
173,CA,A1,CA 2944115 A1,021-492-760-238-579,2015-10-08,2015,CA 2944115 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A;;IB 2015052273 W,2014-03-29,SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,"The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/021-492-760-238-579,Patent Application,no,0,1,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,C07D417/12;;A61K31/427;;A61P39/00,,0,0,,,,DISCONTINUED
174,WO,A1,WO 2015/151001 A1,136-589-697-637-032,2015-10-08,2015,IB 2015052273 W,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A,2014-03-29,SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,"The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/136-589-697-637-032,Patent Application,yes,33,10,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,C07D417/12;;A61K31/427;;A61P39/00,,9,7,108-251-201-453-19X;;050-735-706-708-66X;;010-110-239-299-471;;050-582-206-719-069;;112-819-083-141-446;;004-440-321-786-118;;050-898-949-194-866,10.4155/fmc.10.26;;21426202;;10.1073/pnas.0402765101;;pmc419575;;15148385;;pmc19825;;10.1073/pnas.94.4.1527;;9037087;;10.1002/j.1460-2075.1995.tb07091.x;;7720699;;pmc398185;;10.1158/1078-0432.ccr-05-0327;;16061851;;10.2174/138161206778522047;;17073667;;16088330;;10.1038/sj.pcan.4500796,"ENGLAND; RAWSON, FUTURE MED. CHEM., vol. 2, 2010, pages 775 - 790;;HOYT ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, 2008, pages 1963 - 1966;;BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 3676 - 681;;CRANER, M.J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 8168 - 73;;TOLEDO-ARAL, J. J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1527 - 1532;;KLUGBAUER, N. ET AL., EMBO J., vol. 14, 1995, pages 1084 - 90;;FRASER ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 5381 - 5389;;CURRENT PHARMACEUTICAL DESIGN, vol. 12, 2006, pages 3681 - 3695;;PROSTATE CANCER AND PROSTATIC DISEASES, vol. 8, 2005, pages 266 - 273",PENDING
175,EP,A1,EP 3126360 A1,068-802-282-768-378,2017-02-08,2017,EP 15717252 A,2015-03-27,IN 1170MU2014 A;;IN 566MU2015 A;;IB 2015052273 W,2014-03-29,SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,,LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;WALKE DEEPAK SAHEBRAO;;DAS AMIT KUMAR;;KHAN TALHA HUSSAIN;;BANERJEE MOLOY;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2017-02-22),https://lens.org/068-802-282-768-378,Patent Application,yes,0,0,7,8,0,A61P25/04;;A61P29/00;;A61P39/00;;C07D417/12;;C07D417/12;;C07D417/14;;C07D417/14,C07D417/12;;A61K31/427;;A61P39/00,,1,0,,,See references of WO 2015151001A1,DISCONTINUED
176,WO,A1,WO 2018/163077 A1,074-910-420-424-975,2018-09-13,2018,IB 2018051464 W,2018-03-07,IN 201721008160 A,2017-03-08,INDANYL COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS,"The invention relates to indanyl compounds, their pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising the same for the treatment, management and /or lessening severity of diseases, disorders, syndromes or conditions which are associated with the voltage-gated sodium channels (VGSC). More specifically the present invention provides compounds having the structure of Formula (I).",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR;;BANERJEE MOLOY;;CHAURE GANESH;;DAS AMIT;;JOSHI ADVAIT;;WALKE DEEPAK;;DATRANGE LAXMIKANT;;PATIL PRADEEP;;PALLE VENKATA;;KAMBOJ RAJENDER,,https://lens.org/074-910-420-424-975,Patent Application,yes,28,0,1,1,0,A61P25/00;;C07D213/72;;C07D239/32;;C07D277/38;;C07D401/12;;C07D403/12;;C07D405/12;;C07D413/12;;C07D417/12,C07D403/12;;A61K31/4427;;A61K31/506;;A61P25/00;;C07D213/72;;C07D239/32;;C07D277/38;;C07D401/12;;C07D405/12;;C07D413/12;;C07D417/12,,16,11,108-251-201-453-19X;;043-354-347-284-478;;064-865-606-080-143;;050-735-706-708-66X;;010-110-239-299-471;;050-582-206-719-069;;112-819-083-141-446;;004-440-321-786-118;;050-898-949-194-866;;026-467-180-050-569;;019-065-497-415-17X,10.4155/fmc.10.26;;21426202;;23850655;;10.1016/j.pupt.2013.07.001;;10.1242/jcs.130013;;23986482;;10.1073/pnas.0402765101;;pmc419575;;15148385;;pmc19825;;10.1073/pnas.94.4.1527;;9037087;;10.1002/j.1460-2075.1995.tb07091.x;;7720699;;pmc398185;;10.1158/1078-0432.ccr-05-0327;;16061851;;10.2174/138161206778522047;;17073667;;16088330;;10.1038/sj.pcan.4500796;;10.1080/00397919008051545;;25176194;;10.1016/j.bmcl.2014.08.017,"ENGLAND; RAWSON, FUTURE MED. CHEM., vol. 2, 2010, pages 775 - 790;;HOYT ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, 2008, pages 1963 - 1966;;PULM. PHARMACOL. THER., vol. 26, no. 5, 2013, pages 508 - 509;;INT. J. MOL. SCI., vol. 17, 2016, pages 1479;;SCIENTIFIC REPORTS, vol. 22, no. 5, June 2015 (2015-06-01), pages 11541;;JOURNAL OF CELL SCIENCE, vol. 126, no. 21, 2013, pages 4939 - 4949;;BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 3676 - 681;;CRANER, M.J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, 2004, pages 8168 - 73;;TOLEDO-ARAL, J. J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1527 - 1532;;KLUGBAUER, N. ET AL., EMBO J., vol. 14, 1995, pages 1084 - 90;;FRASER ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 5381 - 5389;;CURRENT PHARMACEUTICAL DESIGN, vol. 12, 2006, pages 3681 - 3695;;PROSTATE CANCER AND PROSTATIC DISEASES, vol. 8, 2005, pages 266 - 273;;HOWBERT ET AL., SYNTH COMMUN, vol. 20, no. 20, 1990, pages 3193 - 3200;;SUN ET AL., BIOORG. MED. CHEM. LETT., vol. 24, no. 18, 2014, pages 4397 - 4401;;LEE ET AL., J. AM. CHEM. SOC., vol. 139, no. 2, 2017, pages 976 - 989",PENDING
177,US,A1,US 2023/0297956 A1,110-038-983-766-658,2023-09-21,2023,US 202217699654 A,2022-03-21,US 202217699654 A,2022-03-21,SYSTEM AND METHOD FOR MANAGING INVOICE EXCEPTIONS,"A method and system for detecting deviation between invoices and receipts are disclosed. In some embodiments, the method includes receiving invoice data and receipt data. The method includes filtering the received data to generate filtered data. The method includes performing line-level matching on the filtered data based on one or more line-level attributes and one or more distance based algorithms. The method then includes determining, from the line-level matching, matched line items and unmatched line items between each pair of the invoice and receipts. The method also includes calculating one or more types of claims for both the matched line items and the unmatched line items to measure a total deviation between the invoices and receipts. The method further includes determining a level of match between the invoices and receipts and generating a recommended matching pair of invoice and receipt based on the level of match. The matches are further improved by user feedback to the recommended pairs which is used to train a machine learning model.",GENPACT LUXEMBOURG S A R L II,KUMARI NILOO;;BANERJEE SAYANTAN;;SHARMA ANIRUDH;;KUMAR RAVI;;HAUSER DAVID I;;MENON SREEKANTH;;ESHWAR BHAVANI;;MANOJ BINDU;;DESHPANDE NIKHIL;;THAKOR ANURAG;;KAPUR AMIT,,https://lens.org/110-038-983-766-658,Patent Application,yes,8,0,1,1,0,G06Q10/0875;;G06N5/022;;G06N5/04;;G06N20/00;;G06V30/412;;G06V30/418;;G06Q10/0875;;G06V30/412;;G06N20/00;;G06V30/387;;G06V30/19093,G06Q10/08;;G06V30/19;;G06V30/32;;G06V30/412,,0,0,,,,PENDING
178,US,A1,US 2016/0110502 A1,014-972-161-350-234,2016-04-21,2016,US 201414517044 A,2014-10-17,US 201414517044 A,2014-10-17,Human and Machine Assisted Data Curation for Producing High Quality Data Sets from Medical Records,"A method for building a Patient's Data Set from a Patient's Data File to provide robust patient care comprising the steps of obtaining a Patient's Data File, building a training set for machine learning through experts' selection of at least one desired feature from the Patient's Data File to create the Patient's Data Set, developing a data mining algorithm to automate extraction of at least one data feature from at least one other Patient's Data File using the training set, the algorithm automatically generating the Patient's Data Set from at least one other Patient's Data File, supplementing the Patient's Data Set with at least one patient input, and analyzing the Patient's Data Set to confirm patient course of treatment.",BETTERPATH INC,BRONSON JONATHAN;;BANERJEE STACY;;COLLINSON BRETT;;GOLDMAN ROBERT;;HASSEIN NABIL;;KHIVESARA AMIT;;KUNTZ G RALPH;;RUSSELL B ADAM;;SINDERBRAND ALEXANDRA;;SINDERBRAND GARY MARK;;SINDERBRAND MATTHEW,,https://lens.org/014-972-161-350-234,Patent Application,yes,3,15,1,1,0,G16H10/60;;G16H10/60;;G06Q50/01;;G06Q50/01;;G16H10/20;;G16H10/20;;G16H50/70;;G16H50/70,G06F19/00;;G06N99/00;;G06Q50/00,,0,0,,,,DISCONTINUED
179,US,B1,US 6261810 B1,093-331-572-865-000,2001-07-17,2001,US 38658899 A,1999-08-31,US 38658899 A;;US 9895698 P,1998-09-03,Enzymatic oxidative deamination process,The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;LUST DAVID A;;SRIVASTAVA SUSHIL K,BRISTOL-MYERS SQUIBB COMPANY (1999-10-12),https://lens.org/093-331-572-865-000,Granted Patent,yes,2,9,14,14,2,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C12N15/09;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,435/119;;435/118;;435/193,22,18,055-792-532-851-126;;066-141-497-990-023;;032-728-154-591-070;;114-619-682-814-274;;028-454-131-133-472;;082-902-765-648-368;;064-397-996-119-618;;013-891-870-160-838;;050-580-471-089-96X;;014-978-026-283-267;;047-294-079-836-486;;028-928-148-811-585;;029-259-061-759-228;;070-383-251-783-098;;000-346-919-904-207;;024-841-374-797-219;;020-533-566-973-694;;155-072-250-959-286,2410914;;pmc390513;;10.1073/pnas.82.15.5131;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/0022-2836(70)90057-4;;5420325;;3092189;;pmc311678;;10.1093/nar/14.16.6745;;2672459;;10.1016/0168-9525(89)90073-5;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/oxfordjournals.jbchem.a123388;;1880121;;344137;;344136;;10.1016/0378-1119(77)90000-2;;10.1038/275617a0;;360074;;386136;;10.1038/281544a0;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;pmc179396;;10.1128/jb.179.17.5300-5308.1997;;9286980;;10.1271/bbb.62.622;;9614692;;6363212;;10.1016/0378-1119(83)90222-6;;6248238;;10.1016/0092-8674(80)90613-3;;10.1073/pnas.74.12.5463;;271968;;pmc431765;;10.1073/pnas.74.2.560;;265521;;pmc392330;;10.1016/s0021-9258(19)34176-6;;5658538,"Houghton et al., Proc.Natl Acad.Sci. 82, 5131-5135 (1985).;;Devereux et al., Nucl.Acids Res. 12:387-395 (1984).;;Needleman et al., J. Mol. Biol. 48:443-453 (1970).;;Smith et al., Adv.Appl.Math 2:482 (1981).;;Gribskov et al., Nucl. Acids Res. 14:6745-6763.;;White et al., Trends Genet. 5:185-189 (1989).;;Morinaga et al., Nucl. Acids. Res. 2:636-639 (1984).;;Taylor et al., Nucl, Acids Res. 13:8746-8764 (1985).;;Kunkel, Proc. Natl. Acad. Sci USA 82:482-492 (1985).;;Sayers et al., Nucl. Acids Res. 16:791-802 (1988).;;Takada et al., J. Biochem. 109:371-376 (1991).;;Bolivar et al., Gene 2:95-113 (1977).;;Chang et al., Nature, 275:617-624 (1978).;;Goeddel et al., Nature 281:544-548 (1979).;;Goeddel et al., Nucl. Acids Res. 8:4057-4074 (1980).;;Park et al. J. Bacteriol 1997, vol. 179, No. 17, pp. 5300-5308.;;Oku et al. Biosci. Biotech.Biochem. 1998, vol. 62, No. 4, pp. 622-627.;;Amann et al., Gene 25, 167-178 (1983).;;Siebenlist et al., Cell 20:269-281 (1980).;;Sanger et al., Proc.Natl.Acad.Sci.USA 74:5463-5467 (1977).;;Maxam et al., Proc.Natl.Acad.Sci.USA 74:560-564 (1977).;;J. Biol. Chem. 243:3557-3559 (1969).",EXPIRED
180,US,B2,US 11321518 B2,054-195-388-875-788,2022-05-03,2022,US 202117200665 A,2021-03-12,US 202117200665 A;;US 201815907237 A,2018-02-27,Machine learning based document editing engine,"A method for machine learning based document editing is provided. The method may include receiving, from a client, one or more inputs associated with a document. A recommendation to include and/or exclude a clause, a term, and/or a line item from the document may be generated by at least processing the one or more inputs with a machine learning model. The recommendation to include and/or exclude the clause, the term, and/or the line item from the document may be provided to the client. Related systems and articles of manufacture, including computer program products, are also provided.",SAP SE,BANERJEE DEBASHIS;;GOVINDAPPA PRASANNA KUMAR;;HERMAN DAVID;;SUDHEENDRA KRISHNA HINDHUPUR VIJAY;;JINADATTA SHRUTHI;;TAMBALI ANILKUMAR;;GANESAN PRAVINTH;;SAXENA AMIT;;RATHI GAURAV;;RAGHUNATHAN BALAJI;;KRISHNAN HARI BABU,SAP SE (2018-02-26),https://lens.org/054-195-388-875-788,Granted Patent,yes,9,0,5,5,0,G06F16/2457;;G06F16/9035;;G06N3/08;;G06N20/00;;G06N3/045;;G06F40/191;;G06N20/10;;G06N3/084;;G06N3/082;;G06N20/20;;G06N5/01;;G06N3/047;;G06N7/01;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/02;;G06N20/00;;G06F40/166,G06F17/00;;G06F40/166;;G06N3/02;;G06N20/00;;G06Q10/10,,0,0,,,,ACTIVE
181,US,A1,US 2021/0200936 A1,131-164-614-493-163,2021-07-01,2021,US 202117200665 A,2021-03-12,US 202117200665 A;;US 201815907237 A,2018-02-27,MACHINE LEARNING BASED DOCUMENT EDITING ENGINE,"A method for machine learning based document editing is provided. The method may include receiving, from a client, one or more inputs associated with a document. A recommendation to include and/or exclude a clause, a term, and/or a line item from the document may be generated by at least processing the one or more inputs with a machine learning model. The recommendation to include and/or exclude the clause, the term, and/or the line item from the document may be provided to the client. Related systems and articles of manufacture, including computer program products, are also provided.",SAP SE,BANERJEE DEBASHIS;;GOVINDAPPA PRASANNA KUMAR;;HERMAN DAVID;;SUDHEENDRA KRISHNA HINDHUPUR VIJAY;;JINADATTA SHRUTHI;;TAMBALI ANILKUMAR;;GANESAN PRAVINTH;;SAXENA AMIT;;RATHI GAURAV;;RAGHUNATHAN BALAJI;;KRISHNAN HARI BABU,SAP SE (2018-02-26),https://lens.org/131-164-614-493-163,Patent Application,yes,0,0,5,5,0,G06F16/2457;;G06F16/9035;;G06N3/08;;G06N20/00;;G06N3/045;;G06F40/191;;G06N20/10;;G06N3/084;;G06N3/082;;G06N20/20;;G06N5/01;;G06N3/047;;G06N7/01;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/02;;G06N20/00;;G06F40/166,G06F40/166;;G06N3/02;;G06N20/00,,0,0,,,,ACTIVE
182,US,B2,US 10977429 B2,132-309-517-898-346,2021-04-13,2021,US 201815907237 A,2018-02-27,US 201815907237 A,2018-02-27,Machine learning based document editing engine,"A method for machine learning based document editing is provided. The method may include receiving, from a client, one or more inputs associated with a document. A recommendation to include and/or exclude a clause, a term, and/or a line item from the document may be generated by at least processing the one or more inputs with a machine learning model. The recommendation to include and/or exclude the clause, the term, and/or the line item from the document may be provided to the client. Related systems and articles of manufacture, including computer program products, are also provided.",SAP SE,BANERJEE DEBASHIS;;GOVINDAPPA PRASANNA KUMAR;;HERMAN DAVID;;SUDHEENDRA KRISHNA HINDHUPUR VIJAY;;JINADATTA SHRUTHI;;TAMBALI ANILKUMAR;;GANESAN PRAVINTH;;SAXENA AMIT;;RATHI GAURAV;;RAGHUNATHAN BALAJI;;KRISHNAN HARI BABU,SAP SE (2018-02-26),https://lens.org/132-309-517-898-346,Granted Patent,yes,9,1,5,5,0,G06F16/2457;;G06F16/9035;;G06N3/08;;G06N20/00;;G06N3/045;;G06F40/191;;G06N20/10;;G06N3/084;;G06N3/082;;G06N20/20;;G06N5/01;;G06N3/047;;G06N7/01;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/02;;G06N20/00;;G06F40/166,G06F17/00;;G06F40/166;;G06N3/02;;G06N20/00,,0,0,,,,ACTIVE
183,US,A1,US 2019/0266231 A1,170-284-308-316-530,2019-08-29,2019,US 201815907237 A,2018-02-27,US 201815907237 A,2018-02-27,MACHINE LEARNING BASED DOCUMENT EDITING ENGINE,"A method for machine learning based document editing is provided. The method may include receiving, from a client, one or more inputs associated with a document. A recommendation to include and/or exclude a clause, a term, and/or a line item from the document may be generated by at least processing the one or more inputs with a machine learning model. The recommendation to include and/or exclude the clause, the term, and/or the line item from the document may be provided to the client. Related systems and articles of manufacture, including computer program products, are also provided.",SAP SE,BANERJEE DEBASHIS;;GOVINDAPPA PRASANNA KUMAR;;HERMAN DAVID;;SUDHEENDRA KRISHNA HINDHUPUR VIJAY;;JINADATTA SHRUTHI;;TAMBALI ANILKUMAR;;GANESAN PRAVINTH;;SAXENA AMIT;;RATHI GAURAV;;RAGHUNATHAN BALAJI;;KRISHNAN HARI BABU,SAP SE (2018-02-26),https://lens.org/170-284-308-316-530,Patent Application,yes,9,8,5,5,0,G06F16/2457;;G06F16/9035;;G06N3/08;;G06N20/00;;G06N3/045;;G06F40/191;;G06N20/10;;G06N3/084;;G06N3/082;;G06N20/20;;G06N5/01;;G06N3/047;;G06N7/01;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/02;;G06N20/00;;G06F40/166,G06F17/24;;G06N3/02,,0,0,,,,ACTIVE
184,AU,A4,AU 2021/102148 A4,057-817-210-848-056,2021-06-10,2021,AU 2021/102148 A,2021-04-22,AU 2021/102148 A,2021-04-22,PROCESS FOR SYNTHESIZING EUROPIUM DOPED GRAPHITIC CARBON NITRIDE (g-C3N4) FOR REMOVAL OF TEXTILE DYES FROM WATER,Abstract The present disclosure seeks to provide a process for synthesizing Europium-doped g C 3N4an efficient remover of textile dyes from water. It will help the scientific community to develop a cost effective way of synthesizing g-C 3N 4 doped with a rare earth element. This is the first probable report of removal of Rh-B by Eu doped g-C 3N 4 . The method is cost friendly. The material has been proven to be same effective under different pH conditions. The system shows good and reliable photo-catalysis with advantage regarding easy synthesis process. The present disclosure provides meaningful guidelines for improving photo-catalytic activity by modifying rare earth elements. Adding 6 gr of urea a nd grn of thioureaJ ina 250 mL beaker anI dissolving in 102 100 rnIlof ethanol by continuous stirring for 1 hour at a tern perature of 80degreeCelsius Re-crystallizing the prepared solution by evaporation of ethanol 104 Crus hiing the crystalIzed produced and the obtained powder is thereafter taken into an alumira crucible 106 Wra ppirig the crucible with foilI pa per to prevent eva poration of nitrogen from the system I V 108 Heating the foil w rapped alumina crucible in a muffle furnace at the tem perature of 60degree Celsius for 5 hours to produce the final product 110 Adding europium nitrate [u(NO)S9] as the precursor of the dopa nt for preparationof Europium doped graphiticcarbon nitride Figure1 (002) (b) -- SampleO dSample A -- SampleB 100) 10 20 30 40 50 W 70 .osa 20 (Degree) Figure2,BANERJEE DIPTONIL;;JANA SANANDA;;KUMAR PRASHANT;;P SHRIVASTAVA VISHNU;;PANDEY S P;;SARKAR SUDARSHAN;;SHARMA AMIT K;;SINGH PAVAN K;;SINGH VARUN K;;UPADHYAY AJAY K,BANERJEE DIPTONIL;;SARKAR SUDARSHAN;;JANA SANANDA;;P SHRIVASTAVA VISHNU;;SINGH PAVAN K;;UPADHYAY AJAY K;;PANDEY S P;;SINGH VARUN K;;KUMAR PRASHANT;;SHARMA AMIT K,,https://lens.org/057-817-210-848-056,Limited Patent,no,0,0,1,1,0,B01J27/24;;B01J35/39,B01J27/24;;B01J35/00,,0,0,,,,INACTIVE
185,CN,A,CN 110196864 A,163-926-777-500-427,2019-09-03,2019,CN 201811485899 A,2018-12-06,US 201815907237 A,2018-02-27,MACHINE LEARNING BASED DOCUMENT EDITING ENGINE,"A method for machine learning based document editing is provided. The method may include receiving, from a client, one or more inputs associated with a document. A recommendation to include and/or exclude a clause, a term, and/or a line item from the document may be generated by at least processing the one or more inputs with a machine learning model. The recommendation to include and/or exclude the clause, the term, and/or the line item from the document may be provided to the client. Related systems and articles of manufacture, including computer program products, are also provided.",SAP SE,BANERJEE DEBASHIS;;GOVINDAPPA PRASANNA KUMAR;;HERMAN DAVID;;SUDHEENDRA KRISHNA HINDHUPUR VIJAY;;JINADATTA SHRUTHI;;TAMBALI ANILKUMAR;;GANESAN PRAVINTH;;SAXENA AMIT;;RATHI GAURAV;;RAGHUNATHAN BALAJI;;KRISHNAN HARI BABU,,https://lens.org/163-926-777-500-427,Patent Application,no,6,0,5,5,0,G06F16/2457;;G06F16/9035;;G06N3/08;;G06N20/00;;G06N3/045;;G06F40/191;;G06N20/10;;G06N3/084;;G06N3/082;;G06N20/20;;G06N5/01;;G06N3/047;;G06N7/01;;G06N3/048;;G06N3/044;;G06N3/045;;G06N3/02;;G06N20/00;;G06F40/166,G06F16/2457;;G06F16/9035;;G06N3/04;;G06N3/08;;G06N20/00,,0,0,,,,PENDING
186,EC,A,EC SP22005485 A,084-363-628-437-890,2022-02-25,2022,EC DI202205485 A,2022-01-21,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A,2019-07-22,COMPUESTOS MACROCÍCLICOS COMO AGONISTAS DE STING Y MÉTODOS Y USOS DE LOS MISMOS,"Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.",LUPIN LTD,WALKE DEEPAK;;KALHAPURE VAIBHAV;;KARCHE NAVNATH;;RAMDAS VIDYA;;BHOSKAR SMITA ADITYA;;BANERJEE MOLOY;;VYAVAHARE VINOD;;PALLE VENKATA;;JADHAV GANESH RAJARAM;;DAS AMIT KUMAR;;GUPTA NISHANT RAMNIVASJI;;KAMBOJ RAJENDER KUMAR,,https://lens.org/084-363-628-437-890,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,0,0,,,,PENDING
187,US,B1,US 10851315 B1,095-430-765-379-996,2020-12-01,2020,US 201916454506 A,2019-06-27,US 201916454506 A,2019-06-27,Processes for increasing an octane value of a gasoline component,"Processes for the production of a gasoline blend. A C 7 portion of a naphtha stream is first isomerized to increase the branched, iso-paraffins, and then, the isomerized effluent is passed to a dehydrogenation reaction zone. In the dehydrogenation zone, the C 7 saturated hydrocarbons are convert to C 7 olefins. The C 7 olefins have a higher octane number than the C 7 saturated hydrocarbons, and the branched olefins have a higher octane number than the normal olefins. The C 7 olefins can be blended in a gasoline pool. C 5 and C 6 hydrocarbons can be isomerized and dehydrogenated as well, separately or with the C 7 components.",UOP LLC,LAPINSKI MARK P;;GATTUPALLI RAJESWAR;;GLOVER BRYAN K;;SHAKUR MOHAMED;;COUCH KEITH A;;PENNINGER MICHAEL W;;BANERJEE SOUMENDRA MOHAN;;BISHT DEEPAK;;PANDEY GAUTAM;;SHARMA AMIT;;JANI PRIYESH JAYENDRAKUMAR;;GARG NISHESH,UOP LLC (2018-06-28),https://lens.org/095-430-765-379-996,Granted Patent,yes,11,1,1,1,0,C10G63/06;;C10G35/04;;C10G63/06;;C10G35/04;;C10G2300/4081;;C10G2300/1044;;C10G2400/02,C10G63/06;;C10G35/04,,0,0,,,,ACTIVE
188,CR,A,CR 20220029 A,034-120-438-885-967,2022-03-14,2022,CR 20220029 A,2020-07-22,IN 202021003961 A;;IN 201921029556 A;;IN 201921051086 A;;IB 2020056875 W,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KAMBOJ RAJENDER KUMAR;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;DAS AMIT KUMAR;;PALLE VENKATA P;;KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;RAMDAS VIDYA;;BHOSKAR SMITA ADITYA;;VYAVAHARE VINOD POPATRAO;;KALHAPURE VAIBHAV MADHUKAR;;WALKE DEEPAK SAHEBRAO,,https://lens.org/034-120-438-885-967,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D519/00;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D498/16,,0,0,,,,PENDING
189,BR,A2,BR 112022001125 A2,023-026-638-994-973,2022-03-15,2022,BR 112022001125 A,2020-07-22,IB 2020056875 W;;IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A,2019-07-22,"Compostos macrocíclicos como agonistas de sting, seus métodos e seus usos","compostos macrocíclicos como agonistas de sting, seus métodos e seus usos. são descritos compostos macrocíclicos tendo a fórmula geral (i) ou (ii), e suas formas tautoméricas, estereo-isômeros, sais farmaceuticamente aceitáveis, hidratos, solvatos e pró-fármacos dos mesmos, sua combinação com medicamentos adequados, processos correspondentes para a síntese, composições farmacêuticas, e usos dos compostos aqui descritos.",LUPIN LTD,AMIT KUMAR DAS;;DEEPAK SAHEBRAO WALKE;;GANESH RAJARAM JADHAV;;BANERJEE MOLOY;;NAVNATH POPAT KARCHE;;NISHANT RAMNIVASJI GUPTA;;RAJENDER KUMAR KAMBOJ;;SMITA ADITYA BHOSKAR;;VAIBHAV MADHUKAR KALHAPURE;;VENKATA P PALLE;;RAMDAS VIDYA;;VINOD POPATRAO VYAVAHARE,,https://lens.org/023-026-638-994-973,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D519/00;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D498/16,,0,0,,,,PENDING
190,EP,A1,EP 4004002 A1,093-592-943-348-64X,2022-06-01,2022,EP 20768090 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF,,LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/093-592-943-348-64X,Patent Application,yes,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,0,0,,,,PENDING
191,AU,A1,AU 2020/319058 A1,112-235-908-075-158,2022-02-17,2022,AU 2020/319058 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,Macrocyclic compounds as sting agonists and methods and uses thereof,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/112-235-908-075-158,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,0,0,,,,PENDING
192,CN,A,CN 114174303 A,057-480-778-519-131,2022-03-11,2022,CN 202080053237 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,Macrocyclic compounds as STING agonists and methods and uses thereof,"Disclosed are macrocyclic compounds having the general formula (I) or (II), and tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, as well as their combinations with suitable medicaments, corresponding methods of synthesis and pharmaceutical compositions, and uses of the compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/057-480-778-519-131,Patent Application,no,6,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/18;;A61K31/4188;;A61K31/4439;;A61K31/454;;A61K31/496;;A61K31/5377;;A61K31/5386;;A61K31/541;;A61K31/662;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P35/00;;A61P35/02;;C07D519/00;;C07F9/6584,,0,0,,,,PENDING
193,CA,A1,CA 3147397 A1,010-588-221-345-428,2021-01-28,2021,CA 3147397 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/010-588-221-345-428,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D498/16;;C07D519/00,,0,0,,,,PENDING
194,PE,A1,PE 20220937 A1,117-785-764-144-756,2022-05-31,2022,PE 2022000120 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,COMPUESTOS MACROCICLICOS COMO AGONISTAS DE STING Y METODOS Y USOS DE LOS MISMOS,"La presente invencion se refiere a un compuesto de formula general (I), su forma tautomerica, su estereoisomero, su sal farmaceuticamente aceptable, donde: G1 es -CH2- o -CH(CH2)n-anillo A-; G2 es -CH=CH-; el anillo A es heterociclilo o heteroarilo opcionalmente sustituido; el anillo B es un anillo aromatico; el anillo C es heteroarilo de cinco miembros opcionalmente sustituido; R1 es heteroarilo opcionalmente sustituido, entre otros; R2 es hidrogeno, alquilo C1-C6 opcionalmente sustituido y cicloalquilo C3-C5 monociclico opcionalmente sustituido; o y m son 1; p es 0 a 2. Son compuestos especificos: acido (1S,4S)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 1); acido (1R,4R)-4-((E)-12-carbamoil-1,15-bis(1-etil-3-metil-1H-pirazol-5-carboxamido)-8,9,16,19-tetrahidro-7H-6,10-dioxa-2,14,15a,19a-tetraazaciclopentadeca[3,2,1-cd:8,9,10-c'd']diinden-4-carboxamido)ciclohexano-1-carboxilico (Compuesto 2); entre otros. Tambien se refiere a una composicion farmaceutica. Dicho compuesto es un modulador de una proteina estimulador de genes de interferon (STING) y/o un complejo proteico STING, siendo util en el tratamiento del cancer y enfermedades infecciosas.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/117-785-764-144-756,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,0,0,,,,PENDING
195,US,A1,US 2022/0289763 A1,032-861-753-695-026,2022-09-15,2022,US 202017628619 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2022-01-17),https://lens.org/032-861-753-695-026,Patent Application,yes,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61P35/00;;C07D519/00,,0,0,,,,PENDING
196,CO,A2,CO 2022001814 A2,047-498-157-146-507,2022-04-29,2022,CO 2022001814 A,2022-02-21,IB 2020056875 W;;IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A,2019-07-22,Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos,"RESUMEN COMPUESTOS MACROCÍCLICOS COMO AGONISTAS DE STING Y MÉTODOS Y USOS DE LOS MISMOS Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;VYAVAHARE VINOD POPATRAO;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;DAS AMIT KUMAR;;BHOSKAR SMITA ADITYA,,https://lens.org/047-498-157-146-507,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,0,0,,,,PENDING
197,CL,A1,CL 2022000145 A1,059-137-328-087-946,2022-09-09,2022,CL 2022000145 A,2022-01-21,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A,2019-07-22,Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos,"Se desvelan compuestos macrocíclicos que tienen la Fórmula general (I) o (II) y sus formas tautoméricas, estereoisómeros, sales farmacéuticamente aceptables, hidratos, solvatos y profármacos de los mismos y su combinación con un medicamento adecuado, procesos correspondientes para la síntesis, y composiciones farmacéuticas y usos de compuestos desvelados en el presente documento.",LUPIN LTD,BANERJEE MOLOY;;RAMDAS VIDYA;;KAMBOJ RAJENDER KUMAR;;KARCHE NAVNATH POPAT;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;PALLE VENKATA P,,https://lens.org/059-137-328-087-946,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D498/16;;C07D519/00,,0,0,,,,PENDING
198,WO,A1,WO 2021/014365 A1,177-512-318-088-03X,2021-01-28,2021,IB 2020056875 W,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/177-512-318-088-03X,Patent Application,yes,25,4,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,C07D498/16;;A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D519/00,,34,20,013-919-705-921-455;;006-540-796-046-165;;059-678-754-664-904;;071-155-481-845-065;;143-833-387-233-062;;114-143-369-006-640;;017-564-093-850-996;;095-894-960-349-974;;010-962-666-867-699;;101-871-534-522-088;;021-629-183-018-537;;088-933-677-738-021;;022-289-311-765-86X;;136-830-108-452-637;;061-761-280-083-081;;008-516-199-192-896;;038-381-680-886-07X;;001-197-073-494-354;;097-745-838-745-600;;023-006-439-394-889,26603901;;10.1038/nri3921;;pmc5004891;;10.1016/j.celrep.2015.04.031;;pmc4440852;;25959818;;10.1158/0008-5472.can-08-2281;;pmc3886718;;19293190;;30405246;;10.1038/s41586-018-0705-y;;10.1208/s12248-010-9183-3;;20437123;;pmc2895432;;25517616;;10.1016/j.immuni.2014.10.019;;pmc5155593;;22453014;;10.1097/ppo.0b013e31824b2404;;10.4049/jimmunol.1300097;;23585680;;pmc3647383;;10.1038/nature07317;;18724357;;pmc2804933;;pmc4335851;;25512416;;10.1128/aac.04321-14;;22770500;;10.1021/jm300623u;;29125711;;10.1002/anie.201711050;;10.1016/s0022-328x(00)00780-4;;21509358;;10.1039/c0ob01236j;;24382747;;10.1002/chem.201303865;;pmc4789673;;10.1021/acsmedchemlett.5b00360;;26985309;;10.1002/anie.200702695;;17729226;;pmc5656929;;28877397;;10.1002/anie.201708967;;25019477;;10.1016/j.ejmech.2014.07.029;;10.1021/om3006307,"NATURE REVIEWS IMMUNOL, vol. 15, 2015, pages 760 - 770;;CELL REPORTS, vol. 11, 2015, pages 1018 - 1030;;J. EXP. MED., vol. 208, 2011, pages 1989 - 2003;;CANCER RES., vol. 69, 2009, pages 3077 - 3085;;NATURE, vol. 564, no. 7736, 2018, pages 439 - 443;;GAUDANA, R. ET AL., THE AAPS JOURNAL, vol. 12, no. 3, 2012, pages 348 - 360;;IMMUNITY, vol. 41, 2014, pages 843 - 852;;J. TRANSL. MED., vol. 10, 2012, pages 205;;CANCER J., vol. 18, 2012, pages 153 - 159;;J. IMMUNOL., vol. 190, 2013, pages 5216 - 5225;;CELL REP., vol. 11, no. 7, 2015, pages 1018 - 30;;NATURE, vol. 455, 2008, pages 674 - 678;;PLOS PATHOG., vol. 11, 2015, pages 12;;ANTIMICROB. AGENTS CHEMOTHER., vol. 59, no. 2, 2015, pages 1273 - 1281;;J LEUKOCYTE BIOL., vol. 89, no. 3, 2011, pages 351 - 357;;""Angew Chem. Intl. Ed. Engl."", vol. 33, 1994, pages: 183 - 186;;FINGL ET AL.: ""The Pharmacological Basis of Therapeutics"", 1975, pages: 1;;SYNTH. COMMUN., vol. 30, no. 9, 2000, pages 1587 - 1591;;J LEUKOCYTE BIO., vol. 89, no. 3, 2011, pages 351 - 357;;JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 15, 2012, pages 6866 - 6880;;""International Edition"", ANGEWANDTE CHEMIE, vol. 57, no. 1, 2018, pages 292 - 295;;J. OF HETEROCYCLIC CHEMISTRY, vol. 30, no. 2, 1993, pages 473 - 476;;EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 158, 2018, pages 184 - 200;;J. OF ORGANOMETALLIC CHEMISTRY, vol. 620, no. 1-2, 2001, pages 94 - 105;;ORG. BIOMOL. CHEM., vol. 9, no. 12, 2011, pages 4498 - 4506;;CHEM. EUR. J., vol. 20, no. 6, 2014, pages 1530 - 1538;;ACS MED. CHEM. LETT., vol. 7, no. 3, 2016, pages 245 - 249;;EUR. J. ORG. CHEM., vol. 17, 2011, pages 3156 - 3164;;""International Edition"", ANGEWANDTE CHEMIE, vol. 46, no. 40, 2007, pages 7671 - 7673;;""International Edition"", ANGEWANDTE CHEMIE, vol. 56, no. 43, 2017, pages 13351 - 13355;;EUR. J. MED. CHEM., vol. 84, 2014, pages 200 - 205;;ORGANOMETALLICS, vol. 31, no. 16, 2012, pages 5958 - 5967;;MEDCHEMCOMM, vol. 5, no. 1, 2014, pages 72 - 81;;EUR. J. ORG. CHEM., vol. 37, 2017, pages 5592 - 5596",PENDING
199,ZA,B,ZA 202201375 B,047-779-153-006-84X,2022-09-28,2022,ZA 202201375 A,2022-01-28,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF,,LUPIN LTD,KARCHE NAVNATH POPAT;;BANERJEE MOLOY;;GUPTA NISHANT RAMNIVASJI;;JADHAV GANESH RAJARAM;;VYAVAHARE VINOD POPATRAO;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KALHAPURE VAIBHAV MADHUKAR;;BHOSKAR SMITA ADITYA;;RAMDAS VIDYA;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/047-779-153-006-84X,Granted Patent,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,,,0,0,,,,ACTIVE
200,MX,A,MX 2022000939 A,196-148-676-539-014,2022-04-06,2022,MX 2022000939 A,2020-07-22,IN 201921029556 A;;IN 201921051086 A;;IN 202021003961 A;;IB 2020056875 W,2019-07-22,MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF.,"Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.",LUPIN LTD,KARCHE NAVNATH POPAT;;PALLE VENKATA P;;RAMDAS VIDYA;;DAS AMIT KUMAR;;WALKE DEEPAK SAHEBRAO;;KAMBOJ RAJENDER KUMAR;;JADHAV GANESH RAJARAM;;KALHAPURE VAIBHAV MADHUKAR;;BANERJEE MOLOY;;VYAVAHARE VINOD POPATRAO;;GUPTA NISHANT RAMNIVASJI;;BHOSKAR SMITA ADITYA,,https://lens.org/196-148-676-539-014,Patent Application,no,0,0,17,17,0,C07D498/18;;C07D519/00;;C07F9/6584;;A61P35/00;;A61P35/02;;A61P31/04;;A61P31/12;;A61P31/18;;A61P31/16;;C07D498/16;;C07D519/00;;A61P35/00;;A61P35/02;;A61P31/00;;A61P31/00;;C07D498/16;;A61P35/00;;A61P35/02;;C07D519/00;;C07D498/18;;A61K31/4188;;A61K31/5386;;A61K31/5377;;A61K31/541;;A61K39/39;;A61P35/00;;A61P31/00;;A61K2039/55511;;A61P35/00;;C07D498/16;;C07D519/00,A61K31/4188;;A61P31/00;;A61P35/00;;A61P35/02;;C07D498/16;;C07D519/00,,0,0,,,,PENDING
201,PH,A1,PH 12018500469 A1,120-689-446-408-195,2018-09-10,2018,PH 12018500469 A,2018-03-05,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/120-689-446-408-195,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
202,KR,A,KR 20180049010 A,158-019-321-806-065,2018-05-10,2018,KR 20187009449 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,전압-개폐 소듐 통로 조절제로서의 술폰아미드 화합물,"본 발명은 치환기가 본원에 기재된 바와 같은 화학식 (I)의 술폰아미드 화합물, 및 전압-개폐 소듐 통로 (VGSC), 특히 NaV1.7의 억제와 관련된 질병, 장애의 치료를 위한 의약에서 이들의 용도에 관한 것이다. 본 발명은 또한 전압-개폐 소듐 통로 (VGSC), 특히 NaV1.7의 억제와 관련된 질환, 장애, 증후군 및/또는 질환의 치료에 유용한 본원에 기재된 화합물 및 이의 약학적으로 허용가능한 염, 이의 약학 조성물에 관한 것이다. 본 발명은 또한 본 발명의 화합물의 제조 방법에 관한 것이다.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/158-019-321-806-065,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4433;;A61K31/506;;A61P25/00;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
203,EP,A1,EP 3344621 A1,154-444-561-307-187,2018-07-11,2018,EP 16770557 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,,LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2019-08-28),https://lens.org/154-444-561-307-187,Patent Application,yes,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
204,US,A1,US 2018/0186777 A1,003-673-839-374-127,2018-07-05,2018,US 201615757103 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2018-03-30),https://lens.org/003-673-839-374-127,Patent Application,yes,0,1,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/12;;A61P29/00;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
205,HK,A1,HK 1257729 A1,002-426-521-268-258,2019-10-25,2019,HK 19100102 A,2019-01-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,,LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/002-426-521-268-258,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D/;;A61K/;;A61P/,,0,0,,,,PENDING
206,AU,A1,AU 2016/314355 A1,032-286-649-589-575,2018-03-15,2018,AU 2016/314355 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,Sulfonamide compounds as voltage-gated sodium channel modulators,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)",LUPIN LTD,JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR;;RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO,,https://lens.org/032-286-649-589-575,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
207,CN,A,CN 108349957 A,054-434-488-771-615,2018-07-31,2018,CN 201680063535 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,Sulfonamide compounds as voltage-gated sodium channel modulators,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates toprocess for the preparation of the compounds of the invention. (I)",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/054-434-488-771-615,Patent Application,no,4,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,1,0,,,"李雯等: ""小分子钠通道阻滞剂镇痛构效关系的研究进展"", 《药学学报》",DISCONTINUED
208,MX,A,MX 2018002746 A,092-628-545-048-807,2019-04-25,2019,MX 2018002746 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS.,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I).",LUPIN LTD,VIDYA RAMDAS;;ADVAIT ARUN JOSHI;;AMIT KUMAR DAS;;DEEPAK SAHEBRAO WALKE;;RAJESHKUMAR MAGANLAL LORIYA;;VENKATA P PALLE;;TALHA HUSSAIN KHAN;;RAJENDER KUMAR KAMBOJ;;VAIBHAV MADHUKAR KALHAPURE;;GANESH NAVINCHANDRA GOTE;;LAXMIKANT SHAMLAL DATRANGE;;PRADEEP RANGRAO PATIL;;MOLOY BANERJEE,,https://lens.org/092-628-545-048-807,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
209,TW,A,TW 201722938 A,157-562-553-826-717,2017-07-01,2017,TW 105128445 A,2016-09-02,IN 3420MU2015 A;;IN 201621011342 A,2015-09-04,Sulfonamide compounds as voltage-gated sodium channel modulators,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/157-562-553-826-717,Patent of Addition,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/12;;A61K31/4433;;A61K31/4439;;A61K31/497;;A61K31/501;;A61K31/506;;A61K31/5377;;A61K31/541;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
210,WO,A1,WO 2017/037682 A1,003-251-228-201-534,2017-03-09,2017,IB 2016055291 W,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/003-251-228-201-534,Patent Application,yes,25,4,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,10,7,108-251-201-453-19X;;010-110-239-299-471;;050-582-206-719-069;;112-819-083-141-446;;004-440-321-786-118;;050-898-949-194-866;;056-635-244-963-286,10.4155/fmc.10.26;;21426202;;pmc19825;;10.1073/pnas.94.4.1527;;9037087;;10.1002/j.1460-2075.1995.tb07091.x;;7720699;;pmc398185;;10.1158/1078-0432.ccr-05-0327;;16061851;;10.2174/138161206778522047;;17073667;;16088330;;10.1038/sj.pcan.4500796;;10.1021/ol301120w;;22646529,"ENGLAND; RAWSON, FUTURE MED. CHEM., vol. 2, 2010, pages 775 - 790;;HOYT ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, 2008, pages 1963 - 1966;;BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 3676 - 681;;TOLEDO-ARAL, J. J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1527 - 1532;;KLUGBAUER, N. ET AL., EMBO J., vol. 14, 1995, pages 1084 - 90;;FRASER ET AL., CLIN. CANCER RES., vol. 11, 2005, pages 5381 - 5389;;CURRENT PHARMACEUTICAL DESIGN, vol. 12, 2006, pages 3681 - 3695;;PROSTATE CANCER AND PROSTATIC DISEASES, vol. 8, 2005, pages 266 - 273;;JACS, vol. 133, no. 20, 2011, pages 7916 - 7925;;ORG LETT, vol. 14, no. 12, 2012, pages 3048 - 3051",PENDING
211,ZA,B,ZA 201801501 B,020-329-012-500-934,2018-12-19,2018,ZA 201801501 A,2018-03-05,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,,LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/020-329-012-500-934,Granted Patent,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,,,0,0,,,,ACTIVE
212,AR,A1,AR 106428 A1,047-375-414-779-082,2018-01-17,2018,AR P160102701 A,2016-09-05,IN 3420MU2015 A,2015-09-04,COMPUESTOS DE SULFONAMIDA COMO MODULADORES DE CANALES DE SODIO REGULADOS POR VOLTAJE,"Reivindicación 1: Un compuesto que tiene la fórmula (1), en donde, A¹ y A² son independientemente hidrógeno o alquilo C₁₋₆ sustituido o no sustituido; o A¹ y A², junto con el átomo de carbono al que están unidos, forman un anillo cicloalquilo de 3 a 6 miembros sustituido o no sustituido o anillo heterocíclico de 4 a 6 miembros; R¹ se selecciona del grupo que consiste en hidrógeno, halógeno, ciano, alquilo C₁₋₆ sustituido o no sustituido y alcoxi C₁₋₆ sustituido o no sustituido; R², que puede ser igual o diferente en cada aparición, se selecciona independientemente del grupo que consiste en halógeno, ciano, alquilo C₁₋₆ sustituido o no sustituido, haloalquilo C₁₋₆, -(CH₂)₀₋₂-S(O)₂-alquilo, -O-R⁶, alcoxialquilo sustituido o no sustituido, cicloalquilo C₃₋₈ sustituido o no sustituido, arilo C₆₋₁₀ sustituido o no sustituido, heteroarilo monocíclico de 5 a 6 miembros sustituido o no sustituido, heterociclilo monocíclico de 4 a 6 miembros sustituido o no sustituido, -C(O)OH, -C(O)O-alquilo y -C(O)NR⁴R⁵; anillo A es heteroarilo de seis miembros monocíclico que contiene 1 a 3 átomos de nitrógeno en el anillo; R³, que puede ser igual o diferente en cada aparición, se selecciona independientemente del grupo que consiste en halógeno, ciano, alquilo C₁₋₆ sustituido o no sustituido y alcoxi C₁₋₆ sustituido o no sustituido; R⁴ y R⁵ independientemente se seleccionan de hidrógeno o alquilo C₁₋₆ sustituido o no sustituido; o R⁴ y R⁵ junto con el átomo de nitrógeno al que están unidos, forman anillo heterocíclico de 5 a 6 miembros sustituido o no sustituido; R⁶ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆ sustituido o no sustituido, haloalquilo C₁₋₆, alcoxialquilo sustituido o no sustituido, cicloalquilo C₃₋₈ sustituido o no sustituido, arilo C₆₋₁₀ sustituido o no sustituido, heteroarilo monocíclico de 5 a 6 miembros sustituido o no sustituido y heterociclilo monocíclico de 4 a 6 miembros sustituido o no sustituido; ‘m’ es un número entero que varía de 0 a 3, ambos incluidos; ‘n’ es un número entero que varia de 0 a 3, ambos incluidos; en donde los sustituyentes para alquilo sustituido o no sustituido, alcoxi sustituido o no sustituido, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, anillo heterocíclico sustituido o no sustituido, alcoxialquilo sustituido o no sustituido son uno o más iguales o diferentes y se seleccionan independientemente del grupo que consiste en hidroxi, halógeno, carboxi, ciano, nitro, oxo (=O), alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxi-alquilo C₁₋₆, alcoxialquilo, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, arilalquilo, cicloalquilo C₃₋₈, cicloalquilalquilo, heteroarilo de 5 a 10 miembros, anillo heterocíclico de 4 a 10 miembros, heterociclilalquilo de 3 a 10 miembros, heteroarilalquilo, -C(O)ORˣ -C(O)Rʸ, -C(S)Rʸ, -C(O)NRˣRᶻ, -NRˣC(O)NRˣRᶻ, -N(Rˣ)S(O)₂Rʸ, -NRˣRᶻ, -NRˣC(O)Rʸ, NRˣC(S)Rʸ, -NRˣC(S)NRˣRᶻ, -S(O)₂NRˣRᶻ, -ORˣ, OC(O)Rʸ, -C(RᵃRᵇ)₁₋₃C₍O₎ORˣ, -C(RᵃRᵇ)₁₋₃C₍O₎NRˣRᶻ, -OC(RᵃRᵇ)₂₋₃-ORˣ, -OC(RᵃRᵇ)₂₋₃-NRˣRᶻ, -OC(RᵃRᵇ)₂₋₃-S(O)₀₋₂Rʸ, -C(RᵃRᵇ)₁₋₃-NRˣRᶻ, -C(RᵃRᵇ)₁₋₃-S(O)₀₋₂Rʸ, -OC(RᵃRᵇ)₁₋₃-C(O)NRˣRᶻ, -OC(RᵃRᵇ)₁₋₃-C(O)ORˣ y -S(O)₀₋₂Rʸ; cada uno de Rˣ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, arilalquilo, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, heteroarilo de 5 a 10 miembros, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; cada uno de Rʸ se selecciona del grupo que consiste en alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, arilalquilo, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, heteroarilo de 5 a 10 miembros, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; cada uno de Rᶻ se selecciona del grupo que consiste en hidrógeno, alquilo C₁₋₆, haloalquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, arilo C₆₋₁₀, arilalquilo, cicloalquilo C₃₋₈, cicloalquenilo C₃₋₈, heteroarilo de 5 a 10 miembros, anillo heterocíclico, heterociclilalquilo y heteroarilalquilo; o Rˣ y Rᶻ junto con el átomo de nitrógeno al que están unidos forman un anillo cíclico de 4 a 8 miembros, saturado o insaturado, sustituido o no sustituido, en donde el anillo cíclico insaturado puede tener uno o dos enlaces dobles; y cada uno de Rᵃ y Rᵇ, independientemente se seleccionan del grupo que consiste en hidrógeno, halógeno y alquilo C₁₋₆ sustituido o no sustituido; o N-óxidos de los mismos o una sal aceptable para uso farmacéutico de los mismos o estereoisómero de los mismos.",LUPIN LTD,RAJENDER KUMAR KAMBOJ;;VENKATA P PALLE;;VAIBHAV MADHUKAR KALHAPURE;;GANESH NAVINCHANDRA GOTE;;AMIT KUMAR DAS;;TALHA HUSSAIN KHAN;;DEEPAK SAHEBRAO WALKE;;LAXMIKANT SHAMLAL DATRANGE;;ADVAIT ARUN JOSHI;;PRADEEP RANGRAO PATIL;;MOLOY BANERJEE;;RAJESHKUMAR MAGANLAL LORIYA;;VIDYA RAMDAS,,https://lens.org/047-375-414-779-082,Patent Application,no,0,0,1,17,0,,C07D405/12;;A61K31/4427;;A61K31/506;;A61P29/00;;A61P35/00;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
213,US,B2,US 10239869 B2,094-862-350-255-206,2019-03-26,2019,US 201615757103 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,Sulfonamide compounds as voltage-gated sodium channel modulators,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly Na V 1.7. The invention also relates to process for the preparation of the compounds of the invention.",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,LUPIN LIMITED (2018-03-30),https://lens.org/094-862-350-255-206,Granted Patent,yes,25,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/12;;A61P29/00;;C07D405/14;;C07D413/14;;C07D417/14,,9,8,108-251-201-453-19X;;145-286-089-588-773;;007-259-642-254-852;;010-110-239-299-471;;050-582-206-719-069;;112-819-083-141-446;;004-440-321-786-118;;050-898-949-194-866,10.4155/fmc.10.26;;21426202;;18289851;;10.1016/j.bmcl.2008.01.123;;10.1016/j.bmcl.2011.04.088;;21570288;;pmc19825;;10.1073/pnas.94.4.1527;;9037087;;10.1002/j.1460-2075.1995.tb07091.x;;7720699;;pmc398185;;10.1158/1078-0432.ccr-05-0327;;16061851;;10.2174/138161206778522047;;17073667;;16088330;;10.1038/sj.pcan.4500796,"England and Rawson, “Isoform-selective voltage-gated Na+ channel modulators as next-generation analgesics”, Future Med. Chem., 2, 775-790 (2010).;;Hoyt et al., “3-Amino-1,5-benzodiazepinones: Potent, state-dependent sodium channel blockers with anti-epileptic activity”, Bioorganic & Medicinal Chemistry Letters, 18, 1963-1966 (2008).;;Chowdhury et al., “Discovery of XEN907, a spirooxindole blocker of Nav1.7 for the treatment of pain”, Bioorganic & Medicinal Chemistry Letters, 21, 3676-681 (2011).;;Toledo-Aral et al., “Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons”, Proc. Natl. Acad. Sci., USA, 94, 1527-1532 (1997).;;Klugbauer et al., “Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells”, EMBO J., 14, 1084-90 (1995).;;Fraser et al., “Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis”, Clin. Cancer Res., 11, 5381-5389 (2005).;;Roger et al., “Voltage-Gated Sodium Channels: New Targets in Cancer Therapy?” Current Pharmaceutical Design, 12, 3681-3695 (2006).;;Diss et al, “A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo”, Prostate Cancer and Prostatic Diseases, 8, 266-273 (2005).;;International Search Report and Written Opinion from International Application No. PCT/IB2016/055291, dated Nov. 22, 2016, 8 pages.",INACTIVE
214,CA,A1,CA 2996263 A1,120-636-442-196-691,2017-03-09,2017,CA 2996263 A,2016-09-03,IN 3420MU2015 A;;IN 201621011342 A;;IB 2016055291 W,2015-09-04,SULFONAMIDE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNEL MODULATORS,"The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention. (I)",LUPIN LTD,RAMDAS VIDYA;;LORIYA RAJESHKUMAR MAGANLAL;;BANERJEE MOLOY;;PATIL PRADEEP RANGRAO;;JOSHI ADVAIT ARUN;;DATRANGE LAXMIKANT SHAMLAL;;WALKE DEEPAK SAHEBRAO;;KHAN TALHA HUSSAIN;;DAS AMIT KUMAR;;GOTE GANESH NAVINCHANDRA;;KALHAPURE VAIBHAV MADHUKAR;;PALLE VENKATA P;;KAMBOJ RAJENDER KUMAR,,https://lens.org/120-636-442-196-691,Patent Application,no,0,0,16,17,0,C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00;;A61P25/00;;A61P29/00;;A61K31/4433;;A61K31/506;;C07D405/12;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D405/12;;A61P29/00,C07D405/14;;A61K31/4427;;A61K31/506;;A61P29/00;;C07D405/12;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
215,AU,B2,AU 758062 B2,083-655-846-946-691,2003-03-13,2003,AU 1999/057976 A,1999-08-31,US 9895698 P;;US 9919964 W,1998-09-03,Enzymatic oxidative deamination process,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL,,https://lens.org/083-655-846-946-691,Granted Patent,no,0,1,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,C12N15/09;;A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,0,0,,,,EXPIRED
216,CA,A1,CA 2342792 A1,111-849-799-547-67X,2000-03-16,2000,CA 2342792 A,1999-08-31,US 9895698 P;;US 9919964 W,1998-09-03,ENZYMATIC OXIDATIVE DEAMINATION PROCESS,The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.< /SDOAB>,BRISTOL MYERS SQUIBB CO,GOLDBERG STEVEN L;;NANDURI VENKATA B;;BANERJEE AMIT;;JOHNSTON ROBERT M;;SWAMINATHAN SHANKAR;;ANDERSON NEAL G;;CRISPINO GERARD;;LUST DAVID A;;MONIOT JEROME L;;PATEL RAMESH N;;WINTER WILLIAM J;;VENIT JOHN J;;SRIVASTAVA SUSHIL;;SZARKA LASZLO J;;TULLY THOMAS P,,https://lens.org/111-849-799-547-67X,Patent Application,no,0,0,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,C12N15/09;;A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,0,0,,,,DISCONTINUED
217,AU,A,AU 1999/057976 A,161-397-519-913-516,2000-03-27,2000,AU 1999/057976 A,1999-08-31,US 9895698 P;;US 9919964 W,1998-09-03,Enzymatic oxidative deamination process,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL,,https://lens.org/161-397-519-913-516,Patent Application,no,0,0,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,C12N15/09;;A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,0,0,,,,EXPIRED
218,EP,A4,EP 1109928 A4,041-677-997-609-899,2004-10-13,2004,EP 99945367 A,1999-08-31,US 9919964 W;;US 9895698 P,1998-09-03,ENZYMATIC OXIDATIVE DEAMINATION PROCESS,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL,,https://lens.org/041-677-997-609-899,Search Report,no,0,0,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C12N15/09;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,6,5,089-237-421-069-810;;086-894-697-374-884;;051-897-864-027-585;;023-244-976-451-651;;020-229-403-691-872,6772093;;10.1128/aac.17.4.679;;pmc283852;;1991735;;pmc207215;;10.1128/jb.173.3.985-988.1991;;10.1128/jb.173.19.6258-6264.1991;;pmc208378;;1917857;;8900065;;10.1111/j.1574-6968.1996.tb08532.x;;10.1016/0378-1097(96)00365-5;;9171867;;10.1021/jm970041e,"KERN B A ET AL: ""L-LYSINE EPSILON-AMINOTRANSFERASE INVOLVED IN CEPHAMYCIN C SYNTHESIS IN STREPTOMYCES LACTAMDURANS"", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 17, no. 4, 1986, pages 679 - 685, XP000909501, ISSN: 0066-4804;;MADDURI K ET AL: ""CLONING AND LOCATION OF A GENE GOVERNING LYSINE EPSILON-AMINOTRANSFERASE, AN ENZYME INITIATING BETA-LACTAM BIOSYNTHESIS IN STREPTOMYCES SPP"", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 173, no. 3, February 1991 (1991-02-01), pages 985 - 988, XP002925395, ISSN: 0021-9193;;COQUE J-J R ET AL: ""A GENE ENCODING LYSINE 6-AMINOTRANSFERASE, WHICH FORMS THE BETA-LACTAM PRECURSOR ALPHA-AMINOADIPIC ACID, IS LOCATED IN THE CLUSTER OF CEPHAMYCIN BIOSYNTHETIC GENES IN NOCARDIA LACTAMDURANS"", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 173, no. 19, October 1991 (1991-10-01), pages 6258 - 6264, XP002925394, ISSN: 0021-9193;;RIUS NURIA ET AL: ""Induction of L-lysine epsilon-aminotransferase by L-lysine in Streptomyces clavuligerus, producer of cephalosporins."", FEMS MICROBIOLOGY LETTERS, vol. 144, no. 2-3, 1996, pages 207 - 211, XP002232534, ISSN: 0378-1097;;ROBL J A ET AL: ""Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase."", JOURNAL OF MEDICINAL CHEMISTRY. UNITED STATES 23 MAY 1997, vol. 40, no. 11, 23 May 1997 (1997-05-23), pages 1570 - 1577, XP002286002, ISSN: 0022-2623;;See also references of WO 0014265A1",DISCONTINUED
219,AU,B2,AU 2002/300926 B2,115-261-605-817-60X,2007-01-18,2007,AU 2002/300926 A,2002-09-05,AU 1999/057976 A;;AU 2002/300926 A,1999-08-31,Enzymatic oxidative deamination process,,BRISTOL MYERS SQUIBB CO,SWAMINATHAN SHANKAR;;LUST DAVID A;;PATEL RAMESH N;;JOHNSTON ROBERT M;;CRISPINO GERARD;;VENIT JOHN J;;GOLDBERG STEVEN L;;SRIVASTAVA SUSHIL;;MONIOT JEROME L;;WINTER WILLIAM J;;NANDURI VENKATA B;;ANDERSON NEAL G;;BANERJEE AMIT;;SZARKA LASZLO J;;TULLY THOMAS P,,https://lens.org/115-261-605-817-60X,Granted Patent,no,0,0,1,1,0,,C12P21/00;;C12P21/02,,0,0,,,,EXPIRED
220,WO,A1,WO 2000/014265 A1,140-263-799-764-205,2000-03-16,2000,US 9919964 W,1999-08-31,US 9895698 P,1998-09-03,ENZYMATIC OXIDATIVE DEAMINATION PROCESS,The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL,,https://lens.org/140-263-799-764-205,Patent Application,yes,0,4,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C12N15/09;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,3,2,028-928-148-811-585;;029-259-061-759-228,pmc179396;;10.1128/jb.179.17.5300-5308.1997;;9286980;;10.1271/bbb.62.622;;9614692,"PARK S.M. ET AL.: ""Cloning and characterization of argR, a gene that participates in regulation of arginine biosynthesis and catabolism in Pseudomonas aeruginosa PAO1"", J. BACTERIOL., vol. 179, no. 17, 1997, pages 5300 - 5308, XP002925503;;OKU H. ET AL.: ""NADH-dependent inhibition of branched-chain fatty acid synthesis in Bacillus subtilis"", BIOSCI. BIOTECH. BIOCHEM., vol. 62, no. 4, April 1998 (1998-04-01), pages 622 - 627, XP002925504;;See also references of EP 1109928A4",PATENTED
221,EP,A1,EP 1109928 A1,154-987-031-836-488,2001-06-27,2001,EP 99945367 A,1999-08-31,US 9919964 W;;US 9895698 P,1998-09-03,ENZYMATIC OXIDATIVE DEAMINATION PROCESS,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL,,https://lens.org/154-987-031-836-488,Patent Application,yes,0,0,14,14,6,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C07K5/062;;C07K5/078;;C12N15/09;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,0,0,,,,DISCONTINUED
222,US,B1,US 6515170 B1,055-986-353-550-120,2003-02-04,2003,US 84322601 A,2001-04-26,US 84322601 A;;US 38658899 A;;US 9895698 P,1998-09-03,Enzymatic oxidative deamination process,"
    The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity. 
",BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;BANERJEE AMIT;;NANDURI VENKATA B;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;TULLY THOMAS P;;SZARKA LASZLO J;;SWAMINATHAN SHANKAR;;VENIT JOHN J;;MONIOT JEROME L;;WINTER WILLIAM J;;ANDERSON NEAL G;;LUST DAVID A;;CRISPINO GERARD;;SRIVASTAVA SUSHIL K,,https://lens.org/055-986-353-550-120,Granted Patent,yes,3,0,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C07D513/04;;C12N15/09;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,562/432;;562/433;;562/426;;562/485;;562/400,27,21,011-956-351-772-463;;086-894-697-374-884;;051-897-864-027-585;;055-792-532-851-126;;066-141-497-990-023;;032-728-154-591-070;;114-619-682-814-274;;028-454-131-133-472;;082-902-765-648-368;;064-397-996-119-618;;013-891-870-160-838;;050-580-471-089-96X;;014-978-026-283-267;;047-294-079-836-486;;070-383-251-783-098;;000-346-919-904-207;;024-841-374-797-219;;020-533-566-973-694;;155-072-250-959-286;;028-928-148-811-585;;029-259-061-759-228,10938417;;10.1016/s0141-0229(00)00233-7;;1991735;;pmc207215;;10.1128/jb.173.3.985-988.1991;;10.1128/jb.173.19.6258-6264.1991;;pmc208378;;1917857;;2410914;;pmc390513;;10.1073/pnas.82.15.5131;;10.1093/nar/12.1part1.387;;6546423;;pmc321012;;10.1016/0022-2836(70)90057-4;;5420325;;3092189;;pmc311678;;10.1093/nar/14.16.6745;;2672459;;10.1016/0168-9525(89)90073-5;;pmc334719;;2830593;;10.1093/nar/16.3.791;;10.1093/oxfordjournals.jbchem.a123388;;1880121;;344137;;344136;;10.1016/0378-1119(77)90000-2;;10.1038/275617a0;;360074;;386136;;10.1038/281544a0;;pmc324219;;6159584;;10.1093/nar/8.18.4057;;6363212;;10.1016/0378-1119(83)90222-6;;6248238;;10.1016/0092-8674(80)90613-3;;10.1073/pnas.74.12.5463;;271968;;pmc431765;;10.1073/pnas.74.2.560;;265521;;pmc392330;;10.1016/s0021-9258(19)34176-6;;5658538;;pmc179396;;10.1128/jb.179.17.5300-5308.1997;;9286980;;10.1271/bbb.62.622;;9614692,"Patel et al, Enzyme and Microbial Technology, 2000, vol. 27, No. 6, pp. 376-389.*;;Kern, B. et al., Antimicrobial Agents and Chemotherapy, American Society for Microbiology, vol. 17, No. 4, pp. 679-685 (1986).;;Madduri, K. et al., Journal of Bacteriology, vol. 173, NO. 3, pp. 985-988 (1991).;;Coque, J. et al., Journal of Bacteriology, vol. 173, No. 19, pp. 6258-6264 (1991).;;Houghton et al. Proc.Natl Acad.Sci. 82, 5131-5135 (1985).;;Devereux et al., Nucl.Acids Res. 12:387-395 (1984).;;Needleman et al., J. Mol. Biol. 48:443-453 (1970).;;Smith et al., Adv.Appl.Math 2:482 (1981).;;Gribskov et al., Nucl. Acids Res. 14:6745-6763.;;Schwartz et al., Atlas of Protein Sequence and Structure, National Biomedical Research Foundatioin, 353-358 (1979).;;White et al., Trends Genet. 5:185-189 (1989).;;Morinaga et al., Nucl. Acids Res. 2:636-639 (1984).;;Taylor et al., Nucl, Acids Res. 13: 8746-8764 (1985).;;Kunkel, Proc. Natl. Acad. Sci USA 82:482-492 (1985).;;Sayers et al., Nucl. Acids Res. 16:791-802 (1988).;;Takada et al., J. Biochem. 109:371-376 (1991).;;Bolivar et al., Gene 2:95-113 (1977).;;Chang et al., Nature, 275:617-624 (1978).;;Goeddel et al., Nature 281:544-548 (1979).;;Goeddel et al., Nucl. Acids Res. 8:4057-4074 (1980).;;Amann et al., Gene 25, 167-178 (1983).;;Siebenlist et al., Cell 20:269-281 (1980).;;Sanger et al., Proc.Natl.Acad.Sci.USA 74:5463-5467 (1977).;;Maxam et al., Proc.Natl.Acad.Sci.USA 74:560-564 (1977).;;J. Biol. Chem. 243:3557-3559 (1969).;;Park et al. J. Bacteriol 1997, No. 17, vol. 179, pp. 5300-5308.;;Oku et al. Biosci. Biotech.Biochem. 1998, vol. 62, No. 4, pp. 622-627.",EXPIRED
223,HU,A2,HU P0104996 A2,195-667-458-130-403,2002-04-29,2002,HU P0104996 A,1999-08-31,US 9895698 P;;US 9919964 W,1998-09-03,ENZYMATIC OXIDATIVE DEAMINATION PROCESS,"A tal lm ny t rgya elj r s ltal nos képletű amino-lakt m-vegyületekelő llít s ra egy ltal nos képletű dipeptid-monomer - ahol P1 amino-védőcsoport, és R1 jelentése hidrogénatom, alkilcsoport vagy -C(=O)-R2csoport, amelyben R2 alkilcsoport - aminotranszfer z enzimmel a-ketoglutar t és adott esetben glutam t oxid z jelenlétében alkalmask""rülmények k""z""tt való érintkeztetésével. Az aminotranszfer z enzimetSpingomonas vagy Pseudomonas fajban, péld ul Spingomonas paucimobilisATCC 202027 t""rzsben in situ termeltetik. A tal lm ny t rgya azaminotranszfer zt kódoló nukleinsav és a nukleinsavat tartalmazó,aktív aminotranszfer zt expressz lni képes, géntechnológiailagmódosított gazdasejt, tov bb az aminotranszfer z két új szubsztr tja,az N-{N-[(benzil-oxi)-karbonil]-L-metionil}-L-lizin és az N-2-{S-acetil-N-[(benzil-oxi)-karbonil]-L-homociszteinil}-L-lizin is. Ó",BRISTOL MYERS SQUIBB CO,ANDERSON NEAL G;;BANERJEE AMIT;;CRISPINO GERARD;;GOLDBERG STEVEN L;;JOHNSTON ROBERT M;;LUST DAVID A;;MONIOT JEROME L;;NANDURI VENKATA B;;PATEL RAMESH N;;SRIVASTAVA SUSHIL KUMAR;;SWAMINATHAN SHANKAR;;SZARKA LASZLO J;;TULLY THOMAS P;;VENIT JOHN J;;WINTER WILLIAM J,,https://lens.org/195-667-458-130-403,Patent Application,no,0,0,14,14,0,A61K38/00;;C07K5/06139;;C07K14/8103;;C12N9/1096;;C12P17/18;;C07K5/06139;;C07K14/8103;;A61K38/00;;C12N9/1096,A61K38/00;;C12N15/09;;C07D513/04;;C07K5/062;;C07K5/078;;C07K14/81;;C12N1/20;;C12N1/21;;C12N9/06;;C12N9/10;;C12P17/18;;C12R1/01;;C12R1/38;;C12R1/465,,0,0,,,,PENDING
224,ES,T3,ES 2397104 T3,120-000-246-003-73X,2013-03-04,2013,ES 03812974 T,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,Procedimiento y productos intermedios para la síntesis de entecavir,"Un procedimiento para preparar entecavir que tiene la fórmula que comprende: (a) tratar un éster de la fórmula en la que Ra es alilo, fenilo, alquilfenilo C1 a C6, o alcoxifenilo C1 a C6; Rb es alquilo C1 a C6; y R es alquilo C1 aC4 o bencilo; con un enol éter de acetona y un ácido para proteger el grupo hidroxi, seguido de tratamiento con un reactivo dehidruro para reducir el resto de éster de ácido carboxílico, y a continuación alquilar el alcohol resultante con unhaluro de bencilo y eliminar el grupo protector hidroxi enol éter para dar un alcohol alílico de la fórmula (b) epoxidar el producto de la etapa (a) con una epoxidación diastereoselectiva para dar un epóxido deciclopentano que tiene la fórmula (c) tratar el epóxido de ciclopentano de la etapa (b) con una sal de metal alcalino de un compuesto de purina defórmula",BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI;;CHEN CHUNG-PIN;;PATEL SUNIL;;EVANS JEFFREY;;LIANG JING;;KRONENTHAL DAVID;;POWERS GERALD;;PRASAD SIVA;;BIEN JEFFREY;;SHI ZHONGPING;;PATEL RAMESH;;CHAN YEUNG;;RIJHWANI SUSHIL;;SINGH AMBARISH;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID,,https://lens.org/120-000-246-003-73X,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
225,EP,A1,EP 2433941 A1,112-624-251-711-795,2012-03-28,2012,EP 11189882 A,2003-12-10,EP 03812974 A;;US 43254902 P,2002-12-11,"Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one","The invention refers to a method for isolating entecavir or an entecavir intermediate from a diluted mixture, the diluted mixture comprising entecavir and water or a mixture comprising an entecavir intermediate and other process reagents comprising: 
(a) adsorbing the diluted mixture onto a hydrophobic resin bed; 
(b) washing the resin bed with water to remove salt; and 
(c) eluting the entecavir or entecavir intermediate from the resin bed with an organic solvent.",BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;CHEN CHUNG-PIN H;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING,,https://lens.org/112-624-251-711-795,Patent Application,yes,8,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07F7/08;;C07F7/18,,11,3,074-165-125-912-194;;016-597-697-673-729;;086-753-455-512-149,10.1016/s0040-4020(02)00440-4;;10.1016/s0040-4020(96)00038-5;;10.1021/jo00128a029,"SUPELCO: ""Chromatographie-Produkte für Analytik una Aufreinigung"", 1998, SUPELCO, XP002669369;;BONINI; RIGHI: ""A Critical Outlook And Comparison of Enantioselective Oxidation Methodologies of Olefins"", TETRAHEDRON, vol. 58, 2002, pages 4981 - 5021, XP004366424, DOI: doi:10.1016/S0040-4020(02)00440-4;;FLEMING, 1., CHEMTRACTS-ORGANIC CHEMISTRY, vol. 9, 1996, pages 1 - 64;;JONES, G.R., TETRAHEDRON, vol. 52, 1996, pages 7599 - 7662;;LI, G.; ANGERT, H.; SHARPLESS, K.B., ANGEW. CHEM. INT. ED., 1996, pages 2813;;J. AM. CHERN. SOC., 1989, pages 3456;;J. AM. CHEM. SOC., 1996, pages 9526;;KHANAPURE, S.; NAJAFI, N.; MANNA, S.; YANG, J.; ROKASH. J., J. ORG. CHEM., vol. 60, 1995, pages 7448;;COREY ET AL., J. MED. CHEM., vol. 36, 1993, pages 243;;GREENE, T.W.; WUTS, P.G.M.: ""Protecting Groups in Organic Synthesis"", 1991, WILEY AND SONS, pages: 199 - 201;;COREY ET AL., J. MED CHEM., vol. 36, 1993, pages 243",DISCONTINUED
226,US,B2,US 10388121 B2,063-006-823-746-667,2019-08-20,2019,US 201615254440 A,2016-09-01,IN 201611020611 A,2016-06-16,Method for providing notifications,"A method for providing notifications is provided. The method includes a tangible user interface (TUI) element the receives an input from a computing device coupled to the TUI element. The input is indicative of an outcome corresponding to a functionality of an application on the computing device. Based on the outcome, the TUI element determines at least one illumination pattern from a plurality of pre-stored illumination patterns. Thereafter, the TUI element generates an output based on the at least one determined illumination pattern.",SAMSUNG ELECTRONICS CO LTD,GUPTA AYUSHI;;BANERJEE PRANTIK;;THOMAS THEOPHILUS;;HAHM KYOUNGWOON;;PRABHAKAR ARUN;;JANARDHANAN GOVIND;;GOVEKAR DHANANJAY L;;CHAVAN SUDHANWA SUHAS;;PASSI NAVNEET;;KUMAR ABHISHEK;;THAKUR AVINASH;;SETIA NITIN;;BHATTACHERJEE SUPRATEEM;;T SANKARA NARAYANAN;;JAKHMOLA HIMANSHU;;CHAWLA SONAM;;AGARWAL REKHA;;SHARMA ATUL;;PRATAP AASHAANK;;MEHER SHANTANU KUMAR;;PS ARUNGEETH;;BANSAL AMIT;;SHARMA KAUSHAL PRAKASH;;JAIN JATIN,SAMSUNG ELECTRONICS CO. LTD (2016-08-17),https://lens.org/063-006-823-746-667,Granted Patent,yes,31,1,5,5,0,G06F3/03;;G06F2203/0339;;G06F3/03547;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/03;;G06F3/03547;;G06F2203/0339;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/0482;;G06F3/14;;G08B3/1025;;G08B6/00,G06F15/02;;G06F3/03;;G06F3/0354;;G06F3/0482;;G06F3/0484;;G06F3/14;;G08B3/10;;G08B6/00;;H04M1/725;;H04N5/232,,2,1,103-487-691-760-772,10.1109/iswc.2004.7,"KOSTOV V., JUN OZAWA, MATSUURA S.: ""Analysis of Wearable Interface Factors for Appropriate Information Notification"", WEARABLE COMPUTERS, 2004. ISWC 2004. EIGHTH INTERNATIONAL SYMPOSIUM ON ARLINGTON, VA, USA 31-03 OCT. 2004, PISCATAWAY, NJ, USA,IEEE, 31 October 2004 (2004-10-31) - 3 October 2004 (2004-10-03), pages 102 - 109, XP010749634, ISBN: 978-0-7695-2186-2, DOI: 10.1109/ISWC.2004.7;;European Search Report dated Apr. 18, 2019, issued in European Patent Application No. 16905576.1.",ACTIVE
227,US,A1,US 2017/0365135 A1,025-577-821-571-024,2017-12-21,2017,US 201615254440 A,2016-09-01,IN 201611020611 A,2016-06-16,METHOD FOR PROVIDING NOTIFICATIONS,"A method for providing notifications is provided. The method includes a tangible user interface (TUI) element the receives an input from a computing device coupled to the TUI element. The input is indicative of an outcome corresponding to a functionality of an application on the computing device. Based on the outcome, the TUI element determines at least one illumination pattern from a plurality of pre-stored illumination patterns. Thereafter, the TUI element generates an output based on the at least one determined illumination pattern.",SAMSUNG ELECTRONICS CO LTD,GUPTA AYUSHI;;BANERJEE PRANTIK;;THOMAS THEOPHILUS;;HAHM KYOUNGWOON;;PRABHAKAR ARUN;;JANARDHANAN GOVIND;;GOVEKAR DHANANJAY L;;CHAVAN SUDHANWA SUHAS;;PASSI NAVNEET;;KUMAR ABHISHEK;;THAKUR AVINASH;;SETIA NITIN;;BHATTACHERJEE SUPRATEEM;;T SANKARA NARAYANAN;;JAKHMOLA HIMANSHU;;CHAWLA SONAM;;AGARWAL REKHA;;SHARMA ATUL;;PRATAP AASHAANK;;MEHER SHANTANU KUMAR;;PS ARUNGEETH;;BANSAL AMIT;;SHARMA KAUSHAL PRAKASH;;JAIN JATIN,SAMSUNG ELECTRONICS CO. LTD (2016-08-17),https://lens.org/025-577-821-571-024,Patent Application,yes,0,9,5,5,0,G06F3/03;;G06F2203/0339;;G06F3/03547;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/03;;G06F3/03547;;G06F2203/0339;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/0482;;G06F3/14;;G08B3/1025;;G08B6/00,G08B3/10;;G06F3/0482;;G06F3/14;;G08B6/00;;H04N5/232,,0,0,,,,ACTIVE
228,EP,A1,EP 3458948 A1,059-359-484-611-635,2019-03-27,2019,EP 16905576 A,2016-09-01,IN 201611020611 A;;KR 2016009813 W,2016-06-16,METHOD FOR PROVIDING NOTIFICATIONS,,SAMSUNG ELECTRONICS CO LTD,GUPTA AYUSHI;;BANERJEE PRANTIK;;THOMAS THEOPHILUS;;HAHM KYOUNGWOON;;PRABHAKAR ARUN;;JANARDHANAN GOVIND;;GOVEKAR DHANANJAY L;;CHAVAN SUDHANWA SUHAS;;PASSI NAVNEET;;KUMAR ABHISHEK;;THAKUR AVINASH;;SETIA NITIN;;BHATTACHERJEE SUPRATEEM;;T SANKARA NARAYANAN;;JAKHMOLA HIMANSHU;;CHAWLA SONAM;;AGARWAL REKHA;;SHARMA ATUL;;PRATAP AASHAANK;;MEHER SHANTANU KUMAR;;PS ARUNGEETH;;BANSAL AMIT;;SHARMA KAUSHAL PRAKASH;;JAIN JATIN,,https://lens.org/059-359-484-611-635,Patent Application,yes,0,0,5,5,0,G06F3/03;;G06F2203/0339;;G06F3/03547;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/03;;G06F3/03547;;G06F2203/0339;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/0482;;G06F3/14;;G08B3/1025;;G08B6/00,G06F3/0484;;G06F3/0481;;G06F3/0488,,0,0,,,,DISCONTINUED
229,EP,A4,EP 3458948 A4,163-200-240-314-621,2019-05-22,2019,EP 16905576 A,2016-09-01,IN 201611020611 A;;KR 2016009813 W,2016-06-16,METHOD FOR PROVIDING NOTIFICATIONS,,SAMSUNG ELECTRONICS CO LTD,GUPTA AYUSHI;;BANERJEE PRANTIK;;THOMAS THEOPHILUS;;HAHM KYOUNGWOON;;PRABHAKAR ARUN;;JANARDHANAN GOVIND;;GOVEKAR DHANANJAY L;;CHAVAN SUDHANWA SUHAS;;PASSI NAVNEET;;KUMAR ABHISHEK;;THAKUR AVINASH;;SETIA NITIN;;BHATTACHERJEE SUPRATEEM;;T SANKARA NARAYANAN;;JAKHMOLA HIMANSHU;;CHAWLA SONAM;;AGARWAL REKHA;;SHARMA ATUL;;PRATAP AASHAANK;;MEHER SHANTANU KUMAR;;PS ARUNGEETH;;BANSAL AMIT;;SHARMA KAUSHAL PRAKASH;;JAIN JATIN,,https://lens.org/163-200-240-314-621,Search Report,no,2,0,5,5,0,G06F3/03;;G06F2203/0339;;G06F3/03547;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/03;;G06F3/03547;;G06F2203/0339;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/0482;;G06F3/14;;G08B3/1025;;G08B6/00,G06F3/0484;;G06F3/03;;G06F3/0481;;G06F3/0488;;H04N5/232,,2,1,103-487-691-760-772,10.1109/iswc.2004.7,"KOSTOV V ET AL: ""Analysis of Wearable Interface Factors for Appropriate Information Notification"", WEARABLE COMPUTERS, 2004. ISWC 2004. EIGHTH INTERNATIONAL SYMPOSIUM ON ARLINGTON, VA, USA 31-03 OCT. 2004, PISCATAWAY, NJ, USA,IEEE, 31 October 2004 (2004-10-31), pages 102 - 109, XP010749634, ISBN: 978-0-7695-2186-2, DOI: 10.1109/ISWC.2004.7;;See also references of WO 2017217592A1",DISCONTINUED
230,WO,A1,WO 2017/217592 A1,160-730-423-392-517,2017-12-21,2017,KR 2016009813 W,2016-09-01,IN 201611020611 A,2016-06-16,METHOD FOR PROVIDING NOTIFICATIONS,"A method for providing notifications is provided. The method includes a tangible user interface (TUI) element the receives an input from a computing device coupled to the TUI element. The input is indicative of an outcome corresponding to a functionality of an application on the computing device. Based on the outcome, the TUI element determines at least one illumination pattern from a plurality of pre-stored illumination patterns. Thereafter, the TUI element generates an output based on the at least one determined illumination pattern.",SAMSUNG ELECTRONICS CO LTD,GUPTA AYUSHI;;BANERJEE PRANTIK;;THOMAS THEOPHILUS;;HAHM KYOUNGWOON;;PRABHAKAR ARUN;;JANARDHANAN GOVIND;;GOVEKAR DHANANJAY L;;CHAVAN SUDHANWA SUHAS;;PASSI NAVNEET;;KUMAR ABHISHEK;;THAKUR AVINASH;;SETIA NITIN;;BHATTACHERJEE SUPRATEEM;;T SANKARA NARAYANAN;;JAKHMOLA HIMANSHU;;CHAWLA SONAM;;AGARWAL REKHA;;SHARMA ATUL;;PRATAP AASHAANK;;MEHER SHANTANU KUMAR;;PS ARUNGEETH;;BANSAL AMIT;;SHARMA KAUSHAL PRAKASH;;JAIN JATIN,,https://lens.org/160-730-423-392-517,Patent Application,yes,9,0,5,5,0,G06F3/03;;G06F2203/0339;;G06F3/03547;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/03;;G06F3/03547;;G06F2203/0339;;G06F3/0304;;G06F3/04883;;H04N23/64;;H04N23/633;;G06F3/0482;;G06F3/14;;G08B3/1025;;G08B6/00,G06F3/0484;;G06F3/0481;;G06F3/0488,,1,0,,,See also references of EP 3458948A4,PENDING
231,TW,B,TW I327568 B,086-316-682-726-90X,2010-07-21,2010,TW 92135079 A,2003-12-11,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1s-(1 alpha, 3 alpha, 4 beta) ]-2-amino-1, 9-dihydro-9- [4-hydroxy-3-(hydroxymethyl) -2-methylenecyclopentyl] -6h-purin-6-one",,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI;;CHEN CHUNG-PIN;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;BANERJEE AMIT;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH;;WANG SHAOPENG;;STOJANOVIC MILAN;;KUCERA DAVID J;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN K;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,,https://lens.org/086-316-682-726-90X,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
232,SI,T1,SI 1644384 T1,062-326-761-222-433,2013-02-28,2013,SI 200332236 T,2003-12-10,US 43254902 P;;US 0339554 W;;EP 03812974 A,2002-12-11,PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR,,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/062-326-761-222-433,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/00;;C07D473/12;;C07D473/18;;C07F7/00;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
233,PT,E,PT 1644384 E,008-448-349-066-106,2013-01-23,2013,PT 03812974 T,2003-12-10,US 43254902 P,2002-12-11,PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR,,BRISTOL MYERS SQUIBB CO,PATEL RAMESH N;;VEMISHETTI PURUSHOTHAM;;POWERS GERALD L;;KRONENTHAL DAVID R;;KUCERA DAVID J;;CHEN CHUNG-PIN H;;PENDRI YADAGIRI R;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;BANERJEE AMIT,,https://lens.org/008-448-349-066-106,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
234,IN,A,IN 606DEN2012 A,050-758-477-644-19X,2015-06-12,2015,IN 606DEN2012 A,2012-01-20,US 43254902 P;;US 0339554 W,2002-12-11,"""A COMPOUND-2""","A compound of formula: wherein Rb is C1 to C6 alkyl; and R20 is hydrogen or benzyl, or a salt thereof.",BRISTOL MAYERS SQUIBB COMPANY,YADAGIRI R PENDRI;;CHUNG-PIN H CHEN;;SUNIL S PATEL;;JEFFREY M EVANS;;JING LIANG;;DAVID R KRONENTHAL;;GERALD L POWERS;;SIVA JOSYULA PRASAD;;JEFFREY T BIEN;;ZHONGPING SHI;;RAMESH N PATEL;;AMIT BANERJEE;;YEUNG Y CHAN;;SUSHIL K RIJHWANI;;AMBARISH K SINGH;;SHAOPENG WANG;;MILAN STOJANOVIC;;DAVID J KUCERA;;RICHARD POLNIASZEK;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;MAOTANG X ZHOU;;PURUSHOTHAM VEMISHETTI,,https://lens.org/050-758-477-644-19X,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,PENDING
235,CN,A,CN 101899063 A,105-812-942-624-193,2010-12-01,2010,CN 201010236000 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,AMIT BANERJEE;;KUCERA DAVID J;;YADAGIRI PENDRI;;CHUNG-PIN CHEN;;PATEL SUNIL S;;EVANS JEFFREY M;;JING LIANG;;KRONENTHAL DAVID R;;POWERS GERALD L;;JOSYULA PRASAD SIVA;;BIEN JEFFREY T;;ZHONGPING SHI;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;SHAOPENG WANG;;MILAN STOJANOVIC;;RICHARD POLNIASZEK;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;ZHOU MAOTANG X;;PURUSHOTHAM VEMISHETTI,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-02-12),https://lens.org/105-812-942-624-193,Patent Application,no,0,3,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,EXPIRED
236,BR,B8,BR PI0317255 B8,096-895-384-731-374,2021-05-25,2021,BR 0317255 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,"processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona método de seu isolamento, preparação do éster e respectivos compostos","processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona. a presente invenção refere-se a processos para preparar o agente antiviral entecavir. também é revelado um processo de adsorção de resina para o isolamento e a purificação de entecavir. também são revelados vários intermediários úteis na preparação de entecavir.",BRISTOL MYERS SQUIBB CO;;BRISTOL MYERS SQUIBB HOLDINGS IRELAND;;BRISTOL MYERS SQUIBB HOLDINGS IRELAND,JEFFREY M EVANS;;AMBARISH K SINGH;;AMIT BANERJEE;;CHARLES LEWIS;;CHUNG-PIN CHEN;;DAVID J KUCERA;;DAVID R KRONENTHAL;;DHILEEPKUMAR KRISHNAMURTY;;GERALD L POWERS;;JEFFREY T BIEN;;JING LIANG;;JOHN THOTTATHIL;;MAOTANG X ZHOU;;MILAN STOJANOVIC;;PURUSHOTHAM VEMISHETTI;;RAMESH N PATEL;;RICHARD POLNIASZEK;;SHAOPENG WANG;;SIVA JOSYULA PRASAD;;SUNIL S PATEL;;SUSHIL K RIJHWANI;;YADAGIRI PENDRI;;YEUNG Y CHAN;;ZHONGPING SHI,BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) (2016-03-08);;BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (C (2019-02-26),https://lens.org/096-895-384-731-374,Amended Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;A61P31/00;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
237,PL,A1,PL 397715 A1,070-559-239-963-260,2012-03-26,2012,PL 39771503 A,2003-12-10,US 43254902 P,2002-12-11,Cyclopentadiene derivative and the process for the preparation thereof,,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN K;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;PATEL RAMESH N;;KUCERA DAVID J,,https://lens.org/070-559-239-963-260,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,PENDING
238,CY,T1,CY 1113829 T1,102-952-858-720-989,2016-07-27,2016,CY 131100055 T,2013-01-22,EP 03812974 A;;US 43254902 A,2002-12-11,ΔΙΕΡΓΑΣΙΑ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΣΥΝΘΕΣΗ ΤΗΣ ΕΝΤΕΚΑΒΙΡΗΣ,Αποκαλύπτονται διεργασίες για την παρασκευή του αντιικού παράγοντα εντεκαβίρη. Μία διεργασία προσρόφησης ρητίνης για την απομόνωση και τον καθαρισμό της εντεκαβίρης αποκαλύπτεται επίσης. Διάφορα ενδιάμεσα προϊόντα χρήσιμα στην παρασκευή της εντεκαβίρης αποκαλύπτονται επίσης.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/102-952-858-720-989,Granted Patent,no,0,0,1,1,0,,C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,ACTIVE
239,IN,A,IN 604DEN2012 A,191-144-629-588-534,2015-08-21,2015,IN 604DEN2012 A,2012-01-20,US 43254902 P;;US 0339554 W,2002-12-11,"""A COMPOUND-3""","A compound of formula: or a salt thereof wherein: A is CH2 or a bond; R27 is hydrogen, benzyl, or SiRd2Rc; R6 is C1 to C4 alkyl or phenyl; and Rd is C1 to C3 alkyl.",BRISTOL MYERS SQUIBB CO,YADAGIRI R PENDRI;;CHUNG-PIN H CHEN;;SUNIL S PATEL;;JEFFREY M EVANS;;JING LIANG;;DAVID R KRONENTHAL;;GERALD L POWERS;;SIVA JOSYULA PRASAD;;JEFFREY T BIEN;;ZHONGPING SHI;;RAMESH N PATEL;;AMIT BANERJEE;;YEUNG Y CHAN;;SUSHIL K RIJHWANI;;AMBARISH K SINGH;;SHAOPENG WANG;;MILAN STOJANOVIC;;DAVID J KUCERA;;RICHARD POLNIASZEK;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;MAOTANG X ZHOU;;PURUSHOTHAM VEMISHETTI,,https://lens.org/191-144-629-588-534,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,PENDING
240,CN,B,CN 101130552 B,113-198-823-464-281,2010-07-28,2010,CN 200710149940 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;JING LIANG;;KRONENTHAL DAVID R;;POWERS GERALD L;;JOSYULA PRASAD SIVA;;BIEN JEFFREY T;;ZHONGPING SHI;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;SHAOPENG WANG;;MILAN STOJANOVIC;;RICHARD POLNIASZEK;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;ZHOU MAOTANG X;;PURUSHOTHAM VEMISHETTI;;AMIT BANERJEE;;KUCERA DAVID J,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-01-07),https://lens.org/113-198-823-464-281,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,EXPIRED
241,AU,B2,AU 2003/300884 B2,122-901-274-781-927,2010-01-21,2010,AU 2003/300884 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,Process and intermediates for synthesis entecavir,,BRISTOL MYERS SQUIBB HOLDINGS IRELAND,BIEN JEFFREY T;;KUCERA DAVID J;;LEWIS CHARLES;;PENDRI YADAGIRI R;;SINGH AMBARISH K;;POWERS GERALD L;;POLNIASZEK RICHARD;;WANG SHAOPENG;;STOJANOVIC MILAN;;KRONENTHAL DAVID R;;RIJHWANI SUSHIL K;;BANERJEE AMIT;;PRASAD SIVA JOSYULA;;CHEN CHUNG-PIN H;;THOTTATHIL JOHN;;VEMISHETTI PURUSHOTHAM;;LIANG JING;;SHI ZHONGPING;;ZHOU MAOTANG X;;EVANS JEFFREY M;;PATEL RAMESH N;;CHAN YEUNG Y;;KRISHNAMURTY DHILEEPKUMAR;;PATEL SUNIL S,BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO (2019-02-21);;BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (2013-09-19),https://lens.org/122-901-274-781-927,Granted Patent,no,2,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,5,3,002-279-503-533-305;;016-593-952-646-990;;106-909-291-742-600,12841754;;10.1021/ol0300571;;10.1016/j.tet.2003.02.001;;10.1016/s0040-4039(01)90105-4,"Bisacchi et al. Bioorg. Med. Chem. Lett. 1997, 7(2), 127-132;;Pearson et al. Org. Lett. 2003, 5(14), 2457-2459;;Humiliere Synlett 1998, 1255-1257;;Ziegler et al. Tetrahedron 2003, 59(45), 9013-9018;;Carceller et al. Tetrahedron Lett. 1984, 25(19), 2031-2034",EXPIRED
242,CA,C,CA 2508811 C,085-183-354-874-943,2014-11-18,2014,CA 2508811 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,"PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1.ALPHA., 3.ALPHA., 4.BETA.)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;KUCERA DAVID J;;BANERJEE AMIT,,https://lens.org/085-183-354-874-943,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/10;;C07C67/00;;C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
243,DK,T3,DK 1644384 T3,098-924-166-756-699,2013-02-11,2013,DK 03812974 T,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,Fremgangsmåde og mellemprodukter til syntese af entecavir,,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;VEMISHETTI PURUSHOTHAM;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/098-924-166-756-699,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
244,TW,A,TW 200504065 A,140-281-097-487-126,2005-02-01,2005,TW 92135079 A,2003-12-11,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1s-(1 alpha, 3 alpha, 4 beta)] -2-amino-1, 9-dihydro-9- [4-hydroxy-3-(hydroxymethyl) -2-methylenecyclopentyl] -6h-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI;;CHEN CHUNG-PIN;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;BANERJEE AMIT;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH;;WANG SHAOPENG;;STOJANOVIC MILAN;;KUCERA DAVID J;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN K;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,,https://lens.org/140-281-097-487-126,Patent of Addition,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
245,KR,A,KR 20090084979 A,155-920-556-869-127,2009-08-05,2009,KR 20097015624 A,2003-12-10,US 43254902 P,2002-12-11,"PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1ALPHA,3ALPHA,4BETA)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed. ® KIPO & WIPO 2009,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/155-920-556-869-127,Patent Application,no,0,4,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/02;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
246,KR,A,KR 20050087831 A,094-155-090-826-320,2005-08-31,2005,KR 20057010722 A,2003-12-10,US 43254902 P,2002-12-11,"PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1ALPHA,3ALPHA,4BETA)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/094-155-090-826-320,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
247,BR,B1,BR 122019020833 B1,133-124-182-980-887,2020-09-01,2020,BR 122019020833 A,2003-12-10,US 0339554 W;;US 43254902 P;;BR PI0317255 A,2002-12-11,"agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona",a presente invenção refere-se a processos para preparar o agente antiviral entecavir. também é revelado um processo de adsorção de resina para o isolamento e a purificação de entecavir. também são revelados vários intermediários úteis na preparação de entecavir.,BRISTOL MYERS SQUIBB HOLDINGS IRELAND,AMBARISH K SINGH;;AMIT BANERJEE;;CHARLES LEWIS;;CHUNG-PIN CHEN;;DAVID J KUCERA;;DAVID R KRONENTHAL;;DHILEEPKUMAR KRISHNAMURTY;;GERALD L POWERS;;JEFFREY M EVANS;;JEFFREY T BIEN;;JING LIANG;;JOHN THOTTATHIL;;MAOTANG X ZHOU;;MILAN STOJANOVIC;;PURUSHOTHAM VEMISHETTI;;RAMESH N PATEL;;RICHARD POLNIASZEK;;SHAOPENG WANG;;SIVA JOSYULA PRASAD;;SUNIL S PATEL;;SUSHIL K RIJHWANI;;YADAGIRI PENDRI;;YEUNG Y CHAN;;ZHONGPING SHI,,https://lens.org/133-124-182-980-887,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;A61P31/00;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
248,BR,B8,BR 122019020833 B8,185-476-724-412-311,2021-07-27,2021,BR 122019020833 A,2003-12-10,US 0339554 W;;US 43254902 P;;BR PI0317255 A,2002-12-11,"agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona",a presente invenção refere-se a processos para preparar o agente antiviral entecavir. também é revelado um processo de adsorção de resina para o isolamento e a purificação de entecavir. também são revelados vários intermediários úteis na preparação de entecavir.,BRISTOL MYERS SQUIBB HOLDINGS IRELAND,AMBARISH K SINGH;;AMIT BANERJEE;;CHARLES LEWIS;;CHUNG-PIN CHEN;;DAVID J KUCERA;;DAVID R KRONENTHAL;;DHILEEPKUMAR KRISHNAMURTY;;GERALD L POWERS;;JEFFREY M EVANS;;JEFFREY T BIEN;;JING LIANG;;JOHN THOTTATHIL;;MAOTANG X ZHOU;;MILAN STOJANOVIC;;PURUSHOTHAM VEMISHETTI;;RAMESH N PATEL;;RICHARD POLNIASZEK;;SHAOPENG WANG;;SIVA JOSYULA PRASAD;;SUNIL S PATEL;;SUSHIL K RIJHWANI;;YADAGIRI PENDRI;;YEUNG Y CHAN;;ZHONGPING SHI,,https://lens.org/185-476-724-412-311,Amended Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;A61P31/00;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
249,BR,A,BR 0317255 A,005-092-911-637-102,2005-11-08,2005,BR 0317255 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,"Processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)- 2-metilenociclopentil]-6h-purin-6-ona","""PROCESSO PARA PREPARAR O AGENTE ANTIVIRAL ¢1S-(1ALFA, 3ALFA, 4BETA)!-2-AMINO-1,9-DIIDRO-9-¢4-HIDRóXI3-(HIDROXIMETIL)-2 -METILENOCICLOPENTIL!-6H-PURIN-6-ONA"". A presente invenção refere-se a processos para preparar o agente antiviral entecavir. Também é revelado um processo de adsorção de resina para o isolamento e a purificação de entecavir. Também são revelados vários intermediários úteis na preparação de entecavir.",BRISTOL MYERS SQUIBB CO,BANERJEE AMIT;;KUCERA DAVID J;;PENDRI YADAGIRI;;CHEN CHUNG-PIN;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) (2016-03-08);;BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (C (2019-02-26),https://lens.org/005-092-911-637-102,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
250,CN,B,CN 101899063 B,135-699-747-095-915,2012-12-12,2012,CN 201010236000 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",,BRISTOL MYERS SQUIBB CO,BANERJEE AMIT;;KUCERA DAVID J;;PENDRI YADAGIRI;;CHEN CHUNG-PIN;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-02-12),https://lens.org/135-699-747-095-915,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,EXPIRED
251,BR,B1,BR PI0317255 B1,010-219-600-296-845,2019-12-24,2019,BR 0317255 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,"processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi-3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona método de seu isolamento, preparação do éster e respectivos compostos","""processo para preparar o agente antiviral [1s-(1alfa, 3alfa, 4beta)]-2-amino-1,9-diidro-9-[4-hidróxi3-(hidroximetil)-2-metilenociclopentil]-6h-purin-6-ona"". a presente invenção refere-se a processos para preparar o agente antiviral entecavir. também é revelado um processo de adsorção de resina para o isolamento e a purificação de entecavir. também são revelados vários intermediários úteis na preparação de entecavir.",BRISTOL MYERS SQUIBB CO;;BRISTOL MYERS SQUIBB HOLDINGS IRELAND;;BRISTOL MYERS SQUIBB HOLDINGS IRELAND,AMBARISH K SINGH;;AMIT BANERJEE;;CHARLES LEWIS;;CHUNG-PIN CHEN;;DAVID J KUCERA;;DAVID R KRONENTHAL;;DHILEEPKUMAR KRISHNAMURTY;;GERALD L POWERS;;JEFFREY M EVANS;;JEFFREY T BIEN;;JING LIANG;;JOHN THOTTATHIL;;MAOTANG X ZHOU;;MILAN STOJANOVIC;;PURUSHOTHAM VEMISHETTI;;RAMESH N PATEL;;RICHARD POLNIASZEK;;SHAOPENG WANG;;SIVA JOSYULA PRASAD;;SUNIL S PATEL;;SUSHIL K RIJHWANI;;YADAGIRI PENDRI;;YEUNG Y CHAN;;ZHONGPING SHI,BRISTOL-MYERS SQUIBB HOLDINGS IRELAND (CH) (2016-03-08);;BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (C (2019-02-26),https://lens.org/010-219-600-296-845,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;A61P31/00;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
252,IN,A,IN 605DEN2012 A,144-954-411-453-928,2015-06-12,2015,IN 605DEN2012 A,2012-01-20,US 43254902 P;;US 0339554 W,2002-12-11,"""A COMPOUND-1""","A compound of formula: or a salt thereof wherein: Ra is alkyl, phenyl, C1 to C6 alkylphenyl, or C1 to C6 alkoxyphenyl; Rb is C1 to C6 alkyl; R20 is hydrogen or benzyl; X is C1, I, or benzyloxy; Ry and Rz are taken together to form, methylene (=CH2), or Ry is OR23, and Rz is -CH2OR24, wherein R23 and R24 are each hydrogen or are taken together to form a ting to define a dioxolane, said dioxolane being optionally substituted with -O(C1-4alkyl) or-O(C=O)( C1-4alkyl); and R25 and R26 are both hydrogen, or one of R23 and R26 is hydrogen and the other is acyl; or R25 and R26are taken together to form =CH(OC1-4alkyl) or =CH(OC(=O)C1-4alkyl).",BRISTOL MAYERS SQUIBB COMPANY,YADAGIRI R PENDRI;;CHUNG-PIN H CHEN;;SUNIL S PATEL;;JEFFREY M EVANS;;JING LIANG;;DAVID R KRONENTHAL;;GERALD L POWERS;;SIVA JOSYULA PRASAD;;JEFFREY T BIEN;;ZHONGPING SHI;;RAMESH N PATEL;;AMIT BANERJEE;;YEUNG Y CHAN;;SUSHIL K RIJHWANI;;AMBARISH K SINGH;;SHAOPENG WANG;;MILAN STOJANOVIC;;DAVID J KUCERA;;RICHARD POLNIASZEK;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;MAOTANG X ZHOU;;PURUSHOTHAM VEMISHETTI,,https://lens.org/144-954-411-453-928,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,PENDING
253,CA,A1,CA 2508811 A1,174-084-181-945-83X,2004-06-24,2004,CA 2508811 A,2003-12-10,US 43254902 P;;US 0339554 W,2002-12-11,PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR,Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,KRISHNAMURTY DHILEEPKUMAR;;THOTTATHIL JOHN;;PENDRI YADAGIRI R;;KRONENTHAL DAVID R;;LEWIS CHARLES;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;VEMISHETTI PURUSHOTHAM;;SHI ZHONGPING;;BIEN JEFFREY T;;ZHOU MAOTANG X;;PATEL RAMESH N;;CHEN CHUNG-PIN H;;LIANG JING;;RIJHWANI SUSHIL K;;CHAN YEUNG Y;;WANG SHAOPENG;;SINGH AMBARISH K;;STOJANOVIC MILAN;;EVANS JEFFREY M;;PATEL SUNIL S;;POLNIASZEK RICHARD;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/174-084-181-945-83X,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
254,US,B2,US 7034152 B2,185-486-162-707-554,2006-04-25,2006,US 73401203 A,2003-12-11,US 73401203 A;;US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;BANERJEE AMIT;;CHAN YEUNG YU;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;KUCERA DAVID J;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,BRISTOL-MYERS SQUIBB COMPANY (2004-04-08),https://lens.org/185-486-162-707-554,Granted Patent,yes,6,3,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07D473/40;;C07F7/08;;C07F7/10;;C07F7/18,544/229;;544/276;;548/215;;556/436;;556/441;;556/473;;556/465;;556/413;;556/443;;556/482;;556/489;;562/126;;568/660,15,10,074-165-125-912-194;;037-876-020-875-920;;082-273-875-910-399;;016-597-697-673-729;;086-753-455-512-149;;034-665-899-020-552;;046-139-419-765-033;;106-909-291-742-600;;002-279-503-533-305;;016-593-952-646-990,10.1016/s0040-4020(02)00440-4;;10.1021/ja00191a067;;10.1021/ja960526c;;10.1016/s0040-4020(96)00038-5;;10.1021/jo00128a029;;10.1002/anie.199628131;;10.1016/0040-4039(91)80038-8;;10.1016/s0040-4039(01)90105-4;;12841754;;10.1021/ol0300571;;10.1016/j.tet.2003.02.001,"Humiliere, SYNLETT 1998, pp. 1255-1257.;;Bonini, C. et al., ""A critical outlook and comparison of enantioselective oxidation methodologies of olefins"", Tetrahedron, vol. 58, pp. 4981-5021 (2002).;;Danishefsky, S.J. et al., ""Novel Stereospecific Silyl Group Transfer Reactions: Practical Routes to the Prostaglandins"", J. Am. Chem. Soc., vol. 111, pp. 3456-3457 (1989).;;Fleming, I., ""Silyl-to-Hydroxy Conversion in Organic Synthesis"", Chemtracts-Organic Chemistry, vol. 9, pp. 1-64 (1996).;;Greene, T.W. et al., Protective Groups in Organic Synthesis, Second Edition, John Wiley & Sons, Inc., publ., pp. 198-201 (1991).;;Griffith, D.A. et al., ""The Total Synthesis of Allosamidin, Expansions of the Methodology of Azaglycosylation Pursuant to the Total Synthesis of Allosamidin. A Surprising Enantiotopic Sense for a Lipase-Induced Deacetylation"", J. Am. Chem. Soc., vol. 118, No. 40, pp. 9526-9538 (1996).;;Jones, G.R. et al., ""The Oxidation of the Carbon-Silicon Bond"", Tetrahedron, vol. 52, No. 22, pp. 7599-7662 (1996).;;Khanapure, S.P. et al., ""An Efficient Synthesis of 4(S)-Hydroxycyclopent-2-enone"", J. Org. Chem., vol. 60, No. 23, pp. 7548-7551 (1995).;;Li, G. et al., ""N-Halocarbamaate Salts Lead to More Efficient Catalytic Asymmetric Aminohydroxylation"", Angew. Chem. Int. Ed. Engl., vol. 35, No. 23/24, pp. 2813-2817 (1996).;;Miyaji, K. et al., ""Synthesis of Corey Lactone Via Highly Stereoselective Asymmetric Diels-Alder Reaction"", Tetrahedron Letters, vol. 32, No. 35, pp. 4557-4560, 1991.;;Carceller et al., Tetrahedron Letters, vol. 25, Issue 19, 1984 pp. 2031-2034.;;Pearson et al., Organic Letters, vol. 5, No. 14, 2003, pp. 2457-2459.;;Humiliere et al., Synlett 1998, pp. 1255-1257.;;Bisacchi et al., Bioorganic & Medicinal Chemistry Letters, vol. 7, Issue 2, 21 1997, pp. 127-132.;;Ziegler et al., Tetrahedron, vol. 59, Issue 45, Nov. 3, 2003, pp. 9013-9018.",EXPIRED
255,CN,B,CN 102675355 B,197-895-070-523-275,2015-05-06,2015,CN 201210089818 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG YU;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-02-12),https://lens.org/197-895-070-523-275,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07C43/178;;C07C67/333;;C07C69/757;;C07D473/12;;C07D473/18;;C07F7/10;;C07F7/18;;C12P7/62,,0,0,,,,EXPIRED
256,CN,B,CN 101130543 B,095-685-717-634-811,2011-06-08,2011,CN 200710149944 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;JING LIANG;;KRONENTHAL DAVID R;;POWERS GERALD L;;JOSYULA PRASAD SIVA;;BIEN JEFFREY T;;ZHONGPING SHI;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;SHAOPENG WANG;;MILAN STOJANOVIC;;RICHARD POLNIASZEK;;CHARLES LEWIS;;THOTTATHIL JOHN K;;DHILEEPKUMAR KRISHNAMURTY;;ZHOU MAOTANG X;;PURUSHOTHAM VEMISHETTI;;AMIT BANERJEE;;KUCERA DAVID J,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-01-07),https://lens.org/095-685-717-634-811,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,EXPIRED
257,US,A1,US 2004/0192912 A1,072-593-345-582-586,2004-09-30,2004,US 73401203 A,2003-12-11,US 73401203 A;;US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one","
   Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed. 
",PENDRI YADAGIRI R.;;CHEN CHUNG-PIN H.;;PATEL SUNIL S.;;EVANS JEFFREY M.;;LIANG JING;;KRONENTHAL DAVID R.;;POWERS GERALD L.;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T.;;SHI ZHONGPING;;PATEL RAMESH N.;;BANERJEE AMIT;;CHAN YEUNG YU;;RIJHWANI SUSHIL K.;;SINGH AMBARISH K.;;WANG SHAOPENG;;STOJANOVIC MILAN;;KUCERA DAVID J.;;POLNIASZEK RICHARD P.;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X.;;VEMISHETTI PURUSHOTHAM,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;BANERJEE AMIT;;CHAN YEUNG YU;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;KUCERA DAVID J;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,BRISTOL-MYERS SQUIBB COMPANY (2004-04-08),https://lens.org/072-593-345-582-586,Patent Application,yes,4,17,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/12;;C07D473/18;;C07F7/08;;C07F7/18,544/276,0,0,,,,EXPIRED
258,PL,B1,PL 212790 B1,093-767-651-571-729,2012-11-30,2012,PL 37726303 A,2003-12-10,US 43254902 P,2002-12-11,"PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1ALPHA,3ALPHA,4BETA)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE",,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN K;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/093-767-651-571-729,Granted Patent,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,EXPIRED
259,CN,A,CN 104788485 A,094-007-932-905-056,2015-07-22,2015,CN 201510061020 A,2003-12-10,US 43254902 P;;CN 200380105614 A,2002-12-11,Process for preparing antiviral agent,Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG YU;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD P;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/094-007-932-905-056,Patent Application,no,3,2,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07C43/178;;C07C67/333;;C07C69/757;;C07D473/12;;C07D473/18;;C07F7/10;;C07F7/18;;C12P7/62,,0,0,,,,EXPIRED
260,JP,A,JP 2010222365 A,050-693-882-994-447,2010-10-07,2010,JP 2010120589 A,2010-05-26,US 43254902 P,2002-12-11,"METHOD FOR PRODUCING ANTIVIRAL AGENT [1S-(1alpha, 3alpha, 4beta)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE","<P>PROBLEM TO BE SOLVED: To provide various methods for preparing entecavir. <P>SOLUTION: Various intermediates useful in the production of entecavir, and a method for producing these intermediates are provided. A resin adsorption process for the isolation and purification of entecavir and the intermediates thereof is also provided. <P>COPYRIGHT: (C)2011,JPO&INPIT",BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;AMIT BANERJEE;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG XIAO FENG;;STOJANOVIC MILAN;;DAVID J KUCERA;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM,,https://lens.org/050-693-882-994-447,Patent Application,no,3,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07D473/18;;A61K31/522;;A61P31/20;;C07B61/00;;C07C67/333;;C07C69/757;;C07D473/12;;C07F7/08;;C07F7/18,,0,0,,,,PENDING
261,PL,A1,PL 377263 A1,032-891-658-612-429,2006-01-23,2006,PL 37726303 A,2003-12-10,US 43254902 P,2002-12-11,"PROCESS FOR PREPARING THE ANTIVIRAL AGENT [1S-(1ALPHA,3ALPHA,4BETA)]-2-AMINO-1,9-DIHYDRO-9-[4-HYDROXY-3-(HYDROXYMETHYL)-2-METHYLENECYCLOPENTYL]-6H-PURIN-6-ONE",,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;LIANG JING;;KRONENTHAL DAVID R;;POWERS GERALD L;;PRASAD SIVA JOSYULA;;BIEN JEFFREY T;;SHI ZHONGPING;;PATEL RAMESH N;;CHAN YEUNG Y;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;WANG SHAOPENG;;STOJANOVIC MILAN;;POLNIASZEK RICHARD;;LEWIS CHARLES;;THOTTATHIL JOHN K;;KRISHNAMURTY DHILEEPKUMAR;;ZHOU MAOTANG X;;VEMISHETTI PURUSHOTHAM;;BANERJEE AMIT;;KUCERA DAVID J,,https://lens.org/032-891-658-612-429,Patent Application,no,0,0,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07D473/12;;C07D473/18;;C07F7/18,,0,0,,,,EXPIRED
262,CN,A,CN 102675355 A,140-190-950-278-345,2012-09-19,2012,CN 201210089818 A,2003-12-10,US 43254902 P,2002-12-11,"Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one",Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.,BRISTOL MYERS SQUIBB CO,PENDRI YADAGIRI R;;CHEN CHUNG-PIN H;;PATEL SUNIL S;;EVANS JEFFREY M;;JING LIANG;;KRONENTHAL DAVID R;;POWERS GERALD L;;JOSYULA PRASAD SIVA;;BIEN JEFFREY T;;ZHONGPING SHI;;PATEL RAMESH N;;YU CHAN YEUNG;;RIJHWANI SUSHIL K;;SINGH AMBARISH K;;SHAOPENG WANG;;MILAN STOJANOVIC;;POLNIASZEK RICHARD P;;CHARLES LEWIS;;JOHN THOTTATHIL;;DHILEEPKUMAR KRISHNAMURTY;;ZHOU MAOTANG X;;PURUSHOTHAM VEMISHETTI;;AMIT BANERJEE;;KUCERA DAVID J,BRISTOL-MYERS SQUIBB IRELAND HOLDING CORP. (2014-02-12),https://lens.org/140-190-950-278-345,Patent Application,no,4,1,55,55,0,C07D473/18;;C07F7/0812;;C07F7/0814;;C07F7/0827;;C07F7/083;;C07F7/081;;C07F7/1804;;A61P31/00;;A61P31/20;;Y02P20/55;;C07D473/18;;C07F7/083;;C07F7/0812;;C07D473/18;;C07F7/0814;;C07F7/0827;;C07F7/081;;C07F7/1804,C07F7/08;;C07C43/178;;C07C67/333;;C07C69/757;;C07D473/12;;C07D473/18;;C07F7/10;;C07F7/18;;C12P7/62,,1,0,,,"ANTHONY J. PEARSON等,: ""Conjugate Additions of Carbon Nucleophiles to Cyclopentadienones"", 《ORG. LETT.》",EXPIRED
